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Abstract
Carbon nanotubes (CNT) and nanofibers (CNF) are used increasingly in a broad array of 
commercial products. Given current understandings, the most significant life-cycle exposures to 
CNT/CNF occur from inhalation when they become airborne at different stages of their life cycle, 
including workplace, use, and disposal. Increasing awareness of the importance of 
physicochemical properties as determinants of toxicity of CNT/CNF and existing difficulties in 
interpreting results of mostly acute rodent inhalation studies to date necessitate a reexamination of 
standardized inhalation testing guidelines. The current literature on pulmonary exposure to 
CNT/CNF and associated effects is summarized; recommendations and conclusions are provided 
that address test guideline modifications for rodent inhalation studies that will improve dosimetric 
extrapolation modeling for hazard and risk characterization based on the analysis of exposure-
dose-response relationships. Several physicochemical parameters for CNT/CNF, including shape, 
state of agglomeration/aggregation, surface properties, impurities, and density, influence toxicity. 
This requires an evaluation of the correlation between structure and pulmonary responses. 
Inhalation, using whole-body exposures of rodents, is recommended for acute to chronic 
pulmonary exposure studies. Dry powder generator methods for producing CNT/CNF aerosols are 
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preferred, and specific instrumentation to measure mass, particle size and number distribution, and 
morphology in the exposure chambers are identified. Methods are discussed for establishing 
experimental exposure concentrations that correlate with realistic human exposures, such that 
unrealistically high experimental concentrations need to be identified that induce effects under 
mechanisms that are not relevant for workplace exposures. Recommendations for anchoring data 
to results seen for positive and negative benchmark materials are included, as well as periods for 
postexposure observation. A minimum data set of specific bronchoalveolar lavage parameters is 
recommended. Retained lung burden data need to be gathered such that exposure-dose-response 
correlations may be analyzed and potency comparisons between materials and mammalian species 
are obtained considering dose metric parameters for interpretation of results. Finally, a list of 
research needs is presented to fill data gaps for further improving design, analysis, and 
interpretation and extrapolation of results of rodent inhalation studies to refine meaningful risk 
assessments for humans.
Carbon nanotubes (CNT) and carbon nanofibers (CNF) are commonly used in commerce, 
and applications are expected to increase in the near future (Zhao and Castranova 2011; De 
Volder et al. 2013). Since approximately 2004, the U.S. Environmental Protection Agency 
(EPA) has reviewed over 60 notices for commercialization of these materials under Section 
5 of the Toxic Substances Control Act. Releases during the manufacture of these fibrous 
carbon nanomaterials, and during the incorporation of CNT/CNF into finished products, 
coupled with results from experimental animal studies showing asbestos-like effects, raised 
considerable human health concerns (Nowack et al. 2013). These exposures are commonly 
in the form of CNT/CNF-containing aerosols, resulting in a need to monitor exposure and 
assess inhalation effects upon workers (National Institute for Occupational Safety and 
Health [NIOSH] 2013). Available data indicate that releases through use and disposal of 
products containing CNT/CNF are far lower (Kingston et al. 2014). In order to assess the 
inhalation toxicity of these fibrous carbon nanomaterials, it is critical to consider whether 
and how testing of these materials differs from methods recommended in existing standard 
test guidelines for assessing effects of aerosols of soluble chemicals and larger solid 
particulates.
This review summarizes the effects of CNT/CNF reported after dosing of the respiratory 
tract and examines respiratory tract testing conducted in rodents to date for these materials. 
It specifically addresses the challenges posed by inhalation testing with CNT/CNF, 
including methods of particle generation, options for animal exposure systems, 
consideration of critical physicochemical properties for characterization of the materials, and 
importance to characterize exposures, determine doses and evaluate responses when 
examining exposure-dose-response relationships. Modifications to existing standard test 
guidelines were recommended to accommodate these challenges.
DOSING METHODS FOR THE RESPIRATORY TRACT
Human exposure to CNT and CNF may occur throughout their life cycle, from their 
manufacture at the workplace to their final disposal, depending on whether processes along 
the life cycle yield airborne inhalable or respirable particulate elements of CNT and CNF. 
Although dermal exposure and ingestion via contaminated food and water may also occur, 
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the major exposure route is inhalation with the respiratory tract as portal of entry, which is 
the focus of this review. When assessing potential effects of airborne CNT and CNF in 
animal studies, equivalent human exposure conditions ideally need to be mimicked by 
considering exposure methods and mode and dosimetric aspects. Although dosing of the 
respiratory tract might also be achieved using bolus type delivery methods, such as 
intratracheal instillation (IT) or oropharyngeal aspiration of material suspended in a 
physiological medium such as 0.9% saline, inhalation is considered the gold standard.
Table 1 highlights some differences between the different methods of dosing the rodent 
respiratory tract with nanomaterials. A main difference is the delivery of material either as a 
bolus exposure (instillation, aspiration) or by inhalation, with the former representing a 
nonphysiological mode of delivery of the liquid suspended material within a fraction of a 
second (very high dose rate), whereas the latter physiological inhalation deposits aerosolized 
materials over an extended period of time (days, weeks, or months, termed low dose rate). 
The high dose rate issue for instillation or aspiration may be mitigated by administering 
bolus-type deliveries at lower doses over the course of weeks. However, multiple exposures 
require multiple anesthetizations, which subsequently increase stress to animals and require 
careful animal monitoring.
A high dose rate and high doses may overwhelm normal defense mechanisms and thus result 
in significant initial pulmonary inflammation, and may also affect disposition of the 
administered material to secondary organs. In addition, the necessary pretreatment of 
nanomaterials with dispersants to prevent their agglomeration in the vehicle medium used 
for instillation/aspiration delivery alters the particle surface, which is likely to impact their 
biokinetics and induction of effects. Inhalation of pristine unmodified nanomaterials avoids 
these sources of potential introduction of artifacts from surface modifications. The impact of 
high doses also needs to be considered when the amounts exceed by orders of magnitude 
dose levels that are expected to be deposited in the respiratory tract of humans under 
realistic inhalation exposure scenarios. The selection of high bolus doses is often justified by 
arguments that the delivered dose is the same—per unit alveolar surface area—as is 
deposited per unit alveolar surface area in humans exposed to occupational exposure levels 
over a 40-yr working life. This ignores completely the effect of dose rate, that is, delivery of 
the same dose over a long period (days, months, years) versus within a fraction of a second 
(Oberdörster 2012; Baisch et al. 2014). Responses induced by such high doses are likely due 
to mechanisms, such as particle overload or effects of homeostasis, that are not operative at 
relevant low doses (Slikker et al. 2004). For example, overload doses of poorly soluble 
particles (PSP) of low toxicity overwhelm the alveolar macrophage clearance function, 
which was shown to induce lung tumors in rats (International Life Sciences Institute [ILSI] 
2000).
Another disadvantage of bolus type delivery is the uneven distribution of the administered 
material throughout the respiratory tract relative to inhalation. A more central deposition of 
the delivered dose and its uneven distribution in the lower respiratory tract occur (Brain et 
al. 1976; Pritchard et al. 1985; Dorries and Valberg 1992; Driscoll et al. 2000). On the other 
hand, the great advantage of bolus-type delivery is the ease of delivering material to the 
lung, requiring no special equipment. Results also allow for the ranking of pulmonary 
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toxicity of materials, and may be useful for qualitative risk assessment, although results are 
inadequate for purposes of quantitative risk assessment. Bolus delivery does not simulate 
normal human inhalation exposure conditions, and therefore an important component for 
risk assessment, that is, exposure to defined airborne concentrations over time, is missing. In 
general, instillation or aspiration may be considered as “proof of principle studies” or 
“hypothesisforming studies” for identifying mechanisms and obtaining information on 
biodistribution, which needs to be verified subsequently by inhalation.
Other bolus type delivery methods that are not listed in Table 1 include laryngeal aspiration 
and intratracheal microspray of liquid suspended nanomaterials (NM) and intratracheal 
insufflation of NM powders (Morello et al. 2009; Penn Century [www.penncentury.com]). 
The latter two involve delivery of a preset dose in a syringe-type dispenser either as liquid 
spray or as dry powder, with the tip of the cannulatype sprayer inserted into the rodent 
trachea approximately 3–5 mm above the main-stem carina, to be delivered in synchrony 
with the inspiration of the animal. Advantages and disadvantages of these are essentially the 
same as those for other bolus type delivery systems, except that insufflation does not require 
dispersant pretreatment of the dry NM.
Delivery of airborne engineered nanomaterials (ENM) to the lung by inhalation is achieved 
in different ways, with the most common being whole-body and nose-only exposures. The 
former requires individual placement of rodents in compartmentalized areas in order to 
avoid huddling of the animals and permits some free movement, whereas their movement is 
severely restricted by placing them in narrow tubes during nose-only exposure with the 
noses protruding into the plenum with continuously supplied aerosol. This induces 
significant stress in the animals (Phalen 2009), as evidenced by a retarded body weight gain 
during longer term nose-only exposures (Coggins et al. 1993, 2011; Pauluhn and Mohr 
1999; Rothenberg et al. 2000). In contrast, contamination of the fur by aerosolized materials 
is restricted to the head and perhaps shoulder area, whereas during whole-body exposure 
aerosol deposition occurs on the whole-body surface area, resulting in some additional 
gastrointestinal (GI) tract exposure due to preening (see more discussion under “Types of 
Inhalation”).
In addition to these two most common inhalation methods, intratracheal inhalation has been 
used, which prevents any external exposure of fur and allows simulation of different 
breathing scenarios, including breath holding. This requires less material to be aerosolized, 
but requires anesthesia throughout the exposure (Oberdörster, Cox, and Gelein 1997; 
Kreyling et al. 2009).
RESPONSES TO CNT/CNF EXPOSURES
Since the mid 1990s, material scientists have developed and perfected methods to arrange 
carbon atoms in a crystalline graphene lattice with a tubular morphology, thus creating CNT. 
CNT may be produced as a single tubular structure to form a single-walled carbon nanotube 
(SWCNT), as a tube within a tube forming a double-walled carbon nanotube (DWCNT), or 
as multiple tubes within a tube forming a multiwalled carbon nanotube (MWCNT). SWCNT 
have a diameter of 1–2 nm, while MWCNT are synthesized with diameters ranging from 10 
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to 80 nm depending upon the number of encapsulated tubes forming the CNT structure. 
CNT range in length from 0.5 to over 30 µm. Therefore, CNT exhibit high aspect ratios and 
may be classified as man-made fibrous materials, according to the World Health 
Organization (WHO) respirable fiber definition, that is, a particle longer than 5 µm, <3 µm 
in diameter, and with an aspect ratio of >3:1 (WHO 1981).
CNT (1) are resistant to acid or heat treatment, (2) exhibit high tensile strength, (3) possess 
unique electrical properties, and (4) may be easily functionalized. Therefore, applications as 
structural materials, electronics, heating elements, in production of conductive fabric, for 
bone grafting and dental implants, and in drug delivery systems are being developed. Recent 
in vitro findings regarding catalytic degradation of carboxylated, but not pristine, SWCNT 
have also been verified for in vivo conditions (Allen et al. 2008; 2009; Liu, Hurt, and Kane 
2010a; Kotchey et al. 2013) With the anticipated increase in the synthesis and 
commercialization of CNT, human and environmental exposure during the life cycle of 
CNT, that is, production, distribution, use, and disposal, is anticipated. Therefore, it is 
critical to determine the bioactivity of CNT and characterize the dose and time dependence 
of possible adverse health effects of exposure to inform risk assessment and development of 
prevention strategies.
A complication in evaluating the potential adverse health effects resulting from pulmonary 
exposure to CNT is the wide range of physicochemical properties among different CNT. For 
example, CNT might be synthesized by three distinctively different processes, resulting in 
differences in chirality and degrees of catalyst contaminants, and exposures may be to raw 
CNT or CNT purified to remove catalytic metals. CNT may be produced with a wide variety 
of fiber widths and lengths, and airborne CNT exhibit a wide range of structural sizes and 
shapes from micrometer agglomerates to nanometer nanoropes. Lastly, CNT may be 
functionalized to alter their physicochemical properties, such as hydrophobicity versus 
hydrophilicity. In addition, doping of MWCNT with nitrogen was found to reduce their 
toxicity significantly (Carrero-Sanchez et al. 2006; Elias et al. 2007).
At present, data are inadequate to determine to what degree biological responses to a given 
CNT and CNF can be generalized as one nanoparticle class. Indeed, reported effects 
following exposure of rodents to CNT by bolus-type delivery or inhalation revealed that 
although responses are qualitatively similar, the magnitude and time course of responses 
may vary significantly, suggesting that quantitative differences in bioactivity are likely 
(Shvedova et al. 2005; 2008; Ryman-Rasmussen, 2009b). Three recent 13-wk inhalation 
studies in rats with two different types of MWCNT and one 13-wk rat inhalation study with 
CNF showed similar results, yet different LOAEL and/or NOAEL were derived (Ma-Hock 
et al. 2009a; Pauluhn 2010; DeLorme et al. 2012; Kasai et al. 2014). The results also 
suggested that MWCNT and CNF might be generically placed into the same hazard 
category. However, additional subchronic inhalation studies with different types of 
MWCNT and CNF are urgently needed to substantiate this suggestion. Indeed, the 
International Agency for Research on Cancer (IARC) (Grosse et al. 2014) recognized this 
uncertainty when classifying only Mitsui-7 MWCNT as possibly carcinogenic to humans 
(Group 2 B) and other MWCNT and SWCNT as not classifiable with respect to 
carcinogenicity (Group 3).
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Indeed, a most recent key study involving 2 year whole body inhalation exposures of rats to 
three concentrations of Mitsui-7 MWCNT confirmed a significant dose-dependent induction 
of neoplastic lesions in the lung (adenoma and carcinoma) at the medium concentration (0.2 
mg/m3; 26%) and high concentration (2 mg/m3; 32%) in male rats and at only the high 
concentration (2 mg/m3; 22%) in female rats. The low concentration (0.02 mg/m3; 4%) was 
not different from controls (4–6 %). (Fukushima, personal communication, 2015). A paper 
with full details of this milestone study is in preparation. The apparently greater sensitivity 
of males vs females is opposite to earlier findings of chronic inhalation studies with poorly 
soluble particles of low cytotoxicity. (Lee et al, 1985) With this confirmation of the 
carcinogenicity of inhaled Mitsui-7 MWCNT the IARC classification is likely to change to: 
Probably carcinogenic to humans (Group 2 A).
PULMONARY RESPONSE TO SWCNT
Due to the low density of CNT, it is anticipated that respirable particles may be generated 
during manufacturing, as a result of transfer, weighing, mixing, and blending of CNT. 
Therefore, inhalation is considered a primary route for human exposure. The pulmonary 
effects attributed to exposure of rodents to SWCNT were first reported in 2004. Warheit et 
al. (2004) exposed rats by IT instillation to high doses of a raw form of SWCNT (0.25–1.25 
mg/rat), with the CNT sample containing 30–40% amorphous carbon, 5% nickel, and 5% 
cobalt. Although suspended in phosphate-buffered saline (PBS) containing 1% Tween 80, 
the SWCNT were highly agglomerated. Pulmonary exposure to SWCNT resulted in a rapid 
but transient inflammatory and injury response, as evidenced by increased levels of 
bronchoalveolar lavage fluid (BALF) neutrophils, lactate dehydrogenase (LDH) activity, 
and protein. Granulomas, predominantly in the terminal bronchioles, were reported 1 wk 
postexposure and persisted through 3 mo postexposure. A 15% rise in mortality rate within 1 
d postexposure was noted and attributed to physical blockage of conducting airways by large 
SWCNT agglomerates. Lam et al. (2004) also reported rapid and persistent granulomas in 
mice after IT instillation of mice to very high doses of SWCNT (0.1–0.5 mg of SWCNT/
mouse). These investigators compared raw (containing 25% metal catalyst) to purified 
(approximately 2% iron [Fe]) SWCNT and found the granulomatous reaction was not 
dependent on metal contamination of SWCNT. The high mass doses induced a maximal 
response, which may have masked an additional effect of the higher Fe content.
Mangum et al. (2006) exposed rats by pharyngeal aspiration to purified SWCNT (0.5 mg/
rat; 2.6% Co and 1.7% Mo) suspended in 1% Pluronic. Data showed no apparent 
inflammatory responses. However, cell proliferation and platelet-derived growth factor 
(PDGF) protein levels were significantly increased 1 d postexposure and significant 
interstitial fibrosis was noted at 21 d postexposure. Shvedova et al. (2005) exposed mice by 
pharyngeal aspiration to purified SWCNT (10–40 µg/mouse). The suspended SWCNT 
preparation, sonicated but with no dispersant, contained micrometer-sized agglomerates as 
well as some smaller nanorope structures. A rapid and transient inflammation and 
pulmonary damage were noted. In addition, granulomatous lesions and interstitial fibrosis 
within 7 d postexposure, which lasted through the 59-d course of the study, were observed. 
Granulomas were associated with the deposition of agglomerates in the terminal bronchioles 
and proximal alveoli, while interstitial fibrosis was associated with deposition of more 
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dispersed SWCNT structures in the distal alveoli. This distinction between deposition site 
(proximal vs. distal alveoli) and response (granulomas vs. interstitial fibrosis) was confirmed 
using gold-labeled SWCNT, which allowed nanoropes structures to be visualized in lung 
tissue (Mercer et al. 2008). As in the Lam et al. (2004) study, the transient inflammatory/
injury response and persistent granulomatous and fibrotic lesions were not markedly 
affected by the presence or absence of catalytic metals using raw versus pure SWCNT 
(Shvedova et al. 2005; 2008).
Mercer et al. (2008) compared the pulmonary response of mice after pharyngeal aspiration 
of a poorly dispersed versus well-dispersed (acetone-dispersed, washed, and suspended in 
PBS with sonication) preparation of SWCNT. It was found that transient inflammation and 
persistent interstitial fibrosis were fourfold greater on an equal delivered mass burden basis 
for well-dispersed SWCNT compared to poorly dispersed SWCNT. Shvedova et al. (2008) 
reported the pulmonary response of mice to inhalation of SWCNT (5 mg/m3, 5 h/d, 4 d). 
Qualitatively, short-term inhalation produced pulmonary responses similar to bolus exposure 
by pharyngeal aspiration, that is, transient inflammation and damage but persistent 
granulomas and interstitial fibrosis. Aerosolization of dry SWCNT resulted in smaller 
structures (count median diameter [CMD] approximately 220 nm) than suspension of 
SWCNT for aspiration (a mixture of µm size agglomerates and smaller nanorope structures). 
Quantitatively, SWCNT were estimated to be fourfold more potent on an equal mass burden 
basis (5–10 µg/lung) in producing inflammation and fibrosis after inhalation (deposited lung 
burden was estimated from aerosol concentration, minute ventilation, duration of exposure, 
and estimated deposition fraction) than was aspiration of less dispersed SWCNT (Shvedova 
et al. 2008). Of interest, the degree of the response to aspiration of well-dispersed SWCNT 
was similar to that for short-term inhalation, using a similar type of SWCNT (Mercer et al. 
2008; Shvedova et al. 2008), suggesting that aspiration exposure may be appropriate for 
testing well-dispersed CNT for purposes of hazard identification.
Murray et al. (2012) compared the potency of SWCNT to crocidolite asbestos after 
aspiration in mice. At 1 and 7 d postexposure, SWCNT (40 µg/mouse) were significantly 
more potent in inducing transforming growth factor (TGF)-beta, a fibrogenic factor, than 
asbestos (120 µg/mouse). In addition, SWCNT were substantially more potent in inducing 
alveolar interstitial fibrosis as evidenced by lung collagen and alveolar wall connective 
tissue thickness than asbestos at 28 d postexposure. Shvedova et al. (2014) confirmed the 
greater fibrotic potency of SWCNT compared to asbestos at 1 year after aspiration in mice. 
The high bolus doses expressed by mass need to be considered which in addition raises the 
question about comparing responses by different metrics: Would surface characteristics such 
as area, charge, and chemistry be more appropriate?
Recently, Shvedova et al. (2013) presented data suggesting that SWCNT may act as a cancer 
promoter. In this study, mice were exposed to SWCNT (80 µg/mouse) or phosphate-
buffered saline vehicle by pharyngeal aspiration. Two days after aspiration, mice were 
inoculated (iv) with Lewis lung carcinoma cells. In vehicle control mice, inoculation with 
cancer cells resulted in lung tumors 21 d after iv injection. However, lung tumor growth was 
significantly greater in mice preexposed to SWCNT as measured by the following: (1) 5-
fold increase in lung weight, (2) 2.5-fold elevation in the number of visible tumors, and (3) 
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3-fold rise in the area of metastatic nodules. Data indicated that this tumor promotion was 
associated with SWCNT-induced upregulation of granulocyte myeloid-derived suppressor 
cells, which would depress antitumor immunity. This may be viewed as an important 
hypothesis-forming study. However, the extremely high bolus dose and dose rate need to be 
compared to dose-response relationships following realistic inhalation exposures.
In summary, pulmonary exposure of mice to SWCNT induced granulomatous lesions 
associated with deposition of micrometer-sized agglomerates as well as rapid and 
progressive interstitial fibrosis associated with migration of smaller SWCNT structures into 
the alveolar septa. Although most studies were conducted in mice, exposure of rats to 
SWCNT also induced granulomas and fibrosis. It should be noted that most of these 
SWCNT studies involved bolus exposure, resulting in high lung burdens at a very high dose 
rate. The single inhalation study with SWCNT involved a relatively high aerosol 
concentration (5 mg/m3) and 5-d exposure duration (Shvedova et al. 2008). Therefore, dose 
rate was still relatively high. Thus, there is the need for 13-wk inhalation studies in rodents. 
Lung burdens from reported bolus exposure studies may be used as guidance for 
determination of aerosol exposure concentration (ideally resulting in low, medium, and high 
doses). Current knowledge gaps include (1) determination of worker exposure to SWCNT 
(aerosol concentration and size distribution of airborne structures), (2) characterization of 
the effect of catalytic metals on pulmonary responses to SWCNT, (3) determination of 
whether inhaled SWCNT can translocate to the pleura or other organs and produce 
intrapleural or systemic effects, (4) determination of whether inhaled SWCNT induce lung 
cancer, (5) evaluation of the degree to which SWCNT agglomerates are dispersed into 
smaller structures upon contact with pulmonary surfactant or cellular enzymes, (6) 
determination of the biopersistence of SWCNT, and (7) elucidation of mechanisms involved 
in these adverse responses.
PULMONARY RESPONSE TO MWCNT
Muller et al. (2005) exposed rats by IT instillation to MWCNT (0.5–5 mg/rat) suspended in 
1% Tween 80. Dose-dependent inflammation, granulomas, and fibrosis were noted, with the 
unground MWCNT (6 µm length) being more potent than ground MWCNT (0.7 µm length). 
At 60 d postexposure, 81% of unground MWCNT were retained in the lung, as determined 
by 0.5% Co impurities, compared to 36% for short MWCNT. Li et al. (2007a) compared the 
pulmonary response of mice exposed to purified MWCNT by IT instillation (50 µg/mouse 
bolus dose) versus inhalation (32.6 mg/m3, 6 h/d, for 5–15 d [estimated deposited dose of 
70–210 µg]). MWCNT aerosolized from dry material were less agglomerated than when 
suspended in 1% Tween 80. Intratracheal instillation produced inflammation and severe 
destruction of alveolar structures, while inhalation predominately resulted in moderate 
pathology consisting of alveolar wall thickening and cell proliferation but general alveolar 
structure was retained. This study demonstrated significant differences in the type and 
degree of pulmonary responses to MWCNT in mice between bolus-type IT instillation and 
inhalation, with higher doses deposited in lung by inhalation resulting in only moderate 
effects compared to severe lesions induced by instillation of lower doses. Yu et al. (2013) 
compared the influence of IT instillation of 100 µg pristine MWCNT to acid-treated 
MWCNT for 6 mo and noted that pristine MWCNT induced pulmonary autophagy 
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accumulation and more potent tumorigenic responses than the acid-treated MWCNT, 
suggesting the importance of physicochemical characteristics in toxicity outcome. Similarly, 
Kim et al. (2010a) found that pristine MWCNT produced more severe acute inflammatory 
cell recruitment in BALF and multifocal inflammatory granulomas compared to acid-treated 
MWCNT in mice IT instilled with 100 µg for 1 wk up to 4 mo. In another study, exposure of 
rats by IT instillation of high doses of purified MWCNT (0.25–1.75 mg/rat) suspended in 
1% Tween 80 produced a rapid but transient inflammatory response and persistent alveolar 
wall thickening (Liu et al. 2008).
Kobayashi et al. (2010) exposed rats by IT instillation to a well-dispersed suspension of 
MWCNT (10–250 µg/rat). Transient inflammation and damage and a granulomatous 
response was observed. No fibrosis was found, but a collagen stain for histopathology was 
not used. In contrast, Porter et al. (2010) reported a rapid and persistent fibrotic response in 
mice after aspiration of a well-dispersed suspension of purified MWCNT (10–80 µg/mouse 
dispersed in a diluted artificial lung lining fluid), using Sirius red staining for collagen. In 
addition, transient inflammation and damage with persistent granulomas at sites of 
agglomerate deposition were noted. Mercer et al. (2011) conducted morphometric analysis 
of the interstitial fibrotic response from the Porter et al. (2010) study. Analysis indicates a 
time- and dose-dependent fibrotic response. At 80 µg of MWCNT/mouse, interstitial fibrosis 
at 28 d postexposure was significantly above control measured as the thickness of alveolar 
wall collagen. At 56 d postexposure, interstitial fibrosis at 40 µg of MWCNT/mouse was 
significantly greater than control at 40 µg of MWCNT/mouse, with non-significant trends 
observed at lower doses.
Similarly, Aiso et al. (2010) reported transient inflammation and damage, and persistent 
granulomas and alveolar wall fibrosis in rats after IT instillation of different MWCNT (40–
160 µg/rat). In a recent report, mice were exposed by inhalation (5 mg/m3, 5 h/d, 12 d) to 
Mitsui-7 MWCNT (lung burden of 28 µg/lung) and alveolar interstitial fibrosis was 
monitored for 336 d postexposure (Mercer et al. 2013a). The thickness of alveolar septal 
collagen increased 14 d postexposure and continued to progress to 70% above control by 
336 d postexposure.
Han et al. (2010; 2015) exposed mice by aspiration to carboxylic or hydroxyl functionalized 
MWCNT (20–40 µg/mouse). These functionalized MWCNT were well dispersed in PBS. 
Similar to other reports, transient inflammation (1 and 7 d post), elevated cytokine 
production (1 day post), and lung injury (1 day post) were found at 20 and 40 µg/mouse. 
Surface functionalization of MWCNT was reported to affect bioactivity, with carboxylated 
or acid-treated MWCNT being less inflammatory and fibrotic while amine-functionalized 
MWCNT were more potent than unmodified MWCNT (Kim et al. 2010a; Yu et al. 2013; 
Bonner et al. 2013; Li et al. 2013; Sager et al. 2014). Reported biodegradation of 
carboxylated SWCNT and MWCNT may be attributed to peroxidases (Zhao, Allen, and Star 
2011; Kotchey et al. 2013).
Pauluhn (2010) exposed male and female rats by nose-only inhalation (0.1–6 mg/m3, 6h/d, 5 
d/wk, 13 wk) to Baytube MWCNT. Aerosolized structures were large, compact 
agglomerates—defined as assemblages by the author—with a mass median aerodynamic 
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diameter (MMAD) of approximately 3 µm. Subchronic inhalation resulted in persistent 
inflammation, lung damage, granulomas, alveolar wall thickening, and increased interstitial 
collagen staining at exposures of 0.4 mg/m3 or higher. Notably, Pauluhn (2010) did not 
generate significant amounts of fibrous or loosely agglomerated structures with Baytube 
MWCNT and described them as assemblages. The non-ibrous morphology of these 
assemblages was used as explanation to characterize responses as being due to volumetric 
overload of alveolar macrophages phagocytizing these structures (Pauluhn 2010). The 
lowest exposure concentration of 0.1 mg/m3 was determined to be the NOAEL. Of special 
importance, the study by Pauluhn (2010) is the only one to determine in a sufficiently long 
postexposure period the retention halftime (T1/2) of the retained MWCNT (shown later in 
Table 3). This demonstrated a prolongation of T1/2 with high lung burdens, similar to other 
persistent particles ranging from more benign (TiO2; carbon black [CB; [Morrow 1988; 
Elder et al. 2005]) to highly reactive known human carcinogens (asbestos; crystalline SiO2 
[Bolton et al. 1983; Hemenway et al. 1990]). Inclusion of a sufficiently long postexposure 
period needs to be a mandatory component of a well-designed repeated inhalation study to 
determine retention kinetics and regression/progression of effects.
Ma-Hock et al. (2009a) reported pulmonary responses of male and female rats to nose-only 
inhalation of MWCNT (0.1–2.5 mg/m3, 6 h/d, 5 d/wk, 13 wk; resultant burden 47–1170 
µg/rat [crudely estimated, no clearance assumed]). The aerosolized MWCNT were well 
dispersed (count median diameter approximately 60 nm). Pulmonary responses included 
increased lung weight, neutrophilic inflammation, and granulomatous inflammation. No 
apparent fibrosis was reported. However, Ma-Hock et al. (2009a) did not use a specific 
collagen stain for histopathologic analysis; consequently, fibrosis may have been 
underscored. To address this, Treumann et al. (2013) reported results of additional 
histopathological analyses describing a slight increase of collagen fibers in the medium- and 
high-dose animals within the microgranuloma, yet no collagen fibers in alveolar walls and 
pleura. One rat of the lowest exposure group (0.1 mg/m3) developed minimal granuloma. 
Data also showed evidence of MWCNT degradation in alveolar macrophages. Overall, data 
demonstrated that the hallmark of asbestos exposure, pleural inflammation and/or fibrosis, 
was absent. The lowest exposure concentration of 0.1 mg/m3 was the LOAEL in this study.
A multidose 2-wk whole-body inhalation study in rats (6 h/d, 5 d/wk) with Mitsui-7 
MWCNT determined a NOAEL of 0.2 mg/m3, whereas significant pulmonary dose-
dependent inflammatory effects were seen in groups exposed to 1 and 5 mg/m3 group 
(Umeda et al. 2013). Inflammatory indicators were decreased at 4 wk postexposure, but 
partially still elevated. MWCNT translocated to the peritracheal lymph nodes, which 
increased in the postexposure observation period. Goblet-cell hyperplasia induced in the 1- 
and 5-mg/m3-exposed rats did largely regress during the postexposure period. The retained 
lung burden (43 µg in 5 mg/m3 group) at the end of the 2-wk inhalation exposure did not 
change significantly in the subsequent 4-wk postexposure period, and evidence indicated 
lengthy in vivo biopersistence of these MWCNT.
In a subsequent whole-body inhalation study, Kasai et al. (2015)1 exposed female and male 
F-344 rats to Mitsui-7 MWCNT at 3 concentrations ranging from 0.2 to 5 mg/m3 (MMAD = 
1.4–1.6 µm) for 13 wk (6 h/d, 5 d/wk) using whole-body inhalation chambers. Retained 
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burden in the left lung, determined by a hybrid marker technology (Ohnishi et al. 2013), 
ranged between 2.3 and 120 µg/rat. Dose-dependent pulmonary inflammation, granulomas, 
and interstitial fibrosis were observed. Kasai et al. (2015) also observed MWCNT in the 
mesothelial lining of rodent diaphragms in the highest exposure group (5 mg/m3). In 
addition, Kido et al. (2014) subsequently noted that subchronic inhalation exposure to 
MWCNT resulted in systematic inflammation as indicated by increases in mRNA 
expression in splenic macrophages. The lowest exposure concentration of 0.2 mg/m3 was 
the LOAEL in this study, indicating that a 2-wk inhalation study where a NOAEL of 0.2 
mg/m3 was found for the same MWCNT in their previous investigation (Umeda et al. 2013) 
was insufficient to derive a longer term NOAEL. It is to be expected that the NOAEL from a 
chronic 2-yr study might be even lower.
Ryman-Rasmussen et al. (2009b) exposed mice to MWCNT by nose-only inhalation (30 or 
1 mg/m3 for 6 h; MMAD 0.18 and 0.16 µm). Lung burdens were not quantified but 
estimated based on assumed deposition efficiencies. Two to 6 wk postexposure, MWCNT in 
alveolar macrophages were detected in the subpleural tissue and mesothelial cells lining the 
lung, as well as subpleural fibrosis in the high-dose group only. Porter et al. (2010) also 
found MWCNT in the subpleural tissue and subpleural lymphatics, with some fibers 
penetrating into the intrapleural space 1–2 mo after aspiration of a well-dispersed suspension 
of MWCNT (20–80 µg/mouse) suspended in diluted artificial lung lining fluid. Mercer et al. 
(2010) conducted morphometric analyses of the Porter et al. (2010) data and noted 
significant migration of MWCNT into the intrapleural space as early as 1 d postexposure 
and at doses of 20 µg/lung. Data demonstrated (using morphometric measurements) that 
12,000 MWCNT penetrated into the intrapleural space at 56 d after aspiration of 80 µg of 
MWCNT in a mouse model, with such penetrations being dose and time dependent at 20 µg/
mouse or higher. Liang et al. (2010) found that MWCNT translocate to the lung and induce 
fibrosis 28 d after intraperitoneal (ip) injection of a large dose of 250 µg MWCNT/mouse or 
greater. These MWCNT had been functionalized with phosphorylcholine to make them 
hydrophilic. The Sakamoto et al. (2009) observations also support translocation of 
intrascrotally administered MWCNT to the thorax, where diaphragmatic granulomatous 
lesions were found. Recently, Mercer et al. (2013b) reported translocation of inhaled 
MWCNT (lung burden 28 µg/mouse) from the lung to the chest wall and diaphragm and 
observed MWCNT in intrapleural lavage fluid. In addition, low but progressive 
translocation of MWCNT was noted from the lung to the lymphatics, liver, kidneys, heart, 
and brain over a 336-d postexposure observation period.
Pauluhn and Rosenbruch (2015) compared pulmonary effects and retention kinetics of 
MWCNT (Baytubes) aerosols generated either as dry powder aerosols or well dispersed 
from a liquid suspension. Rats were nose-only exposed once for 6 h to large agglomerated 
aggregates with MMAD of 2.6 µm from powder generation or to smaller well-dispersed 
structures from liquid nebulization with MMAD of 0.79 µm, at high concentrations of 25–30 
mg/m3. Marked differences were seen in terms of threefold higher initial lung burdens (lung 
burdens were quantified by NIOSH method 5040 and Doudrick et al. 2013) and about 
1Data were furnished by the Japan Bioassay Research Center to Dr. G. Oberdörster. This study was contracted and supported by the 
Ministry of Health, Labor, and Welfare of Japan.
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twofold faster clearance of wet-dispersed MWCNT in the 3-mo postexposure period. 
Macroscopically, lungs from wet-dispersed MWCNT displayed a gray discoloration, which 
was also seen in the enlarged lymph nodes, whereas dry MWCNT-exposed lungs appeared 
normal. Histopathological examination revealed a greater alveolar macrophage response and 
minimal septal thickening in lungs from wet-exposed rats only. Pauluhn and Rosenbruch 
(2015) emphasized the importance of using relevant exposure scenarios of pristine 
nanomaterials rather than artificial conditions when testing nanomaterials, to avoid flawed 
conclusions based on high-dose acute studies. This investigation also highlights the 
necessity of determining lung burdens rather than only knowing exposure concentrations.
A recent investigation indicated that MWCNT act as a strong promoter of lung tumors 
(Sargent et al. 2014). In this study, B6C3F1 mice were injected ip with either corn oil 
(vehicle) or 10 µg/g bw of methylcholanthrene (an initiator). One week later, mice were then 
exposed by whole-body inhalation (5 h/d, 15 d) to either filtered air or MWCNT (Mitsui-7, 5 
mg/m3, resulting lung burden of 31 µg/lung) generated by an acoustical generator as 
described by McKinney, Chen, and Frazer (2009). At 17 mo postexposure, mice were 
euthanized and lung tissue was examined by a board-certified veterinary pathologist for lung 
tumor formation. MWCNT did not significantly increase the incidence of tumor formation 
(percent of mice with a tumor) in mice receiving corn oil. However, MWCNT produced a 
marked rise in tumor incidence in mice treated with the initiator chemical (initiator alone 
having a 50% incidence, while the initiator plus MWCNT group displayed a 90% 
incidence). In addition, MWCNT increased multiplicity (number of tumors/lung) compared 
to the inducer alone from 1.4 to 3.3 tumors/lung, with tumors being significantly larger in 
the initiator plus MWCNT group compared to initiator alone. Pathological analysis indicated 
that tumors were both bronchoalveolar adenomas and bronchoalveolar adenocarcinomas, 
with significantly more malignant tumors in the initiator plus MWCNT mice. This study is 
the first to demonstrate lung cancer promotion after inhalation of MWCNT. Although the 
experimental design of this study was weakened by the absence of negative and/or positive 
particle control groups, a most recent chronic rat inhalation study (see above) confirmed the 
induction of both adenomas and carcinomas in the lung. It is of interest that pharyngeal 
aspiration of 10 µg MWCNT in mice followed by 56 d postexposure revealed significantly 
enhanced expression of a gene set related to human lung cancer, suggesting this technique 
may be utilized for early detection of lung cancer (Guo et al. 2012).
In general, available studies indicate that pulmonary exposure of mice or rats to MWCNT 
induce granulomas and interstitial fibrosis. Evidence also indicates that MWCNT deposited 
in the lung migrate to the pleura and diaphragm. Results are qualitatively similar for both 
bolus exposure studies and inhalation studies. Results also appear to be similar after 
inhalation exposure of both rats and mice when the same MWCNT (Mitsui-7) and aerosol 
dispersion (MMAD of approximately 1.5 um) were employed, as in the Mercer et al. 
(2013a); 2013b) and Kasai et al. (2015) studies. Knowledge gaps include (1) determination 
of typical worker exposure to MWCNT (aerosol concentration and size distribution of 
aerosolized structures), (2) evaluation of the effects and biopersistence of catalytic metals, 
fiber dimensions, and surface functionalization on the pulmonary toxicity of MWCNT, (3) 
determination of the degree to which deposited MWCNT agglomerates disperse into smaller 
structures upon contact with pulmonary surfactant of cellular enzymes, (4) verification of 
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whether MWCNT can induce or promote lung cancer and mesothelioma, and (5) elucidation 
of mechanisms involved with adverse pulmonary responses.
PULMONARY RESPONSES TO CNF
Only three studies evaluating responses following exposures to CNF have been reported, 
two mouse aspiration studies and a 13-wk rat inhalation study. The first mouse study 
(Murray et al. 2012) administered 120 µg of CNF (98.6% elemental carbon; 1.4% iron; 80 to 
160 nm thick; 5–30 µm long) to mice by oro-pharyngeal aspiration, and effects were 
evaluated at 1, 7, and 28 d postexposure. The second mouse study used the same CNF and 
dosing, but followed the induced fibrosis for 1 yr postaspiration (Shvedova et al. 2014). The 
rat inhalation study involved 13-wk (5 d/wk; 6 h/d) inhalation of both male and female rats 
to 3 concentrations (0.54, 2.5, or 25 mg/m3) and filtered air controls with evaluation of 
effects at 1 d and 13 wk postexposure (DeLorme et al. 2012). The CNF were different 
(99.5% elemental carbon, 0.003% iron; 40–350 nm thick; 1–14 µm long) from those of 
Murray et al. (2012) or the Shvedova et al. (2014) studies. Pulmonary responses in the high 
bolus-dosed mice included inflammation (lung lavage increased polymorphonuclear 
leukocytes [PMN], protein, and LDH activity at d 1, which were still significantly elevated 
at 28 d postexposure); established oxidative stress responses; and elevated biochemical 
(collagen) and histochemical (Sirius red) indicators of fibrosis for as long as 1 yr after 
aspiration (Murray et al. 2012; Shvedova et al. 2014). Effects after inhalation exposure of 
rats included dose-dependent elevation in lung weight, still increased in the highest dose 
group at 13 wk postexposure; persistent inflammation (BALF, significant rise in BAL PMN 
and LDH at highest dose) at 1 d and 17 wk postexposure; interstitial thickening; and 
proliferation of Type II cells in the subpleural, parenchymal, and bronchiolar region in the 
high-exposure group, which was persistent for the subpleural region at 13 wk postexposure. 
Indicators of cardiovascular effects (C-reactive protein [CRP]; coagulation parameters; 
histopathology) were not markedly different from controls. A NOAEL of 0.54 mg/m3 was 
determined, and a LOAEL of 2.5 mg/m3 based on minimal inflammation in terminal 
bronchioles and alveolar ducts (DeLorme et al. 2012).
In summary, pharyngeal aspiration of CNF in mice (high bolus dose) resulted in interstitial 
fibrosis. Using bolus dosing, the fibrotic potency of CNF was substantially lower than that 
of SWCNT (Murray et al. 2012; Shvedova et al. 2013). Inhalation exposure of rats to CNF 
over 13 wk resulted in a far lower degree of fibrosis. DeLorme et al. (2012) indicated that a 
lower, more worker-relevant dose rate in this inhalation study might explain this difference. 
However, lung burden was not determined in the inhalation study. The reported MMAD of 3 
µm suggests a lower alveolar deposition compared to a more respirable rat aerosol of ≤2 µm 
MMAD, explaining the low alveolar interstitial fibrosis. Therefore, there remains a need for 
a subchronic inhalation study to a CNF aerosol, in which retained lung burden in the lower 
respiratory tract needs to be measured. Knowledge gaps given for SWCNT and MWCNT 
are also applicable to CNF.
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RESPONSES TO INTRAPERITONEAL INJECTION OF MWCNT
Takagi et al. (2008) reported that injection of MWCNT (3 mg, 109 fibers/mouse) into the 
abdomen of p53± mice resulted in mesothelioma similar to the asbestos positive control. 
The findings in this study have been questioned due to the extremely high dose of MWCNT 
used (Ichihara et al. 2008). The aforementioned caveats associated with nonphysiological 
bolus-type dosing need to be considered. However, a follow-up study also found induction 
of abdominal mesothelioma (25% incidence) after ip injection of 3 µg (106 fibers/mouse) of 
MWCNT (Takagi et al. 2012). Peritoneal and pleural metastatic mesothelioma were also 
reported after intrascrotal administration of MWCNT (1 mg/kg body weight) into rats, with 
the extent of response exceeding that of asbestos when compared on the basis of delivered 
mass as dose metric (Sakamoto et al. 2009). Nagai et al. (2011) administered to rats very 
high doses (1 and 10 mg/rat) of different MWCNT (agglomerated, nonagglomerated, 
tangled, thin [50 nm], and thick [150 nm], including Mitsui MWCNT), which resulted in 
high mortality of the 10-mg-dosed rats and peritoneal mesothelioma at 1 yr in the surviving 
rats for certain groups. The nonagglomerated thinner MWCNT, including Mitsui, produced 
greatest peritoneal inflammation and carcinogenicity, which correlated with their 
crystallinity, sharpness, and rigidity; these properties facilitated piercing of cell membranes 
as observed in additional in vitro studies. Thick MWCNT produced less inflammation and 
carcinogenicity, and tangled MWCNT, even when thin, did not induce mesothelioma. 
Similarly, Muller et al. (2009) noted no mesothelioma over a 2-yr period after abdominal 
injection of very short MWCNT (<1 µm; 20 mg/rat). These negative findings would have 
been predicted by results of Poland and coworkers (2008), who found that abdominal 
injection of 50 µg of long MWCNT/mouse resulted in granulomatous lesions on the 
diaphragm within 2 wk of exposure, while short MWCNT were ineffective, as were tangled 
MWCNT. Murphy et al. (2011) reported that intrapleural injection of long MWCNT (5 µg/
mouse), but not short MWCNT, resulted in persistent (24 wk) inflammation and fibrosis of 
the parietal pleural surface similar to that seen with long amosite.
Results of a large 2-yr ip injection study involving 500 male Wistar rats given a low and 
high dose of 4 different types of MWCNT (50 rats per dose) showed that all MWCNT dosed 
rats developed mesothelioma (Rittinghausen et al. 2014). Administration of high ip doses by 
fiber number was the same for all MWCNT at 1 × 109 and 5 × 109 fibers/rat, equivalent to 
mass bolus doses ranging from 50 µg to 3 mg. When amosite asbestos was used as a positive 
control given as one 10-fold lower ip dose of 0.1 × 109 fibers/rat, 66% mesothelioma 
incidence resulted, whereas only 1 rat in medium-injected controls developed mesothelioma 
(2%). Data indicated that MWCNT were capable of inducing mesothelioma and point to the 
high durability of all CNT. In addition, a higher toxic and carcinogenic potency of straight 
and more needle-like shaped MWCNT was noted and a lower potential for curled, bent, or 
tangled MWCNT, which is similar to the findings of Nagai et al. (2011) reported earlier.
While direct intracavitary injection of MWCNT of straight fiber structures resulted in the 
reported length-dependent inflammatory and fibrosis responses, the occurrence of airborne 
MWCNT as complex tangles raises questions with regard to their translocation to the pleura 
upon inhalation and subsequent pleural effects. Appropriate inhalation studies need to be 
designed. Such an inhalation studies were conducted recently by Mercer et al. (2013a; 
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2013b; Kasai et al. 2015). Mercer et al. (2013b) reported that MWCNT individual fibers 
were observed by enhanced dark-field microscopy in pleural lavagate, chest wall, and 
diaphragm 1 d after inhalation of MWCNT (5 mg/m3, 5 h/d, 12 d; lung burden of 28 µg/
mouse determined by an absorbance assay). The number of MWCNT in the diaphragm 
significantly increased from 1 d to 336 d postexposure. Kasai et al. (2015) also observed by 
electron microscopy translocation of MWCNT to the diaphragm after a 13-wk inhalation of 
Mitsui-7 MWCNT in rats. Fibers were also detected in the pleural lavagate of rats after 
administration of two types of MWCNT (Mitsui-7 and Nikkiso MWCNT) by intratracheal 
spraying of large doses (250 µg 5 times over 9 d for a total of 1.25 mg/rat) (Xu et al. 2012). 
Such high-bolus-dose pulmonary exposure to MWCNT resulted in an increase of 
inflammatory cells in the pleural cavity, inflammatory and fibrotic lesions of the visceral 
pleura, and mesothelial hyperplasia in the visceral pleura as determined 6 h after the last 
dosing. No lesions were observed in the parietal pleura. Xu et al. (2014) recently also 
exposed rats by intratracheal spraying to long-thick (8 µm × 150 nm) and short-thin (3 µm × 
15 nm) MWCNT. Exposure was to 125 µg/rat, 13 times over 24 wk for a total very high 
dose of 1.625 mg/rat. The short-thin MWCNT sample consisted of agglomerated tangles 
with few free fibers. Long, but not short, MWCNT translocated to the pleural cavity and 
deposited in the visceral and parietal pleura. Long MWCNT induced fibrosis in the parietal 
and visceral pleura, and parietal mesothelial proliferative lesions were found after this 24-wk 
treatment, confirming—as previously suggested—the importance of fiber length for 
translocation from deposits in the lung to and effects at remote target sites.
In summary, intracavitary high bolus injection of MWCNT in mice and rats induces 
mesothelioma. MWCNT were found in the pleural lavage, chest wall, and diaphragm after 
inhalation exposure of mice or rats to MWCNT. Successive high-dose nonphysiological 
bolus exposures (over 9 d–24 wk; lung burdens of 1.25–1.63 mg/rat) resulted in pleural 
inflammation and mesothelial hyperplasia. However, induction of lung tumors or 
mesothelioma has not yet been demonstrated after realistic inhalation exposure in a 
noncompromised rodent model. Thus, although the presently available studies confirm a 
carcinogenic hazard of MWCNT, data cannot be used for quantitative risk characterization 
of repeated inhalation exposures. The outcome of an ongoing 2-yr rat inhalation study with 
Mitsui-7 MWCNT (S. Fukushima et al. personal communication, 2014) may provide 
essential information on the carcinogenic potential of inhaled MWCNT. Other knowledge 
gaps include (1) determination of dose and time dependence of pleural effects, (2) 
examination of the impact of fiber dimensions (length and width) and agglomeration/
aggregation state on pleural effects, (3) analysis of the effects of functionalization on 
MWCNT potency, and (4) measuring translocation rates to other potential target sites 
including liver, spleen, CNS, and bone marrow.
SYSTEMIC CARDIOVASCULAR AND NEUROLOGICAL RESPONSES TO 
PULMONARY EXPOSURE TO CNT
Li et al. (2007b) observed that multiple aspirations of SWCNT (20 µg/mouse, every 2 wk, 
for 2 mo) in Apo E −/− mice produced an increased number of aortic plaques. Inhalation of 
MWCNT (26 mg/m3 for 5 h; calculated lung burden of 22 µg) resulted in a depression of the 
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responsiveness of coronary arterioles to dilators 24 h postexposure (Stapleton et al. 2011). 
Further, pharyngeal aspiration of MWCNT (80 µg/mouse) produced an induction of mRNA 
for certain inflammatory mediators and markers of blood–brain barrier damage in the 
olfactory bulb, frontal cortex, midbrain and hippocampus 24 h postexposure (Sriram et al. 
2009). However, Han et al. (2015) demonstrated that pharyngeal aspiration of MWCNT (40 
µg) induced pulmonary inflammatory responses 7 d postexposure with no progression of 
atherosclerosis in apolipoprotein-E-deficient mice.
A recent MWCNT inhalation study in rats reported 24 h after a 5-h inhalation to 5 mg/m3 
pulmonary inflammation and translocation to systemic organs (Stapleton et al. 2012). Data 
also showed an impairment of endothelium-dependent dilation in cardiac coronary 
arterioles, which was not resolved yet by 7 d postexposure, revealing the potential of inhaled 
MWCNT not only to induce pulmonary inflammatory effects but also to produce serious 
extrapulmonary effects after a short-term exposure to a high concentration of 5 mg/m3, 
resulting in an estimated lung burden of 13 µg/rat. In contrast, Warheit, Reed, and DeLorme 
(2013) reported no histopathological changes in heart muscle or cardiovascular tissue and no 
marked changes in C-reactive protein or coagulation parameters between CNF-exposed and 
air-exposed control rats after a 90-d inhalation of CNF (25 mg/m3). It is possible that 
differences of physicochemical properties of these fibrous nanomaterials (hollow vs. solid 
fibers; retained doses, fiber dimension, surface area, or fiber count/mass) may explain these 
results. In addition, it is uncertain how long cardiovascular responses persist or adapt after 
initial exposure (90 d after initial exposure [Warheit, Reed, and DeLorme 2013] vs. 1–7 d 
postexposure [Stapleton et al. 2012]). Further, identifying cardiovascular effects may require 
additional specific methods to determine with high sensitivity effects on the cardiovascular 
system.
Several possible mechanisms have been postulated to explain systemic responses to 
pulmonary exposure to CNT.
Translocation of CNT to Systemic Sites
Translocation of ip MWCNT from the abdominal cavity to the lung was reported by Liang 
et al. (2010). However, thus far there is no apparent evidence that systemic effects noted 
earlier in this report were associated with CNT in the affected tissue. Indeed, aspirated gold-
labeled SWCNT were not found in any systemic organ 2 wk postexposure using 
transmission electron microscopy (TEM) (Mercer et al. 2009). However, the study by 
Stapleton et al. (2012) found low levels of systemic translocation of inhaled MWCNT into 
liver, kidneys, and heart. DeLorme et al. (2012) also observed rare events of translocated 
CNF in brain, heart, liver, kidneys, spleen, intestinal tract and mediastinal lymph nodes, but 
no histopathological changes were seen. Mercer et al. (2013b) documented translocation of 
MWCNT to the lymphatics, liver, kidneys, heart, and brain after inhalation of MWCNT 
(lung burden of 28 µg/mouse). However, this systemic translocation at 336 d postexposure 
was less than 0.25% of the initial lung burden.
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Erdely et al. (2009) reported that aspiration of SWCNT or MWCNT (40 µg/mouse) induced 
a significant increase in blood neutrophils and mRNA expression and protein levels for 
certain inflammatory markers in blood at 4 h postexposure, but not at later times. Such 
pulmonary CNT exposure also significantly elevated gene expression for mediators, such as 
Hif–3α and S100a in the heart and aorta at 4 h postexposure. Evidence also indicates that 
pulmonary exposure to particles alters systemic microvascular function by inducing 
activated PMN to adhere to microvessel walls and release reactive species that scavenge NO 
produced by endothelial cells (Nurkiewicz et al. 2006; 2009). This decreased responsiveness 
of systemic muscle and coronary arterioles to dilators was observed 24 h after inhalation of 
nano-TiO2 at a lung burden of 10 µg (Nurkiewicz et al. 2008; LeBlanc et al. 2009) and after 
inhalation of MWCNT (Stapleton et al. 2012).
Kido et al. (2014) interpreted their finding of increased mRNA expression of inflammatory 
cytokines in splenic macrophages after 3 mo of inhalation exposure of rats to MWCNT as 
indicators of systemic inflammation. Translocated MWCNT were noted in spleen of 
exposed rats, and both splenic macrophages and T-lymphocytes displayed increased 
expression of cytokines/chemokines including interleukin (IL)-2, suggesting a potential 
impact on antitumor activities and general immunosurveillance.
Neurogenic Signals
Intratracheal instillation of SWCNT (250 µg) to rats was found to elevate baroreflex 
function by twofold (Legramante et al. 2009; Coppeta et al. 2007). Although data 
specifically for CNT are not yet available, pulmonary exposure to inhaled ultrafine TiO2 
was reported to stimulate sensory neurons in the lung (Kan et al. 2012). Scuri et al. (2010) 
demonstrated that in vivo inhalation of TiO2 nanoparticles produced upregulation of lung 
neutrophins in weanling and newborn rats but not in adults. Further inhibition of 
sympathetic input to systemic arterioles reversed the decreased responsiveness of 
microvasculature to dilators after pulmonary exposure to ultrafine TiO2 (Knuckles et al. 
2012).
In summary, although a few studies reported cardiovascular responses after pulmonary 
exposure to CNT, the results are far from complete. Dose and time-course relationships for a 
variety of cardiovascular endpoints need to be determined. Mechanisms by which 
pulmonary particles induce cardiovascular responses require elucidation. Although 
MWCNT have been observed in cardiovascular tissue after pulmonary exposure, it is 
unclear whether this tissue burden is sufficient to explain cardiovascular reactions observed. 
Knowledge gaps concerning relationships between CNT/CNF dimensions, surface area and 
surface activity, and possible cardiovascular responses need to be addressed. The finding of 
translocation of inhaled MWCNT to the spleen and activation of splenic macrophages and 
lymphocytes requires further mechanistic studies regarding systemic inflammatory and 
immunomodulatory effects.
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Relationship Between Physicochemical Properties and Toxicity
Physicochemical properties may affect the potential toxicity of nanomaterials. There are 
several extensive lists of properties that could apply to nanomaterials, such as the 18 
properties noted by the OECD (2010). These properties were examined as part of the OECD 
nanomaterial testing program, which examined a set of standardized nanomaterials for 
relevant physicochemical, fate, toxicity, and ecotoxicity endpoints. Other more focused lists 
are intended to correlate health effects with physicochemical characteristics (Bernstein et al. 
2005). There have been efforts to take such focused lists for health effects and narrow them 
even further to apply to nanomaterials in general (Nanomaterial Registry 2014; Warheit 
2008; Nel et al. 2009). The list of properties relevant to all nanomaterials may be narrowed 
when considering health effects of a particular grouping of nanomaterials. For CNT and 
CNF, a possible reduced list of traits is contained in Table 2.
Method of Generation
The manufacturing technique used to produce CNT or CNF may affect all resultant 
physicochemical properties, and hence needs to be considered in order to understand the 
relative potency of the nanoparticle. Carbon nanotube production is accomplished by either 
chemical, physical, or other processes (Rafique and Iqbal 2011). Chemical vapor deposition 
(CVD) is a method for large-scale production of CNT, involving use of a hydrocarbon gas 
such as ethylene, methane, or acetylene; a process gas, either ammonia, nitrogen, or 
hydrogen; and a substrate such as silicon, glass, or alumina with an associated catalyst 
particle such as Fe, Co, or Ni. The nanotube diameter is dependent on the catalyst particle 
size. While most CVD processes produce random groups of CNT, other variants of the 
process might yield vertically aligned CNT and/or DWCNT. A second chemical process, the 
high-pressure carbon monoxide reaction method (HiPco), is also suitable for large-scale 
synthesis of SWCNT. In this method, the catalyst (Fe pentacarbonyl, or a mixture of 
benzene and ferrocene; Ni may also be used) is introduced in the gas phase, with CO used as 
the hydrocarbon gas. A third chemical process to produce SWCNT has been developed that 
uses cobalt and molybdenum catalysts, a silica substrate, and CO gases (CoMoCAT). 
SWCNT may be either metallic or semiconducting. These traits in turn influence their 
commercial applications. Physical processes for CNT production include arc discharge and 
laser ablation. These methods are mostly used for experimental purposes, and produce CNT 
in highly tangled forms, mixed with carbon contaminants and catalysts and therefore likely 
require purification, unlike CVD, which does not require extensive posttreatment. Finally, 
there are miscellaneous processes that are used even less. These include helium arc 
discharge, electrolysis, and flame synthesis methods. Efforts are currently under way to 
produce chirality-pure SWCNT in a lab setting. This is of interest since the electronic and 
optical characteristics of SWCNT are dependent on chirality (Liu, Ma, and Zachariah 2012).
Carbon nanofiber synthesis methods have been summarized by Kim et al. (2013). CNF 
differ from CNT in that they are generally larger in diameter and noncontinuous. CNF are 
produced via catalytic CVD using nanosized metal particles such as Fe, dispersed on a 
ceramic substrate (similar to production of CNT), or by electrospinning of organic polymers 
such as polyacrylonitrile followed by thermal treatment. CNF have special desirable 
thermal, electrical, and mechanical properties. A floating catalyst method (Singh et al. 2002) 
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was also established involving metallocenes solutions as catalyst and benzene as feedstock 
sprayed into a furnace at high temperature to produce CNF in a continuous process at high 
yield. CNF produced by CVD consist of regularly stacked, truncated conical or planar layers 
along the filament length, and differ from CNT, which are comprised of concentric graphene 
tubes that contain an entire hollow core, and are flexible (Murray et al. 2012). In addition, 
such CNF usually behave as semiconductors, and their layer edges are chemically active. 
CNF produced by electrospinning and thermal treatment consist of randomly arranged flat 
or crumpled graphene sheets, with the long axis of the sheets running parallel to the fiber 
axis (Harris 2005). Electrospinning of two immiscible polymer solutions may produce 
porous nanosized fibrous carbon materials, and similar to CNT, CNF may be treated to 
reduce residual catalyst metals.
Shape (Length and Width)
The fiber-like shape of CNT and CNF has some resemblance to asbestos fibers, raising 
concerns that the well-known fibrogenic, carcinogenic, and mesotheliogenic effects 
attributed to asbestos inhalation may also be associated with inhalation of CNT/CNF. 
However, amphibole asbestos are thicker, and consist of straight fibers, many of which 
exceed 15–20 µm in length. Inhalation of these fibers results in “frustrated” phagocytosis by 
alveolar macrophages, with associated inflammatory cytokine release and cell death. 
Serpentine asbestos (chrysotile) consists of more curly thinner fibrils, and hence may be a 
better correlate to CNT tangles. Detailed morphological examination using TEM or 
scanning electron microscopy (SEM) analysis needs to be completed prior to testing.
Ranges of length and width for CNT have been summarized in Donaldson et al. (2006). The 
lengths of CNT are typically several micrometers, although significantly shorter and longer 
fibers have been made. SWCNT diameters vary between 0.7 and 3 nm, while MWCNT 
outer diameters generally are in the 10 to 200 nm range. Although some are straight, most 
SWCNT and MWCNT are bent or curled to form clumps, assemblages, or ropes that are 
longer and wider than the individual nanotube singlets. While CNF might be produced by 
synthesis techniques similar to those of CNT and have a filamentous shape, these differ in 
several ways from CNT: CNF are composed of regularly stacked truncated conical or planar 
layers that run along the filament length and provide chemically active end planes in the 
inner and outer fiber surfaces; unlike CNT, CNF are not comprised of concentric tubes and 
may or may not contain a hollow core (Kim et al. 2013). CNF are flexible, and have 
diameters around 100 nm and an aspect ratio above 100 (Kim et al. 2013).
The size of CNT/CNF aerosols is determined by their agglomeration state, which affects 
their deposition in all regions of the respiratory tract. Depending on the deposited and 
retained dose, CNT/CNF may induce adverse pulmonary effects and translocate to other 
organs and tissues. Fibrous particles/fibers are defined as elongated particles with a length-
to-diameter ratio (i.e., aspect ratio) equal to or greater than 3 to 1 and longer than 5 µm (EPA 
2001; WHO 1981). Respirable (EPA 2001) infers that the particle in question might 
penetrate to the alveolar region upon inhalation. There are considerable differences in fiber 
respirability between lab rodents and humans as discussed later (Inhalable, Thoracic, and 
Respirable CNT and CNF Fractions) and in Appendix A. Translocation from deposition 
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sites of inhaled MWCNT from the lungs of mice to pleural sites, to local lymph nodes, and 
to secondary organs is dependent on agglomeration state and size (Mercer et al. 2013b). In 
this study, translocation rates and amount translocated to secondary organs were low less 
than 0.1% over a year, whereas migration to bronchial-associated lymphatics was much 
higher over 7%. Most of the MWCNT in secondary organs were found in liver, but tiny 
amounts of short single CNT structures were also detected in brain, heart, and kidneys, in 
addition to pleural sites. Whether such low translocation of MWCNT might directly produce 
adverse effects in these distal organs has yet to be determined. Direct ip injection of high 
doses induced inflammation, granulomas, and mesothelioma (Takagi et al. 2008; Poland et 
al. 2008; Rittinghausen et al. 2014).
Several studies using intracavitary bolus injection of MWCNT in rodents demonstrated the 
length dependency of persistent inflammatory responses, which were inversely related to 
clearance at the parietal pleura (Donaldson et al. 2010; Murphy et al. 2011). These results 
confirmed earlier pioneering work with ip injection of long and short asbestos demonstrating 
that the size of lymphatic stomata on the parietal pleural of about 8–10 µm allows efficient 
clearance of short but not of long (> 10–15 µm) fibers (Moalli et al. 1987). Donaldson et al. 
(2010) and Murphy et al. (2011) also showed that inflammatory response to MWCNT 
agglomerates or tangles was less and resolved quickly. Similarly, Nagai et al. (2011) and 
Rittinghausen et al. (2014) reported a low mesotheliogenic response to ip injected tangled 
MWCNT. It should also be noted that even short 5-µm MWCNT may be proinflammatory 
when given at high bolus doses, and similarly that lymphatic clearance pathways in the 
parietal pleura might be blocked by high bolus doses of such short fibers. While the 
relevance of direct injection of a high bolus dose of CNT into pleural or peritoneal cavity as 
surrogate for real-world inhalation exposures is questionable, this method may be 
considered as a proof-of-principle, which needs to be confirmed by realistic inhalation 
exposures.
Agglomeration/Aggregation
The International Organization for Standardization (ISO 2009) defined agglomeration as a 
collection of weakly bound (e.g., van der Waals forces) particles where the resulting surface 
area is similar to the sum of the surface areas of the individual components. Aggregation is 
defined as strongly bound or fused particles where the resulting external surface area may be 
significantly smaller than the sum of the individual surface areas (CEN ISO/TS 27687 2008; 
Jiang, Oberdörster, and Biswas 2009). Agglomeration and/or aggregation of CNT and CNF 
may have important implications for the biodistribution and toxicity of these materials, since 
they may be strongly influenced by the physicochemical properties of the agglomerate 
masses, in addition to the properties of the individual singlets that comprise the 
agglomerates. For example, the 12-d inhalation study by Mercer et al. (2013b) using highly 
agglomerated MWCNT aerosols exhibiting a wide range of agglomerated structures 
revealed a significant increase of singlet MWCNT in lymph nodes and extrapulmonary 
secondary organs, which indicated preferential translocation of MWCNT as singlets, due to 
either a slow process of deagglomeration of agglomerates deposited in the lung, or—if the 
agglomerate structure is kept intact—a slow translocation of MWCNT that were initially 
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deposited as singlets. The former scenario is more likely, given the low number of 
individual singlet MWCNT that were present in the aerosol.
Deposition of agglomerated MWCNT aerosols in the alveolar region of the lung and 
subsequent phagocytosis by alveolar macrophages may result in a high burden when 
expressed as volume. This volumetric load—if exceeding a threshold defined as lung 
particle overload (Morrow 1988)—results in an impairment of alveolar macrophage 
clearance function as suggested by Pauluhn (2010). If significant aggregation is present, 
deaggregation and release of singlet MWCNT in the lung is not likely. The presence of 
aggregation or agglomeration may affect the surface area of the MWCNT bundle, a dose 
metric that was suggested as more appropriate to be used when comparing effects—
including those associated with lung particle overload—of a wide range of different particle 
sizes from nano to micro (Oberdörster et al. 1994b; Tran et al. 2000a; Stoeger et al. 2006). If 
particle surface area is used as the dose metric, the slightly lower surface area of aggregated 
versus agglomerated structures needs to be considered as defined earlier.
Surface Properties
Surface properties of nanomaterials are important determinants of biological/toxicological 
activity. For example, surface charge may affect cellular uptake, and because it is the surface 
of poorly (in vivo) soluble materials that interacts with the organism, surface area (cm2/g 
material) as dose metric has been widely applied in nanoparticle toxicology. Yet this metric 
is often misunderstood by assuming that all nanomaterials fit on a common dose-response 
relationship if specific surface of each material is used as metric. Rather, the surface area 
concept implies that expressing an effect—observed in vitro or in vivo—as a function of 
surface area of poorly soluble materials provides a more meaningful toxicological dose 
metric for hazard ranking than using mass or number of the tested nanomaterial (Donaldson, 
Beswick, and Gilmour 1996; Tran et al. 2000b; Oberdörster, Oberdörster, and Oberdörster 
2005a). If the only difference is the particle size, with all other properties of a nanomaterial 
being the same, a common surface area dose-response relationship can be established for 
this material. Of interest in this regard, the fibrotic potency of SWCNT > MWCNT ≫ CNF 
correlates with their increasing specific surface areas (Murray et al. 2012; Mercer et al. 
2011). An interesting finding supporting the surface area concept is a study by Timbrell et 
al. (1988) demonstrating that the lung fibrosis score of asbestos in miners correlated best 
with the retained asbestos fibers in lung tissue.
Solubility (static in vitro systems) and dissolution (dynamic in vivo system) are important 
determinants of toxicity of nanomaterials in general (Utembe et al., 2015), but solubility/
dissolution are not critical for poorly soluble CNT/CNF. The surface area dose metric 
concept for particles is different from soluble chemicals, where the dissolved mass is the 
appropriate dose metric. An expansion of the surface area concept is to express the maximal 
effect induced by each of a collection of different nanomaterials as effect per unit of their 
surface area derived from the steepest section of their dose-response relationships. This way 
the degree of the effect-inducing potential of each nanomaterial can be compared and ranked 
against each other on the basis of surface reactivity. The surface area normalized maximum 
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responses (per cm2) of different nanomaterials then may reflect their different hazard 
potential for purposes of hazard ranking (Rushton et al. 2010; Duffin et al. 2007).
The plausibility of the surface area concept is supported by findings that surface properties 
determine effects upon contact with cells, receptors, organelles. Thus, Sager et al. (2014) 
found that altering surface properties of MWCNT resulted in different effects and 
bioactivity profiles in a mouse model. The surface area dose metric concept is also likely to 
apply to the fibrous structure of CNT and CNF; however, when present as straight single 
structures, length and diameter also may need to be considered as determinants of their 
biological/toxicological effects, based on the three-dimensional (3D) paradigm that is well 
known from asbestos and glass fiber toxicology (Broaddus et al. 2011), but that is unlikely 
to be applicable for highly tangled/agglomerated CNT.
Ideally, the bioavailable or effective surface area should be the metric for defining surface 
reactivity (response per unit surface area). The gas (mostly nitrogen) adsorption method 
after Brunauer, Emmett, and Teller (BET) (Brunauer, Emmett, and Teller 1938) is generally 
used to determine specific surface area, which, however, needs to be considered only as a 
surrogate for a biologically available surface, whose real definition is still elusive. 
Donaldson et al. (2013) noted the central importance of a biologically effective dose (BED) 
in toxicology, which drives toxic responses and includes particle surface area as one metric. 
Peigney et al. (2001) developed a mathematical model to estimate the surface area of 
bundles of parallel CNT by accounting for the void spaces and also the number of layers in 
MWCNT. Evidence indicated that the calculated values are in good agreement with 
measured data by BET. Given that CNT agglomerates do not usually consist of straight, 
well-aligned parallel tubes, these theoretical calculations are—like BET—not providing 
information on bioavailable surface area.
Surface modification, for example, carboxylation, might affect biopersistence. 
Carboxylation of SWCNT and MWCNT makes them more vulnerable to oxidative 
destruction by peroxidases, which reduces their biopersistence significantly and may point 
to new possibilities to produce less reactive CNT through surface modifications (Zhao, 
Allen, and Star 2011; Kotchey et al. 2013). Carboxylation also makes the CNT more 
hydrophilic and less agglomerated. Carboxylation may decrease the ability of these 
nanoparticles to enter epithelial cells and cross cell membranes, enter the alveolar 
interstitium, and produce fibrosis (Wang et al. 2011; Sager et al. 2014). The ROS-inducing 
potential of CNT expressed per unit surface area may also be determined as a measure to 
categorize CNT and CNF based on their surface reactivity. Cell-free assays and electron 
spin resonance (ESR) spectroscopy were shown to be effective methods to assess this 
property (Rushton et al. 2010; Tsuruoka et al. 2013). In contrast to raw CNT, CNT purified 
to remove catalytic metals do not generate high levels of ROS in cell-free systems (Kagan et 
al. 2006).
Other surface properties and modification, like zeta potential, electrostatic charge, coatings, 
and defects, may also significantly influence their biological/toxicological responses 
(Fenoglio et al. 2008; Shvedova et al. 2005; Tabet et al. 2011; Li et al. 2013; Salvador-
Morales et al. 2008). Indeed, Li et al. (2013) observed that MWCNT functionalized with 
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polyetherimide, which resulted in a strong positive surface charge, were more fibrogenic 
than bare MWCNT after aspiration in a mouse model. In addition, surface charge influences 
the agglomeraton state of CNT/CNF, which impacts their aerodynamic behavior when 
aersolized.
Impurities
Impurities that might affect pulmonary toxicity of CNT and CNF may be present and fall 
into three classes (Donaldson et al. 2006): support material, organics, and metals. Support 
material includes aluminates, silicates, and magnesium oxide. Residual organics include 
amorphous particles, or microstructured particles such as graphite sheets, which might 
arrange into carbon nanofibers or spheres. Little toxicity information is available that 
correlates adverse pulmonary effects with impurity amounts of either support material or 
residual organics. The most commonly used metals in CNT synthesis include Co, Fe, Ni, 
and Mo. CNT may be processed to remove most of the metal catalysts, such as those 
encapsulated in layers of amorphous soot or graphite.
Transition metal complexes and free Fe and Ni are known catalysts of biological free radical 
reactions. Therefore, where metal content was attributed to effects seen, correlations need to 
be considered in light of metal bioavailability. The effects of Fe and Ni catalysts on the 
pulmonary toxicity responses of CNT in three studies were recently reviewed by NIOSH 
(2013). Generally, higher Fe contents up to 18% were not associated with a higher lung 
response (Shvedova et al. 2008; Mercer et al. 2008), suggesting low bioavailability. In 
contrast, bioavailability of a high Ni- content affected the outcome granuloma formation 
(Lam et al. 2004). Bioavailability of metal impurities is a key determinant, as is potential 
contamination with endotoxin (lipopolysaccharide, LPS) which needs to be carefully tested 
(Esch et al. 2010).
Density
The relative density or specific gravity of nanomaterials is often regarded as being of little or 
no importance for interpretation of biological/toxicological effects. However, material 
density and bulk density need to be considered because inhalation is the main route of 
human exposure to CNT and CNF, and aerosol density is an important property to predict 
and understand their aerodynamic behavior and deposition fractions throughout the 
respiratory tract (Park et al. 2004). Further, because (1) cellular uptake of deposited 
materials, in particular by macrophages, results in a volumetric loading that was suggested 
to impair cell function if exceeding approximately 6% of the normal cell volume (Morrow 
1988), and (2) volume and density are highly correlated, data on material density and bulk 
density need to be included in a listing of physicochemical properties for CNT/CNF 
characterization.
Material density of nanomaterials is specifically important for aerosols consisting of singlet 
particles in the aerodynamic size range, that is, above approximately 0.3 µm. In contrast, for 
singlet nanoparticles below 100 nm in the aerosol the main mechanism for their deposition 
in the respiratory tract is by diffusion, for which particle density does not play a role. 
Because airborne nanomaterials rarely occur as singlets, the aerodynamic behavior of their 
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larger agglomerate sizes is determined by the effective density of the agglomerates. 
Difficulties in determining the effective aerosol density were described for regular particles 
(Park et al. 2004; Ku et al. 2007; Liu, Ma, and Zachariah 2012; Miller et al. 2013), but 
solutions have not yet been proposed for bundles/agglomerates of CNT and CNF aerosols. 
To overcome this problem, gas pycnometry was used to determine bulk density of bundled 
MWCNT (Pauluhn and Rosenbruch 2015) using the method of ISO 15901–1 (ISO 2005a). 
Wang et al. (2015) derived an expression for the effective density based on fractal-like 
structure of CNT and fit the equation to measured mass and mobility diameter to obtain 
values for effective density as a function of mobility or outer diameter of CNT 
agglomerates. There is limited applicability of the findings to the respiratory tract because 
calculations were based on CNT transport in an electric field alone. Extension of this model 
to other external forces, such as inertia and gravity, is not justified and requires parallel 
studies. Bulk density may also be assessed by pouring the agglomerated or aggregated CNT 
or CNF into a graduated cylinder and measuring volume and weight (DIN EN 725–9 2006–
05(E) 2006). Depending on conditions of undisturbed pouring (poured density) versus 
tapping the cylinder (tapping density), different values may occur. However, it needs yet to 
be determined whether the results approximate the effective aerosol density when using the 
poured density, whereas the tapping density may approximate the somewhat higher density 
present after uptake into cells for deriving the volumetric burden in macrophages. Thus, 
validated methods to measure aerosol densities of CNT still await general acceptance.
Additional Physicochemical Properties
Other physicochemical parameters of CNT/CNF may influence biological/toxicological 
responses, yet respective information and convincing data are not available. These include 
chirality of MWCNT, their tip configuration, crystallinity, and fiber stiffness, strength, and 
hardness. An important parameter may also be the degree of oxidation, which is rarely 
reported. New findings may reveal other relevant properties. For example, what is the 
biological significance of the recent discovery of high-speed pulse-like water movement 
through CNT, as reported by Sisan and Lichter (2014), using numerical simulations of 
single-file water flow?
Summary
In general, pulmonary exposure of rats or mice by IT instillation, pharyngeal aspiration, or 
inhalation of SWCNT or MWCNT and CNF results in transient inflammation and lung 
damage. Granulomatous lesions and interstitial fibrosis, which are of rapid onset and 
persistent in nature, have also been a common occurrence. Benchmark dose analysis 
(NIOSH 2013) noted no striking differences in responsiveness to CNT between rat and 
mouse models. Indeed, inhalation exposure of mice or rats to the same type of CNT 
(Mitsui-7 MWCNT) resulted in similar responses, that is, pulmonary inflammation, 
granulomas, interstitial fibrosis, and translocation of MWCNT to the pleura (Mercer et al. 
2013a; 2013b; Kasai et al. 2015). The degree of agglomeration does affect deposition site 
and response. Large agglomerates tend to deposit more centrally at the terminal bronchioles 
and proximal alveoli and induce a granulomatous response, while more dispersed structures 
may deposit more peripherally in distal alveoli and produce interstitial fibrosis. The lung 
most likely might be exposed to more dispersed CNT and CNF structures by inhalation than 
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by bolus-type exposure to a suspension of CNT/CNF. When this is the case, the response to 
short-term inhalation may differ from that of the same lung burden given as a bolus dose. 
Thus far, reported data suggest that quantitative differences in bioactivity between different 
types of CNT are likely. For example, on an equal mass basis, SWCNT appear to be more 
potent than MWCNT in producing alveolar interstitial fibrosis (Mercer et al. 2011). Limited 
data available for CNF suggests that the fibrotic potency of CNF is less than that of CNT 
(Murray et al. 2012). Mercer et al. (2011) proposed that specific surface area, dimensions, or 
hydrophobicity correlates with the rate of migration of fibrous nanomaterials to the 
interstitium. However, further investigation is required to resolve this issue.
The influence of manufacturing methods and surface modifications on physical–chemical 
properties of CNT/CNF needs to be considered when analyzing the correlation between 
these properties and toxicity. Understanding these correlations may help predict potential 
toxicities and also for identifying data gaps and research needs to be addressed in future 
studies.
CONSIDERATIONS AND CONCEPTS FOR REALISTIC RODENT 
INHALATION
Ideally, human exposure to CNT and CNF needs to be simulated when performing 
inhalation studies in rodents, not only to identify a potential hazard that is associated with 
such exposure but also to generate data that can be used for risk assessment. Thus, serious 
efforts need to be undertaken to obtain knowledge about exposure concentrations, airborne 
particle size, and size distribution, particularly at the sites of manufacture but also along the 
life cycle of CNT and CNF (packaging, distribution, incorporation into products, 
application, disposal), for potential exposure of workers and consumers. Such data are 
important for generation of an equivalent exposure atmosphere for rodents, taking into 
consideration differences between humans and rodents with respect to inhalability and 
respirability (see Inhalable, Thoracic, and Respirable CNT Fractions subsection). Generation 
of appropriately realistic exposure conditions is critical for purposes of dosimetric 
extrapolation and for risk assessment.
Available Exposure Data
The first available datum concerning airborne levels of CNT in a workplace was reported by 
Maynard et al. (2004). This study evaluated aerosolization of SWCNT in a small lab setting 
that simulated a workplace environment. Results indicated that SWCNT may be aerosolized 
with sufficient agitation. Estimates of the airborne concentration of SWCNT from personal 
air samples suggested that workplace respirable dust concentrations were lower than 53 
µg/m3. Evaluation of activities in a lab handling MWCNT reported significant aerosolization 
during weighing, transferring, and sonication (Johnson et al. 2010). Particle counts over the 
size range of 10–1000 nm were 1,576 particles/ml during weighing and 2776 particles/ml 
during sonication, with CNT structures generated during sonication being less agglomerated 
than those produced during weighing. Han et al. (2008) measured total airborne dust levels 
in a lab producing MWCNT in Korea. Processes such as weighing, blending and spraying 
produced airborne dust levels as high as 400 µg/m3. However, not all these particles were 
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MWCNT, and the MWCNT structures generated varied from agglomerates to more 
dispersed individual fibers. Admixture of background aerosol also needs to be considered. 
Lee et al. (2010) recently monitored workplace total dust levels at seven MWCNT facilities 
using personal samplers, area samplers, and real-time monitoring by SMPS, dust monitor 
and aethalometer. Particle generation was significant during oven opening, catalyst 
preparation, gel spraying, and preparation and sonication of MWCNT. The highest total 
particle concentration was 320 µg/m3 with a mean 106 µg/m3, with number concentrations 
from approximately 7000 to 75,000 per cubic centimeter. Diameters depended on 
manufacturing process, with mode diameters ranging from 20 to 30 nm for catalyst 
preparation and from 120 to 300 nm for ultrasonic dispersion. It should be noted that only a 
fraction of these airborne particle were MWCNT, with metal nanoparticles being a 
significant contributor to the total dust aerosolized in these workplaces.
It should be anticipated that within groups of CNT, for example, MWCNT, displaying 
significant differences between different types of MWCNT with regard to their physical 
(tangles, agglomerates) and chemical (contaminants, surface chemistry) characteristics, at 
least quantitative differences of responses are likely. Examples of response differences are 
apparent from the 13-wk inhalation studies of Pauluhn (2010) and Kasai et al. (2015). The 
latter study, using a more dispersed MWCNT aerosol, reported CNT-specific toxicity. In 
contrast, the first study, using approximately 3-µm agglomerates, attributed pulmonary 
responses to a nonspecific overload mechanism. Surface functionalization may also affect 
the biological potency of MWCNT. Indeed, Carrero-Sánchez et al. (2006) showed that 
nitrogen-doped MWCNT given by different routes of administration to mice produced 
significantly less toxicity than pure MWCNT. In other studies, the biopersistence of 
carboxylated SWCNT and MWCNT was significantly reduced by biodegradation via 
peroxidases, as determined in vitro and in vivo, which reduced inflammatory potential 
(Allen et al. 2008; Liu, Hurt, and Kane 2010a; Kotchey et al. 2013).
Han et al. (2008) measured size distributions of airborne MWCNT in a research facility and 
found a majority of non-fibrous particles and CNT agglomerates of different sizes with few 
single fibers (Figure 1a). Other measurements in commercial and research facilities 
confirmed that only a few single fibers were found, with the majority of the airborne 
structures being agglomerates/clusters of different sizes (Tsai et al. 2009; Methner et al. 
2010) as illustrated in Figure 1b.
Less information is available for CNF exposure measurements. Measurements by Birch et 
al. (2011), Evans et al. (2010), and Dahm et al. (2012; 2013) showed varying airborne 
concentrations, particle shapes, and aerodynamic sizes, depending on the processing site 
within a manufacturing facility. Similar to the findings with CNT, bundled and entangled 
structures were mostly found (Figure 2), as well as nonfibrous structures. Maximum 
concentrations due to uncontrolled transfer and bagging reach 1.1 mg/m3 (Evans et al. 
2010); the dominant mode by particle number of CNF was between 200 and 250 nm for 
both aerodynamic and mobility equivalent diameters, indicating an effective density close to 
unity. Depending on the purification process, significant concentrations of polycyclic 
aromatic hydrocarbons (PAH) and Fe-rich soot were detected in the CNF aerosol, which 
needs to be considered as causative/contributory factors for potential toxicity. There is an 
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urgent need to obtain more information on the characteristics of CNT and CNF in workplace 
air. The suggestion that delivery of CNT and CNF to the respiratory tract of experimental 
animals, by inhalation or by instillation/aspiration, needs to be done with well-dispersed 
materials is not supported by presently published occupational exposure data, which 
uniformly demonstrate highly agglomerated structures in the airborne state (Methner et al. 
2010; Tsai et al. 2009; Han et al. 2008). It may be possible that one aerosol generation 
system is equally well suited for appropriate (workplace representative) aerosolization of all 
different types of CNT and CNF, but this still needs to be verified.
Workplace Monitoring
ISO/TR12885 (ISO 2008) lists and discusses several air monitoring instruments and 
techniques for monitoring nano-aerosol exposure at the workplace by airborne mass, 
number, and size distribution, as discussed later. However, whereas for spherical particles 
the scanning mobility particle sizer (SMPS) and Differential Mobility Analysing System 
(DMAS) provide valuable information of their airborne size distribution as mobility 
diameter of the charged particles, measurements of CNT/CNF of complex structures with 
these devices are hard to interpret. However, the following methods are well suited for 
measuring airborne CNT/CNF size distribution.
The micro-orifice uniform deposition impactor (MOUDI) and nano-MOUDI measure 
aerodynamic diameter, down to 10 nm (at low pressure stages). This measure for 
CNT/CNF may be used as input into the predictive multiple path particle dosimetry 
(MPPD) model for rats and humans if data for the density of the airborne structures are 
available. The advantage of the nano-MOUDI is that airborne particle structures of 
nanosizes are determined based on their aerodynamic deposition behavior achieved with 
a low-pressure system. Particle morphology may then be examined (electron) 
microscopically on the individual stages. Further development into an electrical low 
pressure impactor (ELPI) was achieved by adding a corona charging unit before the 
inlet, so that aerodynamically separated particles can be measured by multichannel 
electrometers in real time based on their charge (Keskinen, Pietarinen, and Lehtimäki 
1992).
Filter samples for gravimetric measurement (µg/m3): Care needs to be taken to adjust 
filter to same humidity before and after sampling to get net weight.
TEM/SEM: With the use of electrostatic precipitator and filter samples length and 
diameter distribution, agglomeration state/tangles can be determined.
While the instruments just described provide accurate measurements for aerosol size 
distribution, caution needs to be observed when measuring CNT and CNF. A condensation 
nuclei counter (CNC)/condensation particle counter (CPC) may safely be used to count the 
number of CNT and CNF in the air because there is no size or shape effect involved in the 
counting process. The differential mobility analyzer (DMA) and SMPS separate 
submicrometer-sized particles based on their mobility in an electric field. It is conceivable 
that CNT and CNF of different shapes might attain the same mobility and be separated 
together thus obscuring size classification. The same limitation holds for the aerodynamic 
particle sizer (APS), which is based on the time of flight of particles. Aerodynamic drag and 
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torque of CNT depend on the shape and orientation of CNT and CNF in the air. Different 
size and shape of CNT and CNF may yield similar drag and torque forces under certain flow 
conditions and hence be grouped together by the instrument. Separation of CNT and CNF in 
a MOUDI or nano-MOUDI impactor is based on their inertial forces, which is a function of 
their orientation in the air. Thus, a shape correction needs to be applied when using these 
instruments. The most reliable technique for size measurements of CNT and CNF is TEM/
SEM, which provides both size and shape. However, electron microscope (EM) sizing is 
time-consuming, provides no real-time measurement, and the measured dimensions (i.e., 
CMD and geometric standard deviation [GSD]) need to be converted to equivalent 
diameters if CNT and CNF deposition is going to be calculated. This will be a most difficult 
task because the density of the aerosol particles has to be known. Given the wide range of 
structures/shapes of aerosolized CNT (Figures 1 and 2), it becomes apparent that it is not the 
density of carbon per se that is important as much as the effective density, which may be 
similar to the packing density. Knowledge regarding the actual density of the CNT aerosol 
in the workplace air may also be needed for using nano-MOUDI results (MMAD and GSD) 
as input values for estimating/predicting deposition in rodent and human lung with the 
MPPD model. While it is presently not possible to integrate a Nano-MOUDI into a personal 
sampler, number concentration (CNC/CPC) and mass concentration of airborne CNT might 
be built into such personal sampler. Asbach et al. (2012) and Meier, Clark, and Riediker 
(2013) tested small samplers that might quality for use as personal samplers.
Inhalable, Thoracic, and Respirable CNT and CNF Fractions
When evaluating the potential toxic and/or carcinogenic effect of CNT/CNF in inhalation 
studies in lab animals or by in vitro testing via aerosol exposure of primary cells or cell 
lines, ideally comparable or identical exposure to human scenarios are required to deliver 
similar doses to target sites or cells of the respiratory tract. In essence, an equivalent human 
exposure concentration (HEC) needs to be defined based on metrics of exposure. 
Calculations of a HEC account for interspecies differences in inhalability, respirability, and 
lung deposition of CNT/CNF. CNT/CNF inhalability, or the inhalable fraction, is defined as 
the fraction of airborne CNT/CNF that penetrates the extrathoracic airways on inhalation. 
Similarly, the thoracic fraction is defined as the fraction of airborne CNT/CNF that travels 
through the head airways and reach the lung. Finally, the respirable fraction is the portion of 
airborne particles that reaches the alveolar region of the lung. The American Conference of 
Governmental Industrial Hygienists (ACGIH 2010) established sampling criteria to define 
these three fractions in terms of induction of hazard in the three regions of the respiratory 
tract and respective defined airborne particle sizes.
Calculation of CNT/CNF inhalability is the first step in ensuring delivering compatible 
doses among exposure settings. While CNT/CNF below 10 µm aerodynamic sizes are 
completely inhalable in humans, only a fraction is inhalable in small animals. In addition, 
losses of CNT/CNF in the extrathoracic passages of each species are different, which 
combined with inhalability differences results in different delivered doses (thoracic and 
respirable fractions) of CNT/CNF to the lower respiratory tract. Therefore, CNT/CNF 
inhalable, thoracic, and respirable fractions need to be examined and accounted for when 
extrapolating results of animal inhalation studies to humans based on the delivered dose of 
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CNT/CNF, or when using known human exposure conditions to design realistic rodent 
inhalation investigations.
There is a wealth of published lab data on penetration of particles into the lungs of humans 
and animals (Aitken et al. 1999; Asgharian, Kelly, and Tewksbury 2003; Berry and Froude 
1989; Breysse and Swift 1990; Hinds, Kennedy, and Tatyan 1998; Hsu and Swift 1999; 
Kennedy and Hinds 2002). In addition, there are recent developments of semiempirical, 
predictive models of particle inhalability in humans and lab animals (Ménache, Miller, and 
Raabe 1995; Brown 2005; Asgharian, Kelly, and Tewksbury 2003). However, there is a 
major data gap on inhalability and respirability of nonspherical and irregularly shaped 
particles such as CNT and CNF. Because of their asymmetric geometry, the orientation of 
CNT/CNF affects penetration and deposition during inhalation in the lungs. Hence, 
inhalability and respirability models for CNT and CNF need to account for differences in 
size characteristics and transport properties as compared to spherical particles. A more 
detailed discussion of inhalable, thoracic, and respirable fractions is provided in Appendix 
A.
Interspecies Extrapolation
Inhalation studies are conducted in lab animals to observe various biological endpoints. 
Interpretations of the findings include extrapolation to human exposure scenarios for 
purposes of human risk assessment. Conversely, if available, human exposure data can be 
extrapolated to animal exposures for the design of inhalation studies to examine biological/
toxicological responses. Thus, interspecies data extrapolation based on various dose metrics 
of exposure is needed to either determine a no-observed-adverse-effect level (NOAEL) as 
input for risk assessment models, or to select realistic exposure levels for animal studies. 
While dosimetry of extrapolation has often been based on the inhaled dose (inhalable, 
thoracic, and respirable fractions), it needs to be based upon the deposited dose because the 
biological outcome is most closely associated with the deposited and not inhaled dose. This 
is particularly important for purposes of extrapolation when deposited and retained taking 
into account clearance doses are to be compared between humans and rodents. Figure 3 
illustrates a conceptual approach of dosimetric interspecies extrapolation. More information 
on extrapolation modeling is provided in Appendix B.
Types of Respiratory-Tract Exposures
Rats or mice might be exposed to CNT/CNF by IT instillation, (Warheit et al. 2004), 
pharyngeal aspiration, (Porter et al. 2010), or inhalation (Shvedova et al. 2008) (Table 1). 
The major advantages of IT instillation or pharyngeal aspiration are that exposure is 
technically simple and inexpensive, requiring little specialized instrumentation, and the lung 
burden is estimated simply from mass of CNT/CNF delivered to the lungs by assuming that 
between 80 and 90% deposits in the alveolar region (Mercer et al. 2010a). The major 
disadvantages of IT instillation and pharyngeal aspiration are nonuniform distribution of 
particles in the lung and the fact that lung burden is delivered as a bolus dose in a fraction of 
a second rather than gradually over time as with inhalation, that is, the dose rate is many 
orders of magnitude different. Both IT instillation and pharyngeal aspiration require that 
CNT/CNF be suspended in a biocompatible fluid. Therefore, agglomeration is an issue, with 
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micrometer-size agglomerates being common when CNT/CNF are suspended in phosphate-
buffered saline (PBS; pH 7.4). To improve dispersion of CNT/CNF, 5–10% serum, 1% 
Pluronic, or 1% Tween 80 has been employed. However, as shown by Dutta et al. (2007) 
and Haniu et al. (2011), the use of such dispersants significantly affects cellular uptake and 
masks potential effects of CNT. Porter et al. (2008) argued that CNT/CNF would interact 
with alveolar lining fluid when deposited in the respiratory region of the lung. Therefore, 
they used a dispersion medium that contained 0.6 mg/ml species-specific serum albumin and 
0.01 mg/ml disaturated phosphatidyl choline (DSPC) in PBS, that is, albumin and DSPC 
levels found in the initial aliquot of rodent BALF. This artificial diluted alveolar lining fluid 
was found to effectively disperse MWCNT, and data suggested that it did not appear to 
mask particle surface activity. However, Gasser et al. (2010) noted that precoating of 
MWCNT with lipids from lung surfactant altered the binding of plasma proteins on their 
surface. Thus, the potential impact of using dispersants when assessing nanomaterial toxicity 
has to be critically considered, since it affects interaction with cells and tissues. As with 
inhalation exposure, it is critical to qualitatively evaluate the structure size distribution by 
electron microscopy of CNT/CNF in suspensions delivered to the lung. The following 
sections focus on inhalation exposures as the physiologically most appropriate method for 
delivery of CNT/CNF to the respiratory tract.
Requirements for an Inhalation System
A critical component of acquiring scientific knowledge is the ability for findings from a 
given lab to be reproduced and extended by other labs. Therefore, simplicity, ease, and 
consistency of operation in maintaining a stable airborne concentration of CNT/CNF is an 
important goal in developing aerosol generation systems for CNT/CNF. McKinney, Chen, 
and Frazer (2009) reported the use of an acoustical generation system for the aerosolization 
of MWCNT. Automated computer control allowed generation of aerosols of stable 
concentrations and particle size distribution with little operator manipulation required. In 
contrast, Baron et al. (2008) reported a generation system for SWCNT that was capable of 
generating a stable output, using a knife mill generator, but required continuous adjustment 
by a well-trained technician. This difference in complexity of operation of generation 
systems reflects the fact that SWCNT agglomerate more avidly than MWCNT. In general, 
the greater the diameter of the CNT/CNF, the straighter and less curled the fibers, and the 
easier they are to disperse. Because this principle also applies to workplace exposures, it is 
important to produce realistic CNT/CNF aerosols with appropriate generation systems.
Inhalation exposures to CNT/CNF using a dry powder aerosolization system is the preferred 
method that best simulates human exposures under real-world conditions. Generating an 
aerosol from a liquid suspension might be problematic, as dispersants may have to be added 
to prevent excessive clumping. Sager et al. (2007) compared the efficiency of dispersing 
nanoparticles (NP) in PBS with and without BALF or in Dipalmitoylphosphatidylcholine 
(DPPC) as the major constituent of the alveolar lining fluid, with and without albumin. 
Based on their finding that DPPC + albumin in PBS was effective, although still less than 
BALF in PBS, for use during in vivo and in vitro studies, Gasser et al. (2012) confirmed that 
using a commercially available lung surfactant to coat MWCNT needs to be considered for 
in vitro studies. Schleh et al. (2013) agreed on the importance of simulating in vivo 
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conditions by coating NP with pulmonary surfactant for in vitro investigations. With regard 
to surfactant precoating of NP to be delivered to the respiratory tract in suspension, 
inhalation, or instillation, it has to be considered that adsorption of proteins/lipids is likely to 
be different from that on pristine particles (Dutta et al. 2007; Haniu et al. 2011; Gasser et al. 
2010). Thus, inhalation studies need to aim to mimic real-world conditions by generating 
aerosols in their original state as would be experienced by humans (Fubini, Ghiazza, and 
Fenoglio 2010). As discussed earlier, since NP aerosols—including CNT/CNF—are present 
in the workplace as agglomerates, there is no need to add dispersants when dosing the 
respiratory tract by inhalation.
As pointed out earlier, it is important to take into consideration inhalability and respirability 
of rodents versus humans when reproducing real-world human exposure conditions for 
experimental exposures of rodents. This may be difficult in cases where long CNT and 
aerodynamically larger agglomerates are present in the workplace aerosol that are respirable 
by humans depositing in human pulmonary region, but are less or not respirable by rodents. 
Enrichment of the aerosol for such longer CNT might be considered to achieve comparable 
lung burdens in rodents. Conversely, depending on the CNT aerosol generation system, 
large rodent nonrespirable agglomerates may be present in the experimental aerosol but are 
not found at the workplace. These may be removed by appropriate preseparators (cyclone; 
impactor) to avoid exposure to high mass concentrations (large agglomerates represent most 
of the aerosol mass) that result in unrealistic high nasal deposits and irrelevant exposure-
dose-response data. Use of grinding and milling may introduce surface artifacts and 
contaminants, which need to be controlled carefully. A prerequisite for establishing 
exposure-dose-response relationships and for dosimetric extrapolation modeling is the 
availability of reproducible methods to accurately (1) characterize and monitor exposure 
atmosphere and (2) determine deposited and retained CNT/CNF burdens in the respiratory 
tract and in extrapulmonary tissues/organs for necessary biokinetic information.
Analysis of Exposure-Dose-Response Relationships
Exposure-dose-response relationships established in rodent inhalation studies as a basis for 
deriving an HEC may be expressed with different dose metrics, either as exposure-response 
or as dose-response relationships. The latter is either based on deposited dose or, preferably, 
on the retained dose in longer term inhalation studies (Figure 3). Comparing these 
relationships between several materials using different dose metrics may provide 
information about the relative hazard ranking of these materials. Figure 4 compares 
exposure-response and dose-response data of subchronic rat inhalation studies with 
MWCNT (Pauluhn 2010; Ma-Hock et al. 2009a; Kasai et al. 2015), carbon black (CB) 
(Elder et al. 2005), and CNF (DeLorme et al. 2012). The subchronic CB study was added as 
a comparison to a well-studied carbon nanomaterial, which is generally viewed as a poorly 
soluble particle (PSP) of low cytotoxicity that has been used in a number of rodent 
inhalation studies related to the lung particle overload phenomenon (Morrow 1988). In order 
to compare the responses to these different materials, the same effect endpoints were 
selected. Increased lung weight was a common endpoint in all five studies for which 
exposure-response relationships can be established.
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Another sensitive quantitative endpoint, pulmonary inflammation as determined by the 
increase of polymorphonuclear leukocytes (PMN), was also used to compare exposure-
response relationships, although for only four of the subchronic inhalation studies; this 
endpoint was not included in the MWCNT study by Ma-Hock et al. (2009a). Of greater 
relevance, however, is a comparison of dose-response relationships, given that deposited and 
retained doses differ significantly between different investigations, because they depend on 
the size distributions of the inhaled aerosol. Two of the subchronic rat inhalation studies, 
Ma-Hock et al. (2009a) and DeLorme et al. (2012), did not determine retained lung burden, 
so approximate lung burdens have to be estimated based on aerosol sizes as input to the 
MPPD deposition model (Figure 4b).
Figure 4a shows that exposure-response correlations for the three MWCNT based on 
increase in lung weight are steeper than those for CB and CNF. Selection of another 
sensitive endpoint of particle-induced pulmonary inflammation, that is, increase of 
neutrophils in lung lavage after 3 mo of exposure, demonstrates the steepest dose-response 
for the two MWCNT, less for CB, and least for CNF. Results of only two MWCNT studies 
might be included in this plot because no lung lavage data are available from Ma-Hock et al. 
(2009a).
However, as stated earlier, due to differences in deposition and retention in the lung for 
different inhaled particulate compounds, the actual retained lung burden rather than inhaled 
airborne concentration is the preferred metric. Further, expressing the retained lung burden 
by different metrics of mass, surface area, or volume of the retained particles may provide 
some mechanistic insight. Figure 4b shows these relationships for the endpoint lung weight 
for all studies. As explained earlier, the retained lung burden data for Ma-Hock et al. 
(2009a) and DeLorme et al. (2012) were estimated. As shown in Figure 4, the metric 
retained particle surface area revealed that the dose-response curves for the three MWCNT 
and the CNF nanomaterials are considerably steeper compared to CB. In contrast, when 
retained doses are expressed as retained mass or retained volume (volume based on bulk, or 
packing densities), CNF and Mitsui-7 MWCNT were not markedly different from CB.
The example of these studies (Figure 4) indicates the importance of including measurement 
of lung burden as endpoint in inhalation studies. While exposure-response relationships 
provide valuable information about the response slope, it is only possible through the 
knowledge of the actual retained lung burden at different times during and after exposure to 
correlate directly a real dose with a measured response and to obtain information about 
retention and clearance kinetics. At a minimum, four animals per time point need to be 
scheduled for dosimetric analysis.
Multidose subchronic or chronic inhalation studies are designed to identify a no-observed-
adverse-effect level (NOAEL) or a lowest-observed-adverse-effect level (LOAEL). Because 
of the costs associated with a 2-yr chronic rat inhalation study, subchronic multidose 90-d 
studies are preferred (Bernstein et al. 2005). Shortening the exposure duration to 4 wk or 
even 5 d (Pauluhn 2009; Ma-Hock et al. 2009b) still needs to be validated as to the 
reliability of obtaining sufficient information regarding chronic toxicity in the primary organ 
of entry as well as secondary remote organs. Mechanisms both of toxicity and of adaptive 
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responses may not have fully developed at shorter exposure durations, such that—until 
further validation data become available—the present standard of a 90-d assay is thus 
preferred. In any case, it is mandatory to add a sufficiently long postexposure observation 
period such that persistence/resolution as well as retention/clearance kinetics in the primary 
and in secondary organs can be determined (Pauluhn 2009). Ideally, the observation period 
needs to approximate at least the normal pulmonary retention halftime (T1/2) of low-toxicity 
poorly soluble particles (PSP), which in the rat is about 60–80 d. This—in conjunction with 
toxicity endpoints—enables one to identify a potential hazard vis-à-vis other PSP.
Expressing retained lung burden of CNT/CNF with different metrics of mass or surface area 
or volume (Figure 4b) facilitates a comparison to a PSP such as CB based on the magnitude 
of an effect per unit of the dose (Rushton et al. 2010). Using the retained particle volume as 
metric for dose is based on Morrow’s hypothesis (1988) that the clearance function of 
alveolar macrophages becomes significantly impaired when the volume of phagocytized 
particles of a poorly soluble particle of low cytotoxicity exceeds 6% of the alveolar 
macrophage volume. With respect to MWCNT, Pauluhn (2009; 2010) suggested that the 
volume of the CNT/CNF tangles (assemblages) might be used to calculate the volumetric 
loading of the macrophages. Thus, not the material density of carbon but the much lower 
effective density of the assemblages needs to be considered. On the other hand, it was 
suggested that the particle surface area is the appropriate metric because it correlates better 
than particle volume with an effect on macrophage clearance function and with alveolar 
inflammatory response in studies involving nanomaterials (Oberdörster, Ferin, and Lehnert 
1994a; 1994b; Tran et al. 2000a). Applying the volumetric macrophage overload hypothesis 
assumes that nanomaterials in general act like PSP particles, whereas the particle surface 
area concept is based on the understanding that the reactivity (e.g., inflammatory potential) 
per unit of the material surface area is material dependent and used as an indicator for 
toxicity ranking (Rushton et al. 2010). As demonstrated in Figure 4b, retained nanomaterial 
surface area in the five 3-mo inhalation studies supports the surface area concept of particle 
dose metric.
Of interest in the context of applying dose metrics to evaluate the toxicity of fiber-shaped 
materials is a study by Timbrell et al. (1988) with asbestos: The exposure metric to 
characterize asbestos exposure is generally expressed as number of WHO-fibers per cubic 
centimeter, yet when Timbrell et al. (1988) correlated the severity of fibrosis in asbestos 
miners with the amount of asbestos fibers retained per unit weight of lung tissue, it turned 
out that surface area, but not number or mass, was the best dose metric (Figure 5). Surface 
area-associated reactivity of nano-sized particles was suggested as metric (Dick et al. 2003; 
Hsieh et al. 2012; Borm et al. 2006; Donaldson, Beswick, and Gilmour 1996). It needs to be 
realized, though, that surface area—generally measured by gas adsorption (BET)—needs to 
be viewed as a surrogate for a biologically active or available surface that is yet to be 
defined. As an example, the reactive oxygen specias (ROS)-inducing capacity per unit 
surface area of a particle may be considered (Rushton et al. 2010).
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Safety of Lab Personnel
Recommendations for engineering controls to protect lab staff working with nanomaterials 
have been provided by NIOSH (2012). The types of engineering controls recommended 
(local exhaust ventilation, chemical hoods, and glove boxes) depend on the state of the 
nanomaterial (free or bound in a matrix; dry or in a liquid) and the energetics of the lab 
process or activity. Personal protective equipment (PPE), including gloves, respirators, and 
protective clothing, is discussed in the NIOSH (2012) publication. It is also of interest to 
consider NIOSH (2013), which is more specific to CNT and CNF.
STRATEGY/CONCEPTS OF INHALATION TESTING FOR CNT/CNF TOXICITY
Objective
The goal is to assess pulmonary and systemic (secondary target organs) responses to inhaled 
CNT/CNF in acute and repeat (subchronic; chronic) rodent inhalation studies mimicking 
relevant exposure conditions of humans. The primary target is the respiratory tract, while 
secondary targets are extrapulmonary organs that are known or suspected to be affected by 
nanomaterial translocation from the primary portal-of-entry, including pleura (still part of 
pulmonary), cardiovascular, liver, spleen bone marrow, kidneys, central nervous system 
(CNS), fetus, other (reproductive organs).
In order to identify secondary target sites, biokinetic studies are essential, including 
retention, clearance, or accumulation of CNT in primary or secondary organs. For this, an 
appropriately sensitive label is needed to determine the disposition of inhaled material 
throughout the body, including elimination pathways. Caution needs to be exercised, since 
any label may alter the physicochemical properties and likely affect biodistribution. In 
addition, it is important that any label be stable and not dissociate/leach. For carbon-based 
aerosols, turbidity measurement of retained material in organs/tissue was used and found to 
yield reproducible results (Elder et al. 2005). However, sensitivity to low concentrations 
may be problematic, and NIOSH Method 5040 (NIOSH 2013) may be an appropriate 
alternative. Mercer et al. (2008) attached 10-nm gold NP or fluorescent quantum dots to 
SWCNT to determine their biodistribution following aspiration in mice. However, such 
labeling is not feasible for large amounts needed for inhalation exposures. Another method 
is slow thermal degradation and measurement of CO2 (Hyung et al. 2007; Peterson and 
Richards 1999; NIOSH Method 5040 with modifications given in CIB 65 [NIOSH 2013]; 
Watson, Chow, and Chen 2005). A modified thermal degradation method with increased 
sensitivity was presented specifically for analyzing CNT/CNF in biological samples. The 
key is a thorough two-step digestion of tissue to completely eliminate low levels of 
interfering tissue carbon, yet avoiding harsh treatment to keep CNT/CNF intact (Westerhoff, 
Doudrick, and Herckes 2012; Doudrick et al. 2013). A promising sensitive method is the use 
of a hybrid marker (Ohnishi et al. 2013). Suggestions to use specific metallic impurities 
embedded in the CNT to quantify their retention may be inaccurate due to possible leaching 
of such metals from CNT in vivo and interference from background levels in tissue. 
Ideally, 14C-labeled CNT may be used, but pose additional problems related to radio-safety 
issues, particularly when used as aerosol.
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When simulating human exposure conditions for designing appropriate CNT/CNF 
exposures, available human exposure data need to be adapted with regard to differences in 
respirability and inhalability between humans and rodents. Three concentrations, 
logarithmically spaced, are recommended, including expected/predicted human exposure 
levels. It is essential for performing risk assessment that at least one dose (maximum 
tolerated dose, MTD) gives a significant response. If human exposure data are not available, 
a worst-case scenario may be assumed by using a rat (rodent) respirable aerosol at several 
mg/m3 as highest concentration. A short-term (approximate 2–4 wk) pilot study is 
recommended as a range finder in order to estimate a maximal functionally tolerated dose 
(MFTD) and NOAEL for the longer-term study, and also to verify proper operation of the 
exposure system and obtain biokinetic data for identification of secondary organs and 
retained doses in these organs.
Methodology: Inhalation of CNT
Aerosolization of CNT/CNF from a dry powder is preferred, rather than from a liquid 
suspension, in order to simulate conditions of human exposure to pristine CNT/CNF. 
Aerosolizing hydrophobic CNT/CNF as an aqueous suspension requires the use of a 
dispersant, which would alter the surface of CNT/CNF and thereby potentially affect 
responses and biodistribution (Pauluhn and Rosenbruch 2015). This is particularly important 
if the goal is to test a specific CNT/CNF under the same conditions to which humans are 
exposed. A detailed physicochemical characterization of bulk and aerosolized material is 
desirable. Concerning the bulk CNT/CNF test material, Table 2 provides some guidance.
The CNT/CNF aerosol generated and delivered to the inhalation system requires special 
attention. A qualitative estimation of structure and size distribution may be determined by 
electron microscopic evaluation of filter samples taken from the inhalation chamber using 
47-mm polycarbonate filters at a sampling rate of 1 L/min. The filters are then analyzed by 
TEM or SEM to determine the range of CNT/CNF structures and agglomeration in the 
breathing zone of the exposed animals. Sampling artifacts on the filter have to be 
considered. CNT/CNF diameter and length may be quantified manually under electron 
microscopy, although it may be difficult depending on the degree of entanglement and 
presence of curved structures. Thus, it is currently not feasible to develop a number limit for 
CNT/CNF due to the absence of counting rules, similar to those for asbestos. Since 
CNT/CNF aerosols are a mixture of agglomerated structures containing various numbers of 
individual CNT/CNF, the issue is which structures are bioactive and need to be counted, and 
which are too agglomerated and are less bioactive and need not be counted. Are singlets 
more bioactive than large agglomerate? Do small agglomerates dissociate in the lung to 
single tubes? Is there an agglomerate size limit that is too large to dissociate? Until these 
questions are answered, development of meaningful counting rules for CNT/CNF is not 
possible.
Particle size distribution may be quantified using a micro-orifice uniform deposit impactor 
(MOUDI) and a nano-MOUDI, thus obtaining a mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD). However, as described earlier, 
appropriate correction factors need to be applied to account for the shape and orientation 
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effects of CNT/CNF in the airborne state. The particle count mode diameter might be 
determined by visual inspection of filters from the various stages of the MOUDI and nano-
MOUDI under a SEM, and if particles on all stages are counted then the count median 
diameter derived. However, this is a rather tedious process. Particle bounce from one stage 
to the next might be minimized by greasing alternate stages of the impactor. The airborne 
concentration of CNT/CNF generated within the exposure chamber may be assessed by 
gravimetric analysis of filter samples.
Impaction diameter for CNT/CNF can be established by correlating measured dimensions of 
CNT/CNF from filter samples to measurements at different stages of the impactor. Similar 
measurements in a diffusion battery and an elutriator are conducted to obtain equivalent 
diameters for diffusion and sedimentation. Alternatively, performing CNT/CNF aerosol size 
distribution with a nano-MOUDI and counting individual structures on each stage by 
TEM/SEM might be used to plot a count distribution and determine from this plot a count 
median aerodynamic diameter (CMAD) and GSD. Scanning mobility particle sizers (SMPS) 
or differential mobility analyzers (DMA) provide count median diameters (CMD) based on 
the electrical mobility properties of the electrically charged CNT/CNF. However, it is 
difficult to interpret the results, which are based on the electrical mobility of equivalently 
charged spherical particles. For purposes of using airborne size distribution to predict 
deposition in the rodent and human respiratory tract (see MPPD model) the MMAD and 
GSD obtained with the nano-MOUDI seem to be best suited for inertial losses, which occur 
in the respiratory tract.
ISO Standard 10808 (ISO 2010a) describes requirements and procedures for monitoring/
characterizing aerosolized NP during inhalation exposures. Number-based particle size 
distribution and mass concentration measurements are described. Four prerequisites for 
proper measurement of airborne particle number based size distribution should be fulfilled:
(1) The method used shall be able to monitor particle size distribution in a 
continuous manner during particle exposures with time resolution appropriate to 
checking the stability of particle size distribution and concentration. (2) The 
measurable range of particle sizes and concentrations in the animal’s breathing 
zone shall cover those of the nanoparticle aerosols exposed to the test system 
during the toxicity test. (3) Particle size and concentration measurements in the 
animal’s breathing zone should be accurate for nanoparticle toxicity testing, and 
can be validated by means such as calibration against appropriate reference 
standards (see ISO/IEC 17025: ISO 2005b). (4) The resolution of particle sizing 
shall be accurate and the range of particle sizes measured shall be sufficiently broad 
to permit conversion from number-based distribution to surface area-based or 
volume-based distribution. (OECD 2012)
These requirements in ISO 10808 are followed by a note that DMAS is the only currently 
available method that meets all the above requirements in the size range below 100 nm (see 
ISO 15900: ISO 2009). However, ISO 10808 also cautions with an important comment that 
“Estimation of particle size from DMAS measurements can result in significant error for 
non-spherical particles. Application of DMAS for non-spherical particles is not 
recommended.”
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With regard to measurement of airborne mass concentration, ISO 10808 stipulates that the 
method selected shall be accurate and sensitive, and defined by the limit of quantification. 
Suggested methods include hte beta attenuation monitor (BAM), tapered oscillating balance 
(TEOM), piezoelectric microbalance, filter gravimetric, and other methods based on 
chemical analysis of particles collected on filter media that meet requirements according to 
ISO/TR 27628 (ISO 2007). A note is added stating that “Mass concentration can be derived 
from number-based size distribution measurement data by making an assumption regarding 
particle density, particularly for spherical particles which may match bulk material density 
(Ku and LaMora, 2009). However, significant errors in calculated mass concentration may 
result if particle density is inaccurate or unknown. Derived mass concentration from 
number-based size distribution data should be accepted only when no other accepted 
methods meet the measuring requirements.” In addition, an important caveat also states that 
“Mass concentration estimation by DMAs (Differential Mobility Analyzer) based on particle 
size can produce error for non-spherical particles.” In case of highly agglomerated structures 
the effective density will be different from material density, as mentioned earlier.
Thus, an appropriate approach for characterization of CNT/CNF aerosols is the use of a 
nano-MOUDI for determining aerodynamic size distribution and a filter-based method 
(gravimetric, chemical) for exposure mass concentration. This would allow derivation of a 
mass-based exposure limit. Monitoring in real time the consistency of the aerosol 
concentration throughout the exposure is necessary and can be accomplished by a 
condensation particle counter (CPC), SMPS, or optical particle counter (e.g., Data-RAM). 
Although measurements would be best done in the animals’ breathing zone, the possibility 
of confounders from animal dander and/or bedding-generated dust needs to be considered, 
so the point of measurement may be selected at the entrance of the CNT/CNF aerosol into 
the inhalation chamber.
Types of Inhalation
Inhalation is considered the gold standard for dosing the respiratory tract. The major 
advantage of inhalation exposure is that it mimics human pulmonary exposure by 
distributing the inhaled material throughout the whole respiratory tract in a physiological 
way over time. It also provides a more even distribution of particles in the lung than bolus 
exposures to particles in suspension. Lastly, agglomeration is less of a problem with 
airborne CNT/CNF than when CNT/CNF are delivered as a suspension in biocompatible 
fluid; therefore, CNT structures and size distribution need to more closely mimic that found 
in workplace aerosols. Available measurements from workplaces show large diversity 
ranging from a few single CNT/CNF structures to mostly agglomerates/tangles, depending 
on the material (Maynard et al. 2009; Han et al. 2008; Tsai et al. 2009; Birch et al. 2011). 
The major disadvantages of inhalation exposure are that it requires specialized and costly 
instrumentation and technical expertise that are not universally available in research 
institutions. Inhalation also requires greater quantities of the test material than bolus 
exposure.
There are two types of inhalation exposure systems, nose-only and whole-body. Clearly, 
both modes of inhalation are superior to bolus-type exposures, as discussed earlier (Table 1). 
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OECD Guidelines seem to favor nose-only exposure, but leave the choice of the mode of 
exposure to the investigators, as stated in OECD GD 39 (OECD 2009b): “While nose-only 
is the preferred mode of exposure, special objectives of the study may give preference to the 
whole-body mode of exposure.” The guidelines also state: “When an animal is confined to a 
restraining tube the observation of its behavior and physical condition is somewhat 
restricted.”
Several studies have addressed pros and cons of either mode of exposure. Phalen (2009) 
summarized specific advantages for whole-body exposures, such as minimal restraint, 
controllable environment, and better suitability for chronic studies, and for nose-only 
exposures, less unintentional exposures of extra-respiratory-tract organs (skin, eyes) and 
lower amounts of material to be aerosolized. In terms of disadvantages, Phalen (2009) 
pointed out the unavoidable additional routes of exposures (skin, eyes, oral), the inefficient 
use of material and higher costs for whole-body exposures versus discomforts due to heat 
buildup, restraint stress, and the need for extra handling (more labor intensive) associated 
with nose-only exposures. However, Phalen (2009) also suggested that well-designed nose-
only systems permit low stress exposure. For example, acclimatization of rodents prior to 
nose-only exposure reduces stress; however, as determined by Narciso et al. (2003), full 
adaptation to restraint requires 14 d of fixed-duration daily restraint. In contrast, the usual 
length of the period of adaptation to nose-only tube exposure is 5 d. Mauderly (1986) 
reported altered respiration and minute volume in rats restrained in nose-only tubes without 
adaptation.
In contrast to significant stress induced by nose-only tube exposure, the nonstressed animals 
exposed in compartmentalized whole-body chambers tend to sleep and may cover their 
noses when curling up and thus reduce aerosol inhalation. This should result in lower 
retained lung burdens. Yeh et al. (1990) compared deposited lung burdens in male and 
female rats (8 groups total at 5 rats/group) either nose-only or whole-body exposed to the 
same TiO2 and brass aerosols for 4 h. The retained lung burdens at 1 h postexposure were 
consistently higher in all 4 whole-body exposed groups (5 rats each of males and females) 
compared to the 4 nose-only groups. Although this was significantly different only for the 
brass-aerosol-exposed rats, results of this study do not substantiate concern that whole-body 
exposures reduce aerosol intake. The differences in lung burden in the Yeh et al. study 
(1990) may be due to differences in the breathing patterns observed between nose–only and 
whole-body exposed rats: Miller et al. (2014), after thorough review of the literature, 
reported a 38% higher breathing rate in rats restrained in nose only tubes compared to 
whole-body breathing. This well-demonstrated difference in breathing frequency – most 
likely due to the higher stress level – between whole-body and nose-only exposures and 
associated effects on minute ventilation and tidal volume will predictably affect deposition 
efficiency and deposition sites of inhaled particles in the respiratory tract.
In the context of the efficiency of aerosols depositing in the respiratory tract, an interesting 
question to consider relates to the relevancy of typically used daytime exposures in 
nocturnal animals. Indeed, a comparison of lung burdens between daytime- and nighttime-
exposed rats for 11.2 h (Hesseltine et al. 1985) revealed an approximately 30% higher 
retained lung dose in the nighttime-exposed rats, which was attributed to increased 
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respiration accompanying nocturnal activity. Such exposure would be comparable to human 
daytime exposure. However, exposing rodents during nighttime by either mode of inhalation 
creates additional problems in terms of limiting food intake (nose-only system) and aerosol 
contamination of feed (whole body system), and it also adds more work.
In a study evaluating 6-h daily nose-only and whole-body inhalation in pregnant mice to air 
or water aerosols from gestation day 6 through 15, Tyl et al. (1994) found—compared to 
whole-body air exposure as control—in both nose-only groups increased maternal toxicity, 
reduced body weights, and reduced maternal gestational weight gain. In the air nose-only 
exposed groups 13.3% of the pregnant females died. No significant differences in fetal 
malformations were found, and evidence indicated that restraint did not markedly affect 
normal embryo/fetal morphologic development but produced indications of maternal 
toxicity. Thomson et al. (2009) interpreted their own findings of enrichment of immune 
response, apoptosis, and signaling terms in nose-only air-exposed mice as being consistent 
with effects due to restraint stress.
An undesirable effect due to restraint stress in rats during subchronic nose-only exposures is 
apparent from published body growth curves shown in studies by Coggins et al. (1993; 
2011) and Stinn et al. (2005). These investigations demonstrated convincingly a retardation 
of body weight gain, even in air-exposed controls, as evidenced by a rise in body weight in 
the postexposure phase immediately following the termination of subchronic or chronic tube 
exposures (Figure 6). Rothenberg et al. (2000) found that even short daily nose-only tube 
exposures of rats to air for 42 d resulted in a 24% lower body weight, although no adverse 
effects on testes or reproductive performance was found. Pauluhn and Mohr (1999) 
confirmed this effect of nose-only exposure on body weight reduction in a 4-wk study in 
rats. Restraint stress-related effects from nose-only exposure in mice were reported by Van 
Eijl et al. (2006) to include reduced body weight gain and increased adrenal weights in a 3-
mo exposure compared to unrestrained littermates. A pronounced hypothermia was 
prevented in this study by heating the metallic nosepiece to 38°C, which, however, did not 
reduce stress experienced by animals. Other studies also demonstrated that restraint or 
immobilization leads to a significant stress response involving activation of the 
hypothalamic–pituitary–adrenal (HPA) and neuroendocrine axes (Fawcett et al. 1994; Pare 
and Glavin 1986; Udelsman et al. 1993; Sistonen et al. 1992).
Restraint stress is a main concern for repeat nose-only exposures of rats. Stress-reducing 
tube designs, which permit easy draining of urine and feces and facilitate dissipation of heat 
by placing the rat’s tail outside the restraint tube, need to be mandatory (Bernstein and Drew 
1980). The rat’s tail is a crucial site for heat exchange; it lacks fur and is well vascularized 
with numerous arterio-venous anastomoses facilitating an increase of blood flow during heat 
stress to dissipate heat via its high surface area to volume ratio (Gordon 1993). Surrounding 
room air might be sufficient to aid cooling of rats. Rothenberg et al. (2000) suggested room 
air temperature of 64–70°F to reduce thermal stress during nose-only exposures.
In addition, a multitube arrangement for exposures of many animals in several layers needs 
to be designed as a flow past nose-only system such that each port has its own aerosol 
delivery line and separate exhaust for the exhaled air (Baumgartner et al. 1980; Cannon, 
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Blanton, and McDonald 1983). This avoids rebreathing the exhalation of other animals, 
which is also a concern for vertical flow whole-body chambers consisting of several layers. 
As suggested by Moss, James, and Asgharian (2006) based on model calculations, the 
airflow directed to the animal’s nose through the delivery line of Cannon-type flow past 
nose-only tubes should be 2.5- to 4-fold higher than the minute ventilation of the animal to 
minimize rebreathing exhaled air. Pauluhn and Thiel (2007) confirmed this suggestion by 
actually measuring that under these conditions there was no increase of CO2 at the 
inhalation port of a flow-past nose-only system, verifying that no rebreathing does occur. 
Given that the additional stress from restraint may be a significant modifying factor of 
aerosol-induced effects in a nose-only exposure study, the choice of either mode of exposure 
needs to be carefully weighed against concerns that with whole-body inhalation, exposure of 
fur/skin and subsequent ingestion of material through preening is greater. However, with 
respect to oral uptake of CNT, Matsumoto et al. (2012) found that daily gavage of rats to 
single and MWCNT for 28 d did not produce death or toxicological effects, even at highest 
daily doses (12.5 mg/kg BW, SWCNT; and 50 mg/kg BW, MWCNT). Thus, lower 
ingestion of CNT from repeat whole-body exposures is not a concern. In contrast to the 
many publications describing significant stress from nose-only exposures, OECD (2009b) 
appears to minimize the significance of restraint tube-induced stress when depicting it as 
“nose-only mode of exposure-specific mild immobilization stress.”
Provided that enough material is available for repeat long-term exposures, the low-stress 
whole-body system is preferable. However, specific circumstances, including low amounts 
of material to be aerosolized or better respirability of dispersed long and straight asbestos 
fibers lining up in the narrow flow past delivery line (D. Bernstein personal communication 
2015), might justify the use of nose-only systems.
As an alternative to whole-body or nose-only exposure, an IT inhalation system for rats was 
used to deliver hazardous or radioactive aerosols that prevents any contamination of the 
skin/fur of the animals (Oberdörster, Cox, and Gelein 1997; Kreyling et al. 2009). Less 
material is also consumed with this method, and eight or more rats may be exposed 
simultaneously for several hours, mimicking different breathing scenarios. However, 
animals are anesthetized and repeat exposures may only be done in weekly intervals, rather 
than on a daily basis, to minimize stress. Less stressful whole-body exposures need to use 
compartmentalized systems with individual units for each animal. The aerosol flow needs to 
be evenly distributed to all units, and daily/weekly rotation of the animals is required if 
locations are downstream or upstream relative to each other.
Aerosol Generators
Different types of generation systems for CNT/CNF have been used, involving liquid 
suspension or dry powder generators. As stated earlier, dry powder systems are preferred 
because they simulate more closely actual human exposures (unless there are situations of 
real-world exposures to CNT/CNF contained in liquid aerosols). Important for delivery of 
the generated aerosols to the animal exposure units is their neutralization via a radioactive 
source (Phalen 2009).
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Generators for droplet (liquid) and dry dust (powder) aerosols were reported (Phalen 2009; 
Wong 2007). The former include diverse jet and ultrasonic nebulizers, for solutes but also 
for poorly or insoluble particles suspended in water or physiological fluids (saline, PBS); the 
latter include various designs ranging from fluidized bed to scrape or brush-type and 
venturi-type feeder systems as described by Wong (2007) and Phalen (2009). Specific for 
metallic NP generation, high-voltage electric sparking between two opposing metal 
electrodes in argon gas, induction of vapor and recondensation or metal evaporation, and 
subsequent condensation in a high temperature tube furnace has been used (Elder et al. 
2006; ISO/FDIS10801: ISO 2010b). The electric spark method was also applied to generate 
carbon NP for use in inhalation studies in humans and rodents (Frampton et al. 2006; 
Oberdörster et al. 2004). However, while all of the listed methods can be used to aerosolize 
spherical NP—albeit with some limitations—CNT/CNF aerosols are best generated by dry 
powder methods that are not destructive yet deliver well-dispersed CNT/CNF that closely 
reproduce known or expected human exposures. Currently, there are no generally accepted 
methods or guidelines specific for inhalation of nano-sized particles. In the past 5 yr, 
extensive efforts have been applied to develop systems to generate an aerosol of CNT/CNF 
for animal inhalation studies. Such generation systems include knife mill, acoustical energy, 
rotating brush, fluidized bed, jet nebulizer, and electrospray aerosolization systems.
Dry Powder Systems
Baron et al. (2008) described a system to generate SWCNT. This system fed acoustically 
fluidized SWCNT through a knife mill to break up agglomerates. The output of the knife 
mill was fed through a settling chamber where SWCNT were electrically discharged. At this 
point, the cutoff aerodynamic diameter was approximately 14 µm. The aerosol was then 
passed through a cyclone with a 50% cutoff at 4 µm and a second cyclone with a cutoff at 2 
µm. The generator system produced a SWCNT aerosol of 5.52 ± 0.25 mg/m3 over an 8-h 
period for 4 d. The output efficiency of the generator was 10–12%. Mass median 
aerodynamic diameter was 4 µm with a count mode aerodynamic diameter of approximately 
240 nm (Shvedova et al. 2008). By adjusting the feed rate, this generation system might 
produce outputs as high as 25 mg/m3. Although this system produced target concentrations 
of a dispersed aerosol of SWCNT, it required constant monitoring and periodic adjustment 
by a well-trained technician to maintain a stable output and size distribution. Since this 
system employed a knife mill, there is concern that SWCNT may be damaged or shortened 
during generation. Great caution needs to be exercised because micronization, depending on 
the method, may significantly increase CNT reactivity, as reported by Ma-Hock et al. 
(2009a) when ball-milling MWCNT.
McKinney, Chen, and Frazer (2009) described a system that produced an aerosol of 
MWCNT using an acoustical generation system. Bulk MWCNT (5 g) were placed in a large 
cylindrical acrylic chamber (18 inches high and 14 inches diameter) enclosed at both ends 
with flexible latex diaphragms (0.02 inches thick) held tightly in place with rubber Orings. 
The cylinder was lined with conductive foil tape, which was grounded to prevent static 
charge buildup. A 15-inch loudspeaker was placed below the bottom diaphragm of the 
cylinder. The speaker was driven by a computer-generated analog signal (a frequency sine 
wave swept back and forth from 10 to 18 Hz over a 20-s period) through an audio amplifier, 
Oberdörster et al. Page 41













thus spanning the resonant frequency of the chamber plus diaphragms. The output of the 
generator was controlled by varying the amplitude of the signal driving the speaker. 
MWCNT, forming a fluidized cloud in the chamber, were collected from the chamber by 
passing clean air into a port at the bottom edge of the cylinder and collecting the aerosolized 
MWCNT from a port at the opposite top edge of the cylinder at an airflow of ≤15 LPM (L/
min). This MWCNT aerosol then entered an exposure chamber where concentration and 
particle size distribution were monitored. Mass output was 10.01 ± 0.18 mg/m3. Mass 
median aerodynamic diameter was 1.5 µm with a geometric standard deviation of 1.7. Count 
mode aerodynamic diameter was ~400 nm. Output of the generator was tightly controlled by 
three different computerized feedback loops to control aerosol concentration by altering 
power of the amplifier, trans-diaphragm pressure by altering airflow into the box enclosing 
the cylinder chamber, and exposure chamber pressure by altering airflow out of the exposure 
chamber. It was stable over many hours of operation. Larger agglomerates can be removed 
by a 2-µm cutoff cyclone (Figure 7).
An improved dispersion method for aerosolizing MWCNT was developed by Taquahashi et 
al. (2013) with the goal of generating predominantly single dispersed fibers by effectively 
removing agglomerates without changing length and diameter. Two preparatory steps were 
involved, starting with suspending MWCNT in tert-butyl alcohol (TB) followed by filtration 
through a vibrating metal sieve of 25 µm, then snap-freezing by liquid nitrogen and vacuum 
sublimination, which removed all TB. Small cartridges loaded with the prepared MWCNT 
were air pressure injected at 6-min intervals into the inhalation chamber, which was 
continuously supplied with an airflow of 15 L/min. The resulting sawtooth-like 
concentration was very stable over 2 h at average concentrations of 1.3 and 2.8 mg/m3, 
depending on the cartridge loads.
Another MWCNT aerosol generation system was developed by Kasai et al. (2014) for 
whole-body rat inhalation exposure. This system, termed a “cyclone sieve method,” involves 
delivery of MWCNT from a hopper-type dust feeder into a vertical cylindrical container in 
which an upward spiraling airstream of filtered air keeps the MWCNT in suspension 
through gravitational and centrifugal forces. At the upper end of the cylinder a vibrating 
sieve (53 µm) limits passage only to smaller aerosols to the animal exposure chamber, 
whereas larger agglomerates settle down into a collection flask at the bottom. This system 
generates a well-dispersed MWCNT aerosol without larger agglomerates, one that 
maintained a stable concentration over a 6-h exposure period. Moreover, particle size 
distribution was similar for airborne mass concentrations ranging from 0.2 to 5 mg/m3, with 
MMAD between 1.04 and 1.33 µm and GSD between 2.7 and 3.4. This system was used 
successfully in the recently finished 90-d (Kasai et al. 2015) and an ongoing 2-yr rat 
inhalation studies with MWCNT (Fukushima personal communication 2014).
Myojo et al. (2009) described a generation system for MWCNT employing a rotating brush 
and fluidized bed (RBG—1000 generator, PALAS GmbH, Karlsruhe, Germany). MWCNT 
were fed (2–20 mm/h) to a rotating brush (1200 rpm) and suspended into an airstream (13.3 
L/min). The aerosolized MWCNT were fed into a two-component fluidized bed (bed: 
irregular stainless-steel beads) to remove agglomerates and stabilize concentration. 
MWCNT aerosol concentration increased linearly with feed rate to the rotating brush (feed 
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rate of 2–20 mm/h, resulting in an output of 5000–20,000 particles/cm3). The generator 
produced a well-dispersed aerosol of MWCNT, as evidenced by electron micrographs of 
filter samples. However, MMAD or CMD were not provided. At a feed rate of 2 mm/h, 
MWCNT aerosol concentration was 4 mg/m3. Calculated concentration of MWCNT surface 
area ranged from approximately 50 to 400 µm2/cm3. Generator efficiency was 11–13%.
Ma-Hock et al. (2009a; 2009b) used a piston-fed rotating stainless-steel brush together with 
a cyclone separator to aerosolize MWCNT: A high output of 30 mg/m3 with MMAD 0.5–
1.3 µm, and GSD 3.1–5.4; CMD 580 nm (Optical Particle Counter) and 60 nm (SMPS). 
Larger agglomerates were present. A similar piston-fed rotating stainless steel brush was 
successfully used in an earlier study for generating glass-fiber aerosols (Bernstein et al. 
1995).
Fujitani, Furuyama, and Hirano (2009) used a sieve shaker generator to disperse MWCNT 
mixed with 5-mm stainless-steel balls in an aluminum cyclone separator, followed by a 
second cyclone. The maximal concentration was 1.2 mg/m3, with a CMD of 300 nm and an 
aerodynamic diameter of 1–2 µm; the aerosol was well dispersed and also had larger 
agglomerates. Concerns are the potential of contamination from steel balls, aluminum, and 
shortening of CNT.
Mitchell et al. (2007) used a screw feeder system to feed MWCNT into a jet mill, and placed 
a cyclone separator before inhalation chamber entry. Varying states of agglomeration were 
seen, more with higher concentration of 5 mg/m3. The MMAD ranged from 0.7 to 1.8 µm, 
and GSD from 2 to 2.5; CMD measured by DMA was 350–400 nm; no information was 
provided concerning exposure stability.
For inhalation of Baytubes, a Wright dust feeder was used. MWCNT were compressed into 
a Wright dust feeder and a slow-moving blade abrasion generated an aerosol that passed 
through a cyclone before dilution and entering the exposure system (Pauluhn 2010). 
Specifically, Baytubes (tight agglomerates of MWCNT) were first micronized, then packed 
into a dust feeder. Resulting MMAD values as measured by impactor were 2.74–3.42, and 
GSD 2–2.14 for concentrations of 0.4–5.68 mg/m3 and agglomerate count by SMPS from 
320 to 1763/cm3.
The CNF aerosols in the subchronic inhalation study by DeLorme et al. (2012) were 
generated by feeding dry CNF material into a glass tube into which a high-pressure air 
stream was directed that carried the resulting CNF aerosol into the exposure chamber. 
Different concentrations were achieved by varying the feed rate into the airstream and/or 
varying the on/off period of the feeder. Resulting MMAD ranged from 1.9 to 3.3 µm at 
concentrations from 0.5 to 25 mg/m3, indicating agglomerated CNF structures.
Li et al. (2007a) described an MWCNT aerosol generation system consisting of a dry 
powder generator with two sequential depositor tiers to retain larger agglomerates before the 
aerosol entered the animal exposure chamber. The resulting MWCNT aerosol was “almost 
respirable,” but the concentration decreased continually over a period of 90 min so that the 
exposures had to be repeated 4 times within a 6-h exposure session.
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Table 3 compares design, exposures, and results of the two 90-day inhalation studies using 
different MWCNT and one CNF inhalation study. The similarity in dosimetry and responses 
is apparent, although there are significant differences in some of the histological findings. A 
NOAEL of 0.1 mg/m3 was found by Pauluhn (2010), whereas this level was a LOAEL in 
the Ma-Hock et al. (2009a) study. Of interest is that the increase in lung weight as indicator 
of overall respiratory toxicity seems to be similar between the Pauluhn (2010) and Ma-Hock 
et al. (2009a) investigations when based on retained lung burden (Table 3). Exposure-
response and dose-response relationships are shown in Figure 4.
Liquid CNT Suspension Systems
Functionalized CNT/CNF that are well dispersed in aqueous or physiological saline can be 
dispersed using jet nebulizers. Careful characterization with regard to size and size 
distribution and agglomeration state of the generated aerosol with appropriate 
instrumentation is mandatory, as it is for the dry powder generation systems. CNT/CNF that 
are not well dispersed in deionized water or saline require use of dispersants for liquid-phase 
aerosol generation, which poses the same problem/concern as for bolus-type dosing by 
instillation or aspiration in terms of altering surface properties, with potential consequences 
for disposition and effects of deposited CNT/CNF in the respiratory tract. In addition, it 
needs to be considered that dissolution/leaching of contaminants (catalysts) may occur in the 
suspension, which may also affect surface properties. In general, dispersion dryers before 
entry into exposure chamber need to be used with CNT/CNF aerosol generated from liquid 
suspensions.
Oyabu et al. (2011) described the generation of a well-dispersed aerosol of MWCNT using a 
nebulization system developed for NP by Shimada et al. (2009). Briefly, an aqueous 
suspension of MWCNT dispersed in 0.5 mg/ml Triton X-100 was atomized by a pressurized 
nebulizer equipped with an ejector to break liquid threads into droplets (Nanomaster, JSR 
Corp., Tokyo, Japan). The nebulizer received clean air (35 L/min) at an inlet pressure of 
0.25 MPa and an ejector pressure of 0.20 MPa. Generated droplets were dried in a heater 
(50°C). The dried MWCNT were then passed into the exposure chamber through a 
deionizer. The exposure concentration was 0.37 ± 0.18 mg/m3. Although neither MMAD 
nor CMD values were reported, scanning electron micrographs of filter samples from the 
exposure chamber indicate that this system produced a well-dispersed aerosol of MWCNT 
with geometric mean diameter of 63 nm and a geometric mean length of 1.1 µm. Use of 
surfactant may have changed surface properties.
Kim et al. (2010b) modified an electrospray nebulizer to generate a well-dispersed aerosol 
of MWCNT. The CNT were fed into an electrospray capillary nozzle as a suspension in 
ethanol at a low feed rate. A high-voltage field between the capillary and a grounded orifice 
plate produced highly charged particles, with the agglomeration state being controlled by the 
feeding rate. Two 210Po radiation sources reduced the charges subsequently, and the 
associated ethanol vapor was reduced efficiently by an activated carbon dryer before 
MWCNT entered the animal exposure system. Airborne size distribution as determined by 
SMPS showed a double peak, 150 nm (singlets) and 400 nm (bundles), finely dispersed. The 
concentration, using one nozzle, was approximately 2 mg/m3. No dissolution/leaching of 
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metal catalyst or ethanol contamination was to be expected. Several nozzles are required for 
higher concentrations.
Ryman-Rasmussen et al. (2009a) used a Retsch mixer mill to grind MWCNT. Subsequently, 
MWCNT were suspended in nonionic surfactant (1% pluronic) in sterile DPBS. Generation 
of aerosol for nose-only exposure of rats was achieved with six jet Collison nebulizers, 
followed by removal of large droplets by a particle trap, and water removal by silica gel 
dryers. MMAD was 714 nm, GSD approximately 2, and CMD 160 nm. High concentrations 
of 103 mg/m3 were measured, consisting of approximately 2 µm agglomerates and 
individual CNT. Concerns are the grinding process and use of dispersant.
Pauluhn and Rosenbruch (2015) also used a Collison-type nebulizer to aerosolize MWCNT 
in a 6 h nose-only exposure of rats to 30 mg/m3 with sodium carboxymethyl-O-cellulose as 
dispersant to compare effects of wet dispersion exposure to those of dry powder generation 
of the same MWCNT. The smaller wet-generated aerosol (MMAD 0.79 µm) induced greater 
effects than larger pristine dry powder aerosols (MMAD 2.6 µm). It is worthwhile noting 
that caution against using unrealistic high-dose acute exposure leading to an incomplete 
picture of potential pulmonary toxicities is required.
A novel approach was suggested by Ahn, Kim, and Yu (2011): Uncoated MWCNT were 
continuously sonicated in 80°C hot deionized water, which lowered surface tension and 
facilitated dispersion and then nebulized via a Collison-type nebulizer with subsequent 
drying of aerosol in a diffusion dryer. This system produced well-dispersed MWCNT 
without the use of dispersant. Stable and high concentrations of 50 mg/m3 were obtained. 
Aerosol size distributions were not determined, and additional information about its use in 
actual inhalation studies should be forthcoming.
As pointed out before, for any generation method it is important to characterize the 
generated CNT/CNF aerosol in sufficient detail in order to ensure adequate dosing of the 
test animals, in particular regarding the respirability of the CNT/CNF aerosols. Limitations 
of measured data have to be critically considered. For example, the use of DMA to 
determine equivalent mobility diameters of CNT/CNF (Ku et al. 2007) is based on 
separation by a mechanism that does not occur in the respiratory tract (i.e., electrical 
mobility), and DMA measurements may be in error if the size of tangled CNT/CNF exceeds 
submicrometers. The mobility diameters of doubly and triply charged CNT/CNF are 
different from singly charged CNT/CNF, on which the DMA separation is based. Key 
should be to replicate as best as possible the CNT/CNF aerosol characteristics that humans 
are exposed to with the proviso that differences in human versus rodent respirability/
dosimetry have to be considered. CNT/CNF may be aerosolized in a variety of shapes, 
which may be grouped to define several CNT/CNF shape categories. A different 
characterization may be needed for each shape. Obtaining different equivalent diameters for 
each shape requires the use of different instruments and might prove to be a challenge, given 
the availability of resources and time.
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Endpoints and General Approach
Based on numerous studies showing the potential of nano-sized particles to translocate 
beyond the portal of entry, thereby potentially producing systemic effects and effects in 
secondary organs, and given MWCNT-specific results indicating translocation to and effects 
at pleural tissues, there is a need to expand presently required endpoints (examination of 
organs, tissues and effects) relative to existing guidelines (EPA 1998; OECD 2009a) and 
guidance (OECD, 2009b) for subchronic/chronic inhalation studies. These include 
incorporation of additional effect endpoints for CNT/CNF inhalation studies, as well as data 
for lung dosimetry and biokinetics.
Biokinetics necessitates the development of appropriate sensitive methods/labels for 
quantifying biodistribution as briefly discussed previously. To measure lung burdens, 
sensitive methods are necessary to reliably measure even low levels of retained CNT/CNF 
(Doudrick et al. 2013; Ohnishi et al. 2013). Because of the concern that CNT/CNF may 
behave like asbestos, there needs to be a specific emphasis on pleural–lymphatic 
translocation and clearance pathways involving lymphatic stomata of the parietal pleura 
(Goodglick and Kane 1996; Donaldson et al. 2010). Thus, harvesting thoracic bifurcational 
lymph nodes as sentinels for clearance of lung-deposited CNT, and superior mediastinal 
lymph nodes and diaphragm as sentinels for clearance from the pleural space (Parungo et al. 
2005), needs to be part of the study design. Indeed, Bernstein et al. (2011) reported that just 
a 5-d inhalation exposure of rats to a high concentration of amosite and chrysotile asbestos 
was sufficient to demonstrate significant inflammatory, granulomatous, and fibrotic 
responses in lung and pleura, including translocation to the pleura for amosite, whereas this 
was not observed with the low-biopersistent chrysotile. In contrast, while pleural 
translocation of aspiration-delivered well-dispersed MWCNT was found (Mercer et al. 
2010), and single MWCNT at pleural sites and diaphragm of rats following inhalation 
exposure were observed (Mercer et al. 2013a,b), translocation of inhaled complex 
agglomerates of MWCNT to the pleural space has still to be demonstrated and remains a 
research gap to be filled. Another important tissue to include is the bone marrow, which was 
found as a site for significant uptake of NP (Bazile et al. 1992; Ballou et al. 2004; Cagle et 
al. 1999; Gibaud et al. 1994; 1996; 1998; Rinderknecht et al. 2007).
To determine retained lung burdens and CNT/CNF translocated to extrapulmonary 
secondary organs and target sites, sensitive analytical methods are necessary to reliably 
quantify even low tissue levels of elemental carbon (EC) of retained/translocated CNT/CNF. 
Early methods developed for measuring retained lung burdens in rats of diesel particles 
following 22–32 wk of inhalation to high concentrations of diesel exhaust used KOH/
ethanol digestion of dried lungs, followed by sonication of the water-resuspended pellet, and 
optical density reading (Rudd and Strom 1981). This method was sufficient to measure the 
expected high lung burdens of 2–10 mg. NIOSH (2003) published a standard method to 
determine carbon from diesel exhaust on filter samples using a thermal optical method 
involving two stages with stepped-up temperature, first in helium and then in an He/O2 
mixture. This allowed separate measurement of organic carbon (OC) and EC. Diesel 
concentrations ranging between 6 and 630 µg/m3 ambient air could be measured, but the 
method was not applied to tissue samples. Mercer et al. (2013a) used a three-step process to 
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determine lung burdens of MWCNT after exposure of mice. Dried lungs were digested in 
KOH/methanol, then in HNO3/methanol, followed by resuspension in dH2O with NP-40. 
Optical density in a spectrophotometer was read after sonication. Lung burdens of 3.125 
µg/ml (sample size 100 µl) (Dale Porter personal communication, 2015) MWCNT were 
detected. Doudrick et al. (2013) developed a programmed thermal analysis (PTA) method to 
quantify CNT in lung tissue. After examining eight different tissue digestion methods, they 
noted that a two-step extraction/digestion method was optimal, consisting of solvable 
(mixture of 2.5% NaOH, 2.5–10% N,N-dimethyldodecylamine N-oxide, 2.5–10% 
polyethylene glycol trimethylnonyl ester) and proteinase K. Two types of MWCN were 
used, with weak thermal stability (high defect density) and strong thermal stability (low 
defect density). Similar to the NIOSH Manual of Analytical Methods (NMAM) (2003) 
method, PTA involved two heating steps: the first in 100% helium to remove any remaining 
OC from tissue, and the second in 90% He/10% O2 to develop the CNT thermogram and 
quantify the carbon content after conversion to methane and detection by flame ionization 
detection (FID). Overall, recovery of MWCNT in spiked lung samples was 98% for lung 
burdens estimated between 1 and 10 µg in rats.
Ohnishi et al. (2013) established a different approach using a novel method to measure with 
high sensitivity retained lung burden of MWCNT-7 (Mitsui) following inhalation and IT 
instillation exposure of rats. Their concept involved adsorption of a PAH marker onto 
MWCNT followed by HPLC detection after desorption of the marker (Figure 8). 
Preparatory steps involved overnight digestion of rat lungs in C99–K200 (lab bleach), which 
was significantly improved by prior formalin fixation of the tissue; centrifugation at 10,500 
× g, addition of Tween 80 mixture (9.6% phosphate buffered saline with 0.1% Tween 80), 
and centrifugation followed by brief concentrated sulfuric acid for complete digestion of 
undissolved tissue components; centrifugation and washing in dH2O and addition of the 
hybrid marker benzo[ghi] perylene (B[ghi]P) for adsorption to MWCNT; centrifugation and 
extraction of marker to acetonitrile; and filtration and quantitative examination of eluate by 
high-performance liquid chromatography (HPLC). Recovery of spiked lung samples was 
92.5%, and the limit of quantitation 0.2 µg in the lung. This is the most sensitive quantitative 
method reported so far and is an important contribution to nanotoxicology, providing the 
scientific community with a tool to establish essential dose-response relationships of 
carbonaceous NM.
As stated earlier, it is desirable to consider realistic human exposure conditions when 
designing rodent inhalation studies with CNT/CNF. Relevant exposure levels and measuring 
respective lung burdens need to be included to obtain exposure-dose-response relationships. 
The analysis of the results needs to take into account dose metrics and response metrics 
when performing dosimetric extrapolation to humans for hazard identification and risk 
assessment purposes. For example, deposited and retained CNT/CNF doses in the lung can 
be expressed per unit alveolar or tracheobronchial surface or per unit lung tissue volume or 
gram lung tissue to normalize doses, which will allow extrapolation between humans and 
rats or mice. The selection of this dose metric is associated with the mode of action; it needs 
to be closely related to effects at the target site within the respiratory tract (i.e., epithelial vs. 
interstitial). Care needs to be taken in the selection of the region associated with the 
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toxicological response, as dose per epithelial surface area will highly depend on the total 
retained amount and total surface area of the selected region.
In addition to dose metric, exposure metrics to characterize inhalation of particles are 
important. Exposure concentrations expressed as mass per cubic meter or number per cubic 
meter or also surface area per cubic meter were all used. Although for spherical NP in a 
well-dispersed state (singlets) these relationships can readily be determined, this is difficult 
for the less uniform and rather complex structures and tangles of CNT/CNF, except for the 
mass/surface area correlation. Thus, knowing this relation, expressing exposure as 
micrograms per cubic meter and determining deposited and retained mass allows one to 
convert a tissue mass dose to particle surface area dose. Additional model development is 
required to estimate tissue dose from retained dose on the surface of the airways.
In general, the use of tissue dose depends on CNT/CNF clearance rate into the interstitial 
space, including dissolution rate of contaminants/impurities, and possible interaction of 
CNT/CNF with interstitial cells. Data with poorly soluble particles indicate that a far greater 
portion of deposited particles in the lung migrates to the interstitium in primates than in rat 
(Nikula et al. 1997; 2001), which is supported by findings in coal mine workers and humans 
exposed to radioactive aerosols (Kuempel et al. 2001; Gregoratto, Bailey, and Marsh 2011). 
However, there is some evidence that—likely due to the hydrophobic nature of CNT—
interstitialization of SWCNT and MWCNT may be substantial in rodents (Mercer et al. 
2008; 2011). Further studies with CNT and CNF are required to describe biokinetics fully.
When expressing the deposited dose per unit surface area (cm2) of airway epithelia, the 
inflation state of the lung needs to be considered: for example, functional residual capacity 
(FRC) versus total lung capacity (TLC). For example, values for the human alveolar surface 
vary widely, from approximately 60 m2 (EPA 2004) to 140 m2 (Gehr, Bachofen, and Weibel 
1978). This range of published values reflects different inflation states of the lung when 
prepared for morphometric analyses, from FRC to TLC. A critical analysis and comparison 
of literature data by Miller et al. (2011) resulted in more definite and authoritative values for 
tracheobronchial and alveolar surface areas of human and rat lungs at FRC (Table 4).
Normal breathing starts at FRC such that the epithelial surface area available for deposition 
of inhaled particles is FRC plus the opening of additional surface by the tidal volume. 
Considering the tidal cycling of inhalation and exhalation during breathing, the approximate 
average epithelial surface area for particle deposition is determined by FRC + ½TV, which 
is close to the surface of FRC, but lower than at TLC. Thus, lung inflation state at FRC is 
the more appropriate for dosimetric considerations and comparisons; it ranges from about 35 
to 45% of TLC for different species. Table 4 shows values for the upper respiratory tract 
reported by Keyhani, Scherer, and Mozell (1997) and Kimbell et al. (1997). It is important 
for dosimetric comparison of experimental results of different rat inhalation studies and for 
purposes of dosimetric extrapolations to humans that researchers base assessments on the 
same well-justified and accepted values. Table 4 shows that for both species the alveolar 
region has essentially the same (98.3–99.3%) relative surface area, whereas there is a large 
difference between species for the less than 1% overall surface area of the nasal area.
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Diverse methods to evaluate the biodistribution of CNT following different routes of 
administration have been used. These include TEM, radioactive and stable isotope labeling, 
Raman spectroscopy, near-infrared (NIR) spectroscopy, x-ray and other fluorescence, and 
metal impurity analysis. Liu et al. (2010b), after reviewing these methods and discussing 
their advantages and disadvantages, concluded that analytical methods for quantitation need 
to be improved and that optimization of biodistribution methods is urgently needed. The in 
vivo stability of any label has to be carefully confirmed. Other methods include thermo-
optical analysis (Hyung et al. 2007; Peterson and Richards 1999; NIOSH Method 5040: 
NIOSH 2013; Watson, Chow, and Chen 2005; Westerhoff, Doudrick, and Herckes 2012; 
Doudrick et al. 2013) and turbidity measurement of retained carbonaceous material after 
tissue digestion (Rudd and Strom 1981). The most sensitive method appears to be the use of 
a hybrid marker, described by Ohnishi et al. (2013).
A minimum number of pulmonary endpoints—in addition to lung weight—measured at 
various time points postexposure needs to include an evaluation of inflammation, lung 
damage, granulomatous lesions, and interstitial fibrosis. Inflammation and damage may be 
evaluated by analysis of fluid obtained by BALF. Lung lavage after euthanasia may be 
performed in situ (lavaging via tracheal cannula without opening thorax), after opening the 
thorax in situ (lung expands more easily) or after excising the lungs and trachea en bloc and 
lavaging outside (on wetted gauze with gentle massaging of the lungs). Three to five 
repeated lavages using physiological saline or PBS are usually performed. The excised lung 
lavage results in significantly greater numbers of lavaged cells, probably due to retrieving 
more cells from the lung periphery. Lung cell damage may be determined by measuring 
LDH activity in the acellular fluid obtained from the first or combined first and second 
lavage aliquot. Alveolar air–blood barrier damage/integrity may be measured as the protein 
or albumin level in this acellular BALF. Selected cytokine and chemokine (IL–1, tumor 
necrosis factor [TNF] α, macrophage inflammatory protein [MIP]-1, etc.) levels in the first 
acellular BALF might also be measured as markers of inflammation. In addition, TGF-β 
levels in the first acellular BALF would be useful as an indicator of fibrogenic stimulation. 
Total BALF cells and cell differentials, in particular neutrophil counts, would be a sensitive 
indicator of pulmonary inflammation. Oxidant stress may be monitored by measuring total 
antioxidant levels in lung tissue. These assays are described in mouse and rat models after 
exposure to CNT (Lam et al. 2004; Warheit et al. 2004; Shvedova et al. 2005; Porter et al. 
2010).
Histopathological analysis, using both light and electron microscopy, also needs to be 
conducted. Analyses needs to include a qualitative evaluation of the deposition sites of 
CNT/CNF agglomerates and more dispersed structures, pathological evaluation of 
granulomatous lesions (onset, distribution, and persistence), and a quantification of 
interstitial fibrosis (collagen) in Sirius red-stained lung tissue determining onset, 
distribution, and progression. Examples of such histopathological quantification for CNT 
were described by Mercer et al. (2008) for SWCNT and Mercer et al. (2010; 2011) for 
MWCNT.
Cell proliferation in response to CNT/CNF exposure is a useful indicator of hyperplasia for 
a potential pre-neoplastic response and may be quantified using the BrDU method (Warheit 
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et al. 2004; DeLorme et al. 2012). In addition, histopathological analysis for bronchiole and 
alveolar epithelial and mesothelial hyperplasia and hypertrophy is of value (Porter et al. 
2010).
Acute pulmonary exposure to high doses of CNT were found to produce adverse 
cardiovascular effects, including (1) oxidant stress in aortic and cardiac tissue, (2) an 
increase in aortic plaque lesions in ApoE−/− mice (Li et al. 2007b), and (3) inhibition of the 
ability of coronary arterioles of rats to respond normally to dilators (Stapleton et al. 2011; 
2012). Therefore, systemic response to pulmonary CNT/CNF exposure may be monitored 
by histological evaluation of aortic plaque formation in ApoE−/− (atherosclerotic sensitive) 
mice and by monitoring the responsiveness of the rat tail artery to vasomodulating factors 
(Krajnak et al. 2009). In addition, systemic inflammatory response to pulmonary exposure to 
CNT/CNF may be monitored by measuring the ability of peripheral blood PMN leukocytes 
to produce reactive oxygen species (ROS) in response to ex vivo stimulation (Nurkiewicz et 
al. 2006) or determining blood mRNA expression or protein for selected inflammatory 
markers (Erdely et al. 2009). Blood fibrinogen and measurement of platelet activation may 
be used as markers for potential thrombogenic effects (Khandoga et al. 2004). While some 
of these measurements require specific methodological expertise and cannot easily be 
incorporated into a 90-d inhalation study, other endpoints determining acute-phase systemic 
responses from analysis of blood samples (e.g., fibrinogen; IL-6; CRP) may readily be 
incorporated into the design of acute, subchronic, and chronic studies. The timing of blood 
sample biomarker assays needs to be carefully considered, as some biomarkers may be 
expressed transiently.
There may be value in conducting genomic or proteomic analyses on lung tissue samples to 
obtain mechanistic information concerning pathways involved in pulmonary responses. This 
depends on the study objective; it would be useful though to save specific organs for later 
analysis. For example, lungs, bronchus-associated lymphatic tissue, lymph nodes, and other 
identified target tissues/organs could be rapidly removed and frozen at −80°C.
Evaluation
Although dosing of the respiratory tract with CNT/CNF can easily be achieved by bolus-
type delivery of liquid suspension, or insufflation as powder, directly into the trachea, this 
cannot mimic physiological inhalation exposures in terms of disposition within the 
respiratory tract and with respect to the normally low inhaled deposition rate in the lung. 
Therefore, inhalation exposures of lab animals are most appropriate for toxicity testing. 
Selecting a method for the generation of CNT/CNF aerosols that closely resembles 
exposures that workers/consumers may experience requires a careful evaluation of aerosol 
generator technology, CNT/CNF aerosol characterization, and dosimetric issues. As 
indicated, a key consideration of an experimental exposure-dose-response design is to 
include doses and distribution in the respiratory tract of experimental animals that are 
predicted to be present in exposed humans.
The detailed discussion of inhalability and respirability in this review should provide 
guidance in this respect. This enables one not only to establish exposure-response 
relationships—which are often not easy to interpret—but to develop more comprehensive 
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exposure-dose-response data. A critical evaluation of exposure-dose-response information 
from rodent inhalation studies may serve as a basis for risk assessment by considering 
different endpoints for pulmonary and secondary organ effects as well as systemic effects.
In addition to the analysis of exposure-dose responses, information about biokinetics 
provides essential information to the overall assessment of potential adverse effects of CNT/
CNF. However, as previously discussed, sensitive methods to quantify low levels of 
CNT/CNF in tissue still need to be developed and refined. In the absence of such data, 
visualization of CNT/CNF in lung and secondary organs by light and electron microscopy 
together with markers of exposure, such as pleural plaque formation or molecular biology-
based effects, provides qualitative or descriptive proof for the existence of biokinetic 
pathways.
DISCUSSION
Types and Purpose of Inhalation Toxicity Testing
Assessing the potential of CNT/CNF exposure to induce adverse responses in the respiratory 
tract and in secondary organs requires the design and use of inhalation exposures. While 
dosing of the respiratory tract by noninhalation methods may be useful for purposes of 
toxicity ranking, inhalation avoids potential problems associated with bolus-type delivery or 
with pretreatment of the pristine CNT/CNF. Thus, while one goal of mimicking human 
exposure to CNT/CNF aerosols is achieved by administering them to rodents by inhalation, 
the appropriate methodology with respect to characterizing airborne properties of CNT/CNF 
also needs to be considered in order to reproduce the equivalent for rodent exposures.
The durations of experimental inhalation studies may range from acute short one-time to 28-
d exposures to chronic repeat daily exposures for up to 2 yr. The purpose and some design 
and methodological details of these different exposures are summarized in Table 5. These 
range from using results of short-term studies to establish long-term study concentrations via 
data for accumulation, retention, and clearance kinetics; to identification of potential short- 
and long-term hazards in the respiratory tract, extrapulmonary tissues, and organs; to 
determination of a NOAEL; to collection of biokinetic data; and to risk assessment and 
dosimetric extrapolation.
General Guidelines for Inhalation Toxicity Testing
Guidelines have been issued by the U.S. EPA and OECD describing general requirements 
for testing chemicals by inhalation, including animal selection, concentration level selection, 
repeat exposure durations, exposure chambers and exposure conditions, data evaluation, 
quality control, data reporting, and many other details (EPA 2000; OECD 2009a; 2009b). 
Both guidelines focus on 90-d subchronic inhalation studies and both suggest nose-only 
exposures as the preferred method over whole-body, to minimize secondary oral exposure 
due to preening of the fur deposits. However, the stress induced by long-term nose-only 
exposure in restraining tubes is significant and affects the animals’ growth and physiology 
(discussed earlier, Types of Inhalation). An earlier EPA guideline (EPA 2001) that applies to 
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chronic toxicity/carcinogenicity testing of fibrous particles allowed for either nose-only or 
whole-body exposure.
Although these guidelines do not specifically address nanotechnology-related testing 
requirements, they are useful in terms of providing general recommendations for performing 
a subchronic 90-d inhalation study. For example, the EPA (2001) test guidelines provided 
valuable guidance that are applicable for testing NP, including concentrations, selections, 
lung burden analysis, and BALF analysis. As another example, the introduction to the 
OECD (2009a) guideline states:
Subchronic inhalation toxicity studies are primarily used to derive regulatory 
concentrations for assessing worker risk in occupational settings. They are also 
used to assess human residential, transportation, and environmental risk. This 
guideline enables the characterization of adverse effects following repeated daily 
inhalation exposure to a test article for 90 days (approximately 10% of the lifespan 
of a rat). The data derived from subchronic inhalation toxicity studies can be used 
for quantitative risk assessments and for the selection of concentrations for chronic 
studies. This Test Guideline is not specifically intended for the testing of 
nanomaterials.
The OECD (2009a) Summary reads:
This revised Test Guideline 413 (TG 413) has been designed to fully characterize 
test article toxicity by the inhalation route for a subchronic duration (90 days), and 
to provide robust data for quantitative inhalation risk assessments. Groups of 10 
male and 10 female rodents are exposed 6 hours per day during a 90 day (13 week) 
period to a) the test article at three or more concentration levels, b) filtered air 
(negative control), and/or c) the vehicle (vehicle control). Animals are generally 
exposed 5 days per week, but exposure for 7 days per week is also allowed. Males 
and females are always tested, but they may be exposed at different concentration 
levels if it is known that one sex is more susceptible to a given test article. This 
guideline allows the study director the flexibility to include satellite (reversibility) 
groups, interim sacrifices, bronchoalveolar lavage (BALF), neurologic tests, and 
additional clinical pathology and histopathological evaluations in order to better 
characterize the toxicity of a test article.
Some specific requirements listed in OECD (2009a) include the target concentrations 
selected need to identify target organ(s) and demonstrate a clear concentration response:
• The high concentration level should result in toxic effects but not produce lingering 
signs or lethality that would prevent a meaningful evaluation.
• The intermediate concentration level(s) should be spaced to produce a gradation of 
toxic effects between that of the low and high concentration.
• The low concentration level should produce little or no evidence of toxicity and
A satellite (reversibility) study may be used to observe reversibility, 
persistence, or delayed occurrence of toxicity for a post-treatment period 
of an appropriate length, but no less than 14 days. Satellite (reversibility) 
Oberdörster et al. Page 52













groups consist of 10 males and 10 females exposed contemporaneously 
with the experimental animals in the main study. Satellite (reversibility) 
study groups should be exposed to the test article at the highest 
concentration level and there should be concurrent air and/or vehicle 
controls as needed.
Another guidance document relates to acute inhalation toxicity testing of chemicals in 
general (OECD 2009b). General recommendations are presented, addressing the principle of 
the test, monitoring of exposure conditions including inhalation chamber design, and 
statistical analysis of data. One crude endpoint for this acute test is mortality (LC50), 
although nonlethal points are also considered. The preferred exposure mode again is nose-
only, although for special objectives and longer duration studies whole-body chamber 
exposures may be given preference. Recommendations for aerosol size are given as MMAD 
between 1 and 4 µm and GSD 1.5–3.
As discussed earlier (Types of Inhalation), nose-only exposures may not be advisable for 
exposures to NP aerosols because of the associated significant stress resulting in retarded 
body weight gain and other stress-related effects. Further, CNT ingested due to fur preening 
appear to be cleared from the gut quickly without significant toxicity (Matsumoto et al. 
2012). CNT/CNF inhalation studies should not be conducted with an MMAD of 4 µm, since 
this is close to the upper limit of the thoracic fraction for rodents (Figure 2). Specific 
guidelines for nanomaterials should consider workplace exposure conditions and include 
inhalability and respirability differences between humans and rodents. Some of these items 
are already addressed in the first nanomaterial-specific guidance issued by OECD (OECD 
2012). Thus, lower MMAD and particularly CMD up to several hundred nanometers—
depending on actual workplace data—need to be included in future nano-specific guidelines, 
including aerosols of CNT/CNF.
A specific recommendation for optimal aerosol sizes for rodents would be an MMAD up to 
2 µm with a geometric standard deviation up to 3. Table 6 lists deposition efficiencies for 
rats and mice for MMAD from 1 µm to 3 µm, and geometric standard deviations from 1 to 3. 
The low deposition efficiency of 3-µm particles becomes obvious, considering that 
seemingly small differences in deposition fractions result in large differences of retained 
lung burdens during a subchronic or chronic exposure; retained lung burdens would be even 
less for 4-µm MMAD particles, which would not be ideal for exposing rodents. 
Instrumentation to determine median aerodynamic diameters (low pressure and regular 
impactors) and count median diameters (diffusion or electrical mobility particle size 
spectrometers) of the aerosols is used. Rats are the preferred species for inhalation exposures 
to poorly soluble particles because of their greater sensitivity to detect fibrotic and 
carcinogenic responses relative to mice (ILSI 2000).
Nanotechnology-Specific Guidelines
Presently no guidelines specific for CNT/CNF inhalation testing have been issued; however, 
several newer guidelines that focus on nanotechnology should briefly be mentioned for 
interested readers because of their close connection to the topic of this document.
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ISO Standard 10808 (ISO 2010a) “specifies requirements for, and gives guidance on, the 
characterization of airborne nanoparticles in inhalation chambers for the purpose of 
inhalation toxicity studies in terms of particle mass, size distribution, number concentration 
and composition.” It includes definitions of physical characteristics of nanoparticles and 
emphasizes the importance of precise characterization of the test material for establishing a 
quantitative relationship between the observed toxicological outcome and the dose metrics 
used. The physical and chemical properties include median and mean size, size distributions, 
number and mass concentrations, composition, surface area, electrical charge, surface 
characterization, hygroscopicity, and shape. Obviously, shape becomes very important for 
CNT/CNF but is not further discussed in the guidance document. Agglomeration and 
aggregation state also need to be added, as should be purity and contaminants.
ISO 10808 further describes measuring systems for airborne nanosized particles, describes 
general and specific monitoring methods, and discusses assessment of results. 
Measurements of number-based size distributions by DMA is suggested as the only method 
to fulfill all of the requirements for continuous monitoring and accuracy of size and 
concentration in the animals’ breathing zone with high resolution that permits conversion 
from number-based distribution to surface-area-based or volume-based distribution. 
However, an important caveat is highlighted in the document for nonspherical particles by 
cautioning that DMA-derived particle size measurement might result in significant error 
and, therefore, that DMA application for nonspherical particles is not recommended.
With regard to mass-concentration measurements, gravimetric measurements of material 
collected on membrane filters, beta attenuation mass monitor (BAM), tapered element 
oscillating microbalance (TEOM), and piezoelectric microbalance are listed. Estimation of 
mass by DMA is also mentioned for NP when particle density is known (Ku and De La 
Mora 2009). However, it is cautioned again that for nonspherical particles DMA-based mass 
estimates might produce errors, and significant errors in calculated mass concentration may 
result if particle density is inaccurate or unknown.
Maynard et al. (2006) and Ku et al. (2006) used tandem mobility–mass analysis consisting 
of a DMA and aerosol particle mass analyzer (APM) to characterize shape and structure of 
SWCNT and of CNF. However, while certain morphological features correlated with mass 
can be assessed, this method is not suitable for routine analyses. In particular, the DMA–
APM system is useful for well-defined fibers/spheres, but not for larger, irregular complex 
structures and tangles.
Specific recommendations regarding characterization of experimental CNT/CNF aerosols 
are not given in ISO 10808. Gravimetric sampling for mass concentration data is a reliable, 
though discontinuous, method. The meaning of DMA and SMPS for continuous real-time 
measurement of the electrical mobility diameter of CNT/CNF is not clarified, as there is no 
agreement how to interpret the data (Ku et al. 2007). As alternative, a micro-orifice uniform 
deposit impactor (MOUDI) provides an MMAD and the GSD for size distributions down to 
0.1 µm; if used as a low pressure impactor, or nano-MOUDI, aerodynamic size distributions 
to approximately 10 nm can be determined, although in a discontinuous mode (see Figure 
9). The different shapes, structures, and agglomerate sizes are collected based on the 
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aerodynamic properties of the CNT/CNF aerosols. These data are useful for dosimetric 
extrapolation modeling.
ISO/FDIS10801 (ISO 2010b) is specific for generation of silver NP through an evaporation 
(heating of solid silver)–condensation method and reiterates general principles of NP 
properties, their measurements, monitoring, and exposure system operations.
Two ISO technical reports (TR) relate to health and safety assessment at the workplace 
relevant to nanotechnologies. ISO/TR 27628 (ISO 2007)—workplace atmospheres/ultrafine 
nanoparticle and nanostructured aerosols/inhalation exposure characterization and 
assessment—contains sections on source and formation of occupational nano-aerosols, and 
strategies for their exposure characterization and exposure assessment, including 
measurement of airborne size distribution by electrical mobility analysis (SMPS) and by 
aerodynamic inertial impaction. Problems associated with the interpretation of SMPS data 
when sampling nanofibers and nanotubes are pointed out. These are due to the ill-defined 
electrical charging of such structures, as has been described in the OECD documents 
summarized earlier.
Supplementing Current Guidelines
Several issues of importance for risk assessment purposes have not been addressed in 
currently existing testing guidelines. Some have been alluded to previously, but are included 
here again with some additional details.
Particle Size Distributions for Worst-Case Inhalation Testing—As pointed out 
earlier in Table 6, optimal particle sizes for inhalation exposure of rodents to dose the 
alveolar region of the rodent lung should not exceed an MMAD of 2 µm with a GSD up to 3. 
It would in fact be ideal if experimental exposure atmospheres were correlated to the 
aerosols to which humans are exposed under real-world occupational or environmental 
conditions. However, most often these aerosols are of larger, agglomerated sizes with 
MMAD that are significantly larger, approaching the limits of rodent respirability. 
Micronization of the agglomerated structures as conducted by Pauluhn (2010) for exposing 
rats to MWCNT may be one solution to make the aerosol rodent respirable. As indicated by 
Pauluhn (2010), care has to be taken that the method of micronization does not alter other 
physicochemical properties, which in many cases may be difficult to achieve. Still, the 
objective of a general testing strategy should be to expose the experimental animals to 
materials that are similar to the pristine materials to which humans are exposed.
To verify appropriate dosing, sensitive analytical methods for quantifying retained doses of 
CNT/CNF in rodent lungs need to be available (Doudrick et al. 2013; Ohnishi et al. 2013) so 
that exposure-dose-response relationships can be established (Figure 4). A minimum of 
three concentrations (plus zero control) should be planned, with the highest at the maximum 
aerosol concentration (MAC) to deliver the maximum tolerated dose (MTD), and the lowest 
concentration, if possible, being at the NOAEL (Vu et al. 1996; Morrow et al. 1996; 
Oberdörster 1997). The MAC should induce significant toxicity without substantially 
altering the normal life span of the animals, whereas the lowest concentration should not 
induce toxicity, and some signs of toxicity should be induced at an appropriately spaced 
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intermediate concentration. Measuring retained lung burdens following inhalation exposure 
of any duration should be mandatory, to be determined in the postexposure recovery phase 
to define retention and clearance kinetics.
With regard to defining an MFTD for PSP of low cytotoxicity, Muhle et al. (1990) followed 
suggestions by Morrow (1986) and proposed to use a maximum functionally tolerated dose 
(MFTD) for these types of particles. Muhle et al. (1990) defined it—based on Morrow 
(1986)—as “the maximum lung burden above which macrophage-mediated lung clearance 
is significantly impaired,” and suggested as a reasonable criterion a two- to four-fold 
increase in the alveolar retention half time of the tested or suitable surrogate particulate 
material. However, one has to be careful in applying this concept of MFTD indiscriminately 
to any particulate nanomaterial without confirmation that the material to be tested indeed is 
a PSP material. For example, exposure to crystalline silica and amphibole asbestos—known 
human carcinogens—also induces significant retardation of alveolar retention halftimes for 
particles, easily exceeding an assumed MFTD based on volumetric dust overloading of the 
lung. Although the MFTD concept still is meaningful for such highly reactive persistent 
particles, it may well be that other endpoints of toxicity are more sensitive, showing 
significant adverse effects (toxicity) before alveolar macrophage mediated clearance 
function is affected. Thus, before uncritically focusing solely on this concept of MFTD for 
nanomaterials, other sensitive endpoints also need to be considered.
Benchmark and Reference Materials—The availability of benchmark and reference 
materials will facilitate the interpretation of results of rodent inhalation studies. Reference 
materials are defined as “sufficiently homogeneous and stable with respect to one or more 
specified properties … [and] established to be fit for its intended use in a measurement 
process” (ISO 2006). Benchmark materials should be well characterized physicochemically 
and toxicologically for a specific response endpoint and serve as a point of reference for 
comparing dose-response relationships for use in risk assessment (Oberdörster et al. 2005b; 
Kuempel et al. 2012). Although, reference and benchmark materials may serve different 
purposes, ideally, a toxicologically well characterized benchmark material should also be 
metrologically characterized as reference or certified reference material.
Examples of traceable certified reference materials for use in metrology of nanomaterials 
that are available at the National Institute for Standards and Technology (NIST) include gold 
(10, 30, 60 nm), polystyrene (60, 100 nm), TiO2, and SWCNT (NIST 2012). No MWCNT 
reference is yet available. Officially sanctioned benchmark materials for purposes of 
toxicological comparative hazard and risk assessment have not been established. However, 
Figure 4 shows an example of comparing responses observed in 3-mo rat inhalation studies 
with CNT and CNF, using as benchmark the data of a previously performed 3-mo rat 
inhalation study with particles for a rather benign material (CB, negative benchmark 
control). Ideally, a highly toxic material (e.g., crystalline SiO2, asbestos) could be selected 
as a positive benchmark. However, it was not possible to identify a subchronic rat inhalation 
study with appropriate endpoints (lung lavage data, lung weight, multidose). If possible, rats 
would be exposed to positive and/or negative control at the same time; however, given the 
extraordinary high demand on labor and costs, simultaneous exposures are impractical and 
not recommended, so the search for previous appropriately performed inhalation studies is 
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suggested. Preferably, benchmark materials should be of similar type and inhalation 
exposures be of the same duration as used for the material to be tested, but this is impossible 
for MWCNT given the lack of other prior multidose subchronic MWCNT or CNF inhalation 
studies.
Postexposure Observation—Adding a postexposure recovery or observation period is 
essential for any type of inhalation exposure, whether subacute, subchronic, or chronic. This 
not only enables one to obtain information on clearance of the retained lung burden, but also 
provides evidence of progression or regression of effects observed at the end of exposure. 
The duration of the postexposure recovery should be at least 1–2 mo for shorter exposures, 
and approximately 3 mo for subchronic exposures, and longer for chronic 2-yr exposures. 
The clearance kinetics of different retained lung burdens provide valuable information as to 
whether the alveolar macrophage clearance function for particles has been affected dose-
dependently. Thus, a postexposure period of 60–70 d—which is the physiological retention 
half time for PSP of low cytotoxicity in rats—needs to be considered as minimum duration 
for the shorter exposures, and longer recovery times for subchronic and chronic studies. 
Knowledge about progression of fibrotic or other health effects or their potential revision 
over this time period is helpful for planning subsequent studies and for risk assessment 
process. Pauluhn (2010) added a 6-mo postexposure observation period to the 3-mo 
MWCNT rat inhalation study to determine T½ in the different exposure groups (Table 3).
Monitoring Exposure Atmospheres—Use of static size-selective samplers using 
inertial cascade impactors is discussed in some detail in ISO/TR 27628 (ISO 2007). 
Potential problems due to overloading (altering impactor characteristics) and bouncing 
(skewing particle size distribution) are identified. Of importance for nano-aerosols including 
CNT/CNF, the use of low pressure impactors (nano-MOUDI) is acknowledged, yet longer 
sampling times for the expected low mass in the 10- to 100-nm particle sizes are required 
with the potential of overloading the upper stages (>0.5–1 µm). An example of a lab-
generated MWCNT aerosol for toxicity testing is shown in Figure 9. Size selective pre-
separators may be necessary to avoid upper-stage overloading.
The monitoring and characterization by available instruments discussed in ISO TR27628 for 
monitoring nano-aerosol exposure are summarized in a table in this document according to 
mass, number and surface area as endpoints. This table is updated in a second workplace 
related ISO documentation, ISO/TR12885 (ISO 2008), which is directed at the protection of 
workers. A major aspect in this ISO guidance document is sampling of particles at the 
workplace and their characterization. Four tasks are listed to accomplish this: (1) assessment 
of personal exposure for compliance with regulations, (2) determination of personal 
exposure for linking with potential adverse health effects in epidemiological studies, (3) 
identification of major emission sources for establishing targeted control plan, and (4) 
assessment of efficiency of control systems deployed.
An additional purpose for workplace sampling and characterization that is not listed in the 
document, but indirectly serves to protect workers’ health and to prevent adverse effects, is 
providing information on the design of relevant animal inhalation studies to assess potential 
acute and long-term toxicity and the correlation with exposure metrics and dose metrics. In 
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the already-mentioned table of ISO TR 12885, the metrics of mass, number, and surface area 
are separately grouped as both directly measured and calculated by specific instruments. 
This table is reproduced here with an addition for applicability to CNT/CNF aerosols (Table 
7).
Chapter 5 of ISO TR 12885, entitled “Exposure assessment to nanomaterials,” is a useful 
contribution to our discussion of characterizing CNT/CNF aerosols. This chapter not only 
provides valuable suggestions for exposure assessment at workplaces, which is necessary 
complementary information for performing risk assessment together with results of well-
designed animal studies, but the aerosol measurement methods discussed in ISO TR12885 
can also be applied to characterizing exposures of animal inhalation studies with CNT/CNF. 
Table 7 expands the table of that ISO document and is expanded to include additional 
information on the applicability of measurement methods to CNT/CNF aerosols. Future 
developments of an ideal universal real-time monitoring device that simultaneously 
measures all three exposure metrics (mass, number, surface area) as well as aerodynamic 
and mobility behavior may be envisioned (Maynard and Aitken 2007), but its realization is 
unlikely, at least within the next decade.
Evaluation of Carcinogenicity and Toxicity
The International Agency for Research on Cancer (IARC) convened a Monograph meeting 
in October 2014, to evaluate—among other compounds—evidence for labeling CNT with 
respect to carcinogenicity (Grosse et al. 2014). Based on the data of mesothelioma induction 
by MWCNT-7 in several studies in mice and rats, the Working Group concluded that there 
is sufficient evidence of carcinogenicity for MWCNT in animals, limited evidence for two 
other types of MWCNT, and inadequate evidence for SWCNT. Given that there was 
inadequate evidence in humans and sufficient evidence in two animal species, MWCNT-7 
were classified as “possibly carcinogenic to humans” (Group 2B), and other MWCNT and 
SWCNT as “not classifiable as to their carcinogenicity to humans” (Group 3). Thus, the 
IARC Working Group acknowledged that differences in biological activities between 
distinct MWCNT need to be considered for carcinogen classification, given also that 
mechanistic evidence for carcinogenicity is not strong for any specific CNT. Since the IARC 
(2014) carcinogenicity classification for MWCNT is presently based on bolus-type ip 
injection studies in rodents, the outcome of a 2-yr multidose rat inhalation study with 
MWCNT-7 with respect to their carcinogenicity will be crucial for a final classification of 
these MWCNT as either a Group 1 or Group 2A or 2B carcinogen. The 2-yr inhalation study 
has been completed, and results will be published in the near future (Fukushima et al. 
personal communication).
Results of three of the subchronic inhalation studies in rats with MWCNT and CNF (Table 
3) have been used to derive occupational exposure levels (OEL) for workplace exposure 
based on different methods of extrapolation modeling of a NOAEL or LOAEL of toxicity 
observed in the rat studies. NIOSH (2013) derived a Recommended Exposure Level of 2 
µg/m3 and 1 µg/m3 for MWCNT and CNF using a Benchmark Dose (BMD) approach; 
Aschberger et al. (2010) used the approach based on guidance by Registration, Evaluation, 
Authorization and Restriction of Chemicals (REACH) in Europe to derive OEL of 2 µg/m3 
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and 1 µg/m3 for two different MWCNT. In contrast to these extremely low values, Pauluhn 
(2010), using dosimetric extrapolation and the volumetric overload concept, derived 
specifically for the MWCNT Baytubes an OEL of 50 µg/m3. Results of a 2-yr rat inhalation 
study with MWCNT are forthcoming (Fukushima et al. personal communication) and will 
be essential for deriving more definitely an OEL.
RECOMMENDATION/CONCLUSION
General
• Inhalation is the preferred method to obtain data necessary for risk assessment of 
pulmonary exposure to CNT/CNF. Intratracheal instillation or pharyngeal 
aspiration may be useful exposure techniques for hazard characterization and for 
screening various types of CNT/CNF for relative toxicity. However, effects due to 
bolus delivery (very high dose rate) need to be considered and—if dispersants are 
used to suspend CNT/CNF in a liquid—responses and biokinetics may be altered.
• The rat is the preferred rodent species. Rats have been found in studies with fine 
particles to be more sensitive regarding fibrosis and lung tumor responses than 
mice. In addition, the availability of larger tissues is of advantage (e.g., lavage of 
only the right lung and save the left lung for histology/histochemistry). Rodent 
respirability (Table 6) has to be considered to optimize deposition in the lower 
respiratory tract (MMAD ≤ 2 µm). One may increase sensitivity to observe lung 
cancer or mesothelioma with KO mouse models, which would provide information 
concerning mechanisms of action. In general, mesothelioma induction by inhaled 
fibrous particles in rats is a rare event, and hamsters would be the preferred species 
for this endpoint (McConnell et al. 1999).
• Whole-body exposure is less stressful and thus preferred over nose-only exposure, 
in particular for 90-d and longer inhalation studies.
• At present, 90-d inhalation studies are preferred (Bernstein et al. 2005; see 
objectives in Table 5), with CNT/CNF aerosol characterization according to 
OECD/EPA general guidelines for performing a subchronic study. In general, 
OECD test guidelines, guidance, and good laboratory practices for subchronic 
inhalation studies are applicable; however, modification noted here should be 
considered. Physicochemical properties of the as-produced and as-administered 
material should be characterized (Table 8).
• Use a minimum of three concentrations that include a NOAEL and an MTD. 
Determination of retained lung burden is essential in order to express results based 
on dose-response data rather than only as exposure-response relationship. Risk 
assessment prefers at least one dose that gives a positive response (e.g., MTD). 
However, use of a dose for this purpose far exceeding the MTD may be of little 
practical value and leads to erroneous conclusions.
• Inclusion of a postexposure observation/recovery period is highly desirable. This 
would be specifically important for the highest concentration to determine 
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regression, persistence, or progression of effects, and to determine retention/
clearance kinetics in primary and secondary organs.
• A 28-d inhalation exposure may provide sufficient information with added 
postexposure observation/recovery time. Shorter repeat exposures (5–10 d) 
designed to achieve the same retained lung burdens as in a 90-d study by using 
higher concentrations need to consider the potential impact of significant 
differences in dose rate.
• Precede the 90-d inhalation study with an acute 1- to 10-d inhalation study with 3 
or more concentrations in order to identify effects; estimate exposure 
concentrations for subchronic 90-d study; and verify aerosol characteristics and 
evenness of chamber distribution and general tolerance of the animals to exposure. 
(Inhalation study may be preceded by dose-response study with intratracheal 
instillation (rats), oropharyngeal aspiration (mice), to identify types of effects.)
Sample Preparation of CNT/CNF for Inhalation
Use pristine material as experienced by human inhalation exposures; no treatment with 
dispersant or sonication to mimic human exposure, but consider rodent/human differences in 
respirability. Aerosolization from liquid suspension needs to consider likely impact of 
alteration of pristine CNT/CNF. Micronization of non-rat-respirable larger agglomerates 
needs to assure that no alteration of CNT or CNF surfaces is introduced.
Aerosol Generation
• Generators: Dry powder generators are highly preferred. Sufficient agitation is 
required to achieve CNT/CNF aerosols that would be representative of the size 
distribution of CNT/CNF structures found at human exposure sites. Need to avoid 
changing CNT/CNF morphology (cutting, shearing, breaking) and producing 
CNT/CNF contamination (addition of metals) from a generator device. If a liquid 
suspension is used, consider alteration of surface properties of the pristine material 
due to dispersants.
• It is key to mimic human exposure in terms of aerosol characteristics and 
concentrations. Therefore, it is essential to obtain available information about such 
human exposure at workplaces and to consumers. However, to allow for adequate 
penetration of CNTs and CNFs into the lower respiratory tract, the generated 
aerosol of singlets, agglomerated structures, or aggregated structures should be 
administered to rodents with an MMAD of less than or equal to 2 µm, and GSD not 
exceeding 3.
• If no human exposure data are available, generate a rodent-respirable CNT/CNF 
aerosol (mix of individual structures and agglomerated versus well-dispersed 
forms). In order to optimize the composition of such mix, knowledge about effects 
of preferentially single CNT/CNF structures and of preferentially tangles of 
CNT/CNF would be helpful (see Research Gaps).
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• Consider including the use of positive (asbestos) and negative (CB) benchmark 
controls where feasible. Otherwise, considering the high cost of nanomaterial 
inhalation studies, data on new CNT/CNF should be anchored to preexisting 
studies with appropriate benchmark materials. (See Research Gaps for identifying 
reference CNT/CNF.)
CNT Aerosol
Characterization/Monitoring—Evaluate size distribution, mass, number concentration, 
agglomeration/aggregation state (see later description), density, and other physicochemical 
characteristics, such as surface properties, impurities, length, diameter, dissolution, and 
leaching (in vivo and in vitro) related to biodurability/biopersistence. Table 8 lists 
recommendations for characterization of CNT/CNF aerosols occurring for human exposures 
(workplace, consumer) and experimental animal exposures. They are identified by their 
essentiality for CNT/CNF based on the general recommendations on nanomaterial 
characterization by participants of a 2005 ILSI Workshop (Oberdörster et al. 2005b).
Endpoints—
• As listed in the OECD and EPA 90-d inhalation guidelines, one should monitor 
conventional standard endpoints listed there. Of particular importance are lung 
weight changes as integrating indicator of adverse effects.
In addition, the following should be considered as
a. Mandatory:
• Pulmonary endpoints should include lung lavage (BALF) analysis for lung 
damage (cellular, biochemical, cytokines) related to inflammation and 
oxidative stress.
• Retained lung burden at end of exposure and in postexposure period to 
establish exposure-dose-response relationships and clearance kinetics as 
essential data for purposes of risk assessment.
• Histopathology (see existing guidelines) should include specific staining for 
fibrosis and analysis of granulomatous lesions, cell proliferation and pleural 
response.
b. Optional, evaluation of:
• Cardiovascular effects (heart rate, blood pressure, microvascular effects, 
levels of clotting factors in the blood).
• Systemic effects (acute-phase proteins to assess systemic inflammation, e.g., 
fibrinogen, CRP, IL-6).
• CNS effects (markers of inflammation and damage; behavioral tests).
• Bone-marrow effects and effects in other sensitive organs.
• Dosimetry/biokinetics: Evaluation of deposition, translocation, 
accumulation, elimination/clearance (e.g., lung; pleura; liver; spleen; heart; 
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CNS; bone marrow) and for determining pulmonary retention T½ should be 
included as an important goal in the study design. This requires sensitive 
analytical methods for detecting retained CNT/CNF in the primary and 
secondary targets. Analysis of CNT/CNF retention separately for BALF 
cells, supernatant, and lung tissue and lymph nodes (bifurcational vs. 
supramediastinal) is desirable.
Instrumentation—The usefulness and limitations of instruments for measuring size, mass, 
and number concentration needs to be understood (Table 7):
• Mass, gravimetric (filter; mass only; averaging over time): nano-MOUDI 
(aerodynamic size distribution and mass, see Figure 9, averaging over time); 
TEOM (real-time monitoring mass only); APS (optical short time, size, number, 
and mass, but only above approximately 300 nm).
• Number: CPC (real-time, no size information; okay for monitoring stability); 
SMPS; DMAS (size distribution with unknown relevancy; caveats).
• Morphology, shape: TEM; SEM; scanning transmission electron microscopy 
(STEM).
• Surface area: BET.
Data Analysis—Could include:
• Interpretation of aerosol characterization data.
• Evaluation of exposure-dose-response dose response, including the NOAEL and 
postexposure time course (retention; persistence/resolution of effects).
• Considering the need for a risk assessment if the NOAEL is at a high exposure 
concentration of rodent-respirable aerosol (>50 mg/m3) and results demonstrate 
high lung burden (>2 mg/g) in a 28-d or even 90-d study (including 90-d recovery 
period).
• Dosimetric extrapolation to humans (dose/alveolar epithelial surface area) of 
deposited dose (only short-term; no retention data needed) and retained dose 
(preferable, but retention T½ required).
Research Gaps/Needs—A number of publications have pointed out potential risks of 
nanomaterials as discussed at the beginning of this document. After reports described 
mesothelioma-inducing asbestos-like effects of MWCNT in 2008/2009, concerns increased 
and CNT/CNF-specific reviews (Donaldson et al. 2006; 2010) and documents (NIOSH 
Intelligence Bulletin, 2013) emphasized the need for preventive measures, avoiding 
exposure, and called for more research to understand the risk of CNT/CNF exposure. In fact, 
the NIOSH Intelligence Bulletin (2013) derived a recommended exposure level for CNT and 
for CNF of 1 µg/m3.
The ultimate goal is to develop a scientifically well supported realistic risk assessment of 
CNT/CNF inhalation exposure. Are all CNT/CNF to be treated the same in terms of their 
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potential or potency of causing fibrosis, cancer, and diverse systemic adverse effects? Most 
likely there may be differences in bioactivity between SWCNT and MWCNT and CNF, as 
well as differences within each group (raw vs. purified CNT/CNF, functionalization, length 
or width, agglomerated vs. dispersed).
There is an urgent need to address this using inhalation as the most prominent route of 
exposure, and carrying out appropriately designed and executed studies is key. Although IT 
instillation or pharyngeal aspiration studies may be useful in ranking the relative bioactivity 
of various CNT/CNF, they cannot replace inhalation studies. A future goal is to move from 
reliance on in vivo studies toward acceptance of alternative testing strategies including 
predictive validated in vitro screening tests. This should be a high priority, requiring highly 
focused research efforts and sufficient funding.
The following list of research needs was generated to fill data gaps for improving the design, 
analyses, interpretation, and extrapolation of results of inhalation studies in order to refine 
our ability to perform meaningful risk assessments in the absence of human epidemiological 
data. Addressing these research needs will lead to the development of new concepts for 
assessing the biokinetics and toxicity of inhaled CNT/CNF and for the understanding of 
results from acute and chronic inhalation studies:
• Determine accumulation and clearance kinetics: T½ and translocation to secondary 
target organs (pleura; CNS; bone marrow).
• Compare results of inhalation exposure of individual versus heavily agglomerated 
CNT/CNF: Is response different?
• Define inhalability and respirability of highly variable CNT/CNF aerosol shapes 
and incorporate into existing predictive deposition models.
• Determine the suitability of a 28-d inhalation study plus postexposure period to 
replace 90-d subchronic study.
• Perform chronic inhalation study (1 yr or longer + long postexposure period) to 
determine tumorigenic (rat, lung tumor) and mesotheliogenic (hamster 
mesothelioma) potential of MWCNT that tested positive in ip studies.
• Measure equivalent diameters in various instruments that simulate CNT/CNF 
deposition in the lung, such as impactor (impaction diameter), diffusion battery 
(diffusion diameter), elutriator (sedimentation diameter). (These diameters are 
needed to assess the CNT/CNF dose to the lung.)
• Determine in vivo translocation to pleura of inhaled CNT/CNF tangles versus 
inhaled single CNT/CNF, considering also rigidity and flexibility, as well as length 
and diameter.
• Develop and optimize sensitive detection/quantification methods in tissue for 
deposited/translocated CNT/CNF.
• Develop a validated method to determine effective density of CNT/CNF aerosol.
• Identify reference material for CNT/CNF (positive and negative controls).
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• Compare effects of liquid aerosol (+ surfactant) versus dry aerosol at the same 
deposited dose.
• Evaluate inhalation exposure-dose-response data with dose as mass, number, and 
surface area: impact of dose metric?
• Compare/correlate acute and long-term effects and biokinetics of instilled (single/
repeat dosing) versus inhaled CNT/CNF.
• Correlate in vivo with in vitro response to develop and validate simple predictive 
high-throughput assays, as part of a tiered testing approach incorporating in vitro 
(cell-free and cellular) and in vivo (acute, repeat) studies emphasizing exposure-
dose-response analysis.
• Develop a universal monitoring instrument for combined measurement of aerosol 
exposure characteristics for mass, number, surface area, volume distribution, and 
morphology (Wang et al. 2011).
• Determine exposure data during CNT/CNF life cycle.
• Determine in vivo (lung, secondary tissues) adsorption of proteins and change in 
associated particle surface properties and the impact on kinetics and effects in vivo.
• Identify underlying mechanisms of toxicity and its dependence on dose.
• Investigate stability of agglomerates depositing in the lung: Does lung surfactant 
and/or tissue motion disperse CNT/CNF? Dispersion is likely to facilitate 
interstitial uptake.
• Investigate species differences in biological sensitivity to CNT/CNF between 
rodents and humans.
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APPENDIX A: RESPIRATORY-TRACT FRACTIONS
Inhalability
To develop a model for CNT/CNF inhalability, one must first characterize airborne CNT/
CNF. Unlike particles, which can be represented by their diameters, CNT/CNF are described 
by several characteristics dimensions called equivalent diameters. Equivalent diameters are 
identified with respect to the physical mechanism(s) controlling the transport of CNT/CNF 
in the respiratory tract. A reduction in inhalability will result when inhaled CNT/CNF are 
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prevented from entering the extrathoracic passages due to their inertias. Therefore, 
inhalability of CNT/CNF depends on their equivalent diameter for impaction (or impaction 
diameter). The following model illustrations are with the assumption of CNT/CNF being 
present as single, straight fibers. Conditions (shape factor) will be different for complex 
structures of tangles, agglomerates, and aggregates. Once the shape of CNT/CNF is 
characterized, impaction diameter is obtained by equating the drag and inertial forces of 
CNT/CNF for an equivalent spherical particle. For example, by assuming that CNT/CNF are 
shaped as cylinders and are randomly oriented in the air, an expression for equivalent 
diameter for impaction (dei) may be found as (Asgharian and Price, 2006)
(1)
where df, β, and ρ are the CNT/CNF diameter, aspect ratio, and mass density, respectively. 
Predictive models for the inhalability of particles may be extended to CNT/CNF by 
replacing particle diameter with equivalent impaction diameter. The majority of existing 
predictive models of particle inhalability are related to particle diameter (Ménache, Miller, 
and Raabe 1995; Brown 2005). However, particle inertia depends both on its diameter and 
traveling velocity. Asgharian, Kelly, and Tewksbury (2003) developed a semiempirical 
expression for rat inhalability based on measurements obtained from a series of brief nose-
only inhalation studies in which rats were exposed to titanium dioxide particles. The 
following expression was proposed to calculate the inhalability:
(2)
where Q is the inhalation flow rate. By fitting Eq. (2) to inhalability measurements in rats, 
coefficients α, δ, and γ were found to be 19.87, −1.5532, and −0.7466, respectively. In 
humans, coefficients α, δ, and γ were reported as 0.1361, 0.9906, and −0.8527 for oral 
breathing and 4.451 × 10−4, 2.168, and 0.3778 for nasal breathing (Asgharian and Price, 
2006). A plot of CNT/CNF inhalability versus equivalent diameter for impaction is given in 
Figure A-1. Breathing flow rates of 15 LPM and 7.4 ml/s were used in Eq. (2) for humans 
and rats, respectively. CNT/CNF inhalability is greater for humans than for rats and 
increases further during by oral breathing than nasal breathing. In humans, CNT/CNF of 10-
µm impaction diameter or smaller CNT/CNF are 100% inhalable. Rats have a significantly 
lower inhalability than humans, with about 90% of 1-µm and 50% of 3-µm CNT/CNF being 
inhalable.
The shape of CNT/CNF affects their aerodynamic properties and thus transport and 
deposition in lung airways. The shape has been found to be complex and to vary quite 
considerably based on filter sample observations; however, it has not been characterized so 
far and thus cannot be described mathematically at the present time. The current version of 
MPPD assumes CNT/CNF to be shaped as cylinders. In addition, those CNT/CNF that are 
not straight may be described by equivalent diameters for impaction, sedimentation, and 
diffusion. Deposition of these particles can be estimated from the MPPD model for spherical 
particles. Thus, the fiber and spherical particle models of MPPD may be jointly used to 
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predict deposition as first order of approximation. The degree of inaccuracy cannot be 
estimated until a mathematical model for different shape CNT/CNF are developed. The fiber 
version of the model will be made available in the near future. CNT/CNF sizes (1 and 3 µm) 
are for equivalent diameter for impaction in Eq. (2). This diameter can take on different 
dimensions as described in Eq. (1) to give the desired impaction diameters of 1 and 3 µm. 
Experimentally, impaction diameter can be measured by an impactor.
Thoracic Fraction
A fraction of inhaled materials is deposited in the extrathoracic airways, and the remaining 
inhaled materials that escape deposition are considered to be penetrable into the thoracic 
region. The thoracic fraction of CNT/CNF is the net effect of two filtering mechanisms: 
inhalability (IF) and removal efficiency in the head airways (η). Therefore, the thoracic 
fraction (TF) of CNT can be described by
(3)
Losses of inhalable CNT/CNF in the head airways are by inertial impaction. Hence, the 
same as for inhalability, CNT/CNF thoracic fraction will depend on equivalent diameter for 
impaction and inhalation flow rate. Loss efficiency expressions for CNT/CNF are obtained 
by replacing particle diameter with CNT/CNF impaction diameters. For humans, nasal and 
oral breathing deposition efficiencies may be given by (Rudolf, Kobrich, and Stahlhofen 
1990; Rudolf et al. 1986; and Stahlhofen, Rudolf, and James 1989)
(4)
(5)
where Vt is the tidal volume. Similarly, for rats, the following relationship was proposed by 
Zhang and Yu (1993):
(6)
Respirable Fraction
Additional losses of CNT/CNF occur while passing through conducting airways of the lung, 
mainly by inertial impaction for micrometer and larger size CNT/CNF and Brownian 
diffusion of smaller CNT/CNF sizes. Consequently, the amount of CNT/CNF that reaches 
the alveolar region or the respirable fraction is lower than thoracic fraction. A lung 
deposition model such as MPPD is needed to calculate the total conducting airway losses 
based on available deposition efficiency expressions for impaction and diffusion losses. The 
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respirable fraction of CNT/CNF is found by correcting TF for the total loss fraction of 
CNT/CNF in the conducting airways. The respirable fraction depends on CNT/CNF size and 
lung and breathing parameters.
APPENDIX B: EXTRAPOLATION
Extrapolation Based on Inhaled Dose
Inhaled dose refers to the amount of CNT/CNF that reaches different regions of the 
respiratory tract, and it should not serve as a basis for human risk estimates deduced from 
laboratory animal studies. Since the ability of CNT to reach various locations of the lung 
depends on the filtering efficiencies in the passing airways, one needs to calculate the 
inhalable, thoracic, and respirable fractions to use as the basis for interspecies 
extrapolations.
Extrapolation across lab testing and human exposure scenarios may involve two cases. The 
intention in case 1 is to set up an exposure atmosphere in the lab setting (animal inhalation 
studies) based on the human exposure scenario.
Thus, an equivalent CNT/CNF size and concentration will be sought for the exposure 
systems to deliver the same dose to humans and laboratory animals. Size equivalency in case 
1 will be based on an equal inhaled dose metric of exposure (i.e., inhalable, thoracic, or 
respirable fractions). The opposite is to be achieved in case 2, where human equivalent 
concentration is sought for a given animal inhalation exposure concentration. Again, 
extrapolation across exposure scenarios will be based on the dose-metric of equal inhalable, 
thoracic, or respirable fraction. The same dose equivalent can also be considered as a goal 
for in vitro studies, either for conventional exposure via suspension in culture medium or via 
aerosol in an Air Liquid Interface (ALI) system. The medium concentration could be 
interpreted as the equivalent exposure atmosphere in the lung regions of interest.
Figure B-1 describes scenario 1, in which equivalent CNT/CNF sizes will be calculated for 
the design of an animal inhalation study. Given that the thoracic fraction depends on the size 
of CNT/CNF, there will be an equivalent CNT/CNF size in animal studies for each 
CNT/CNF size in the human exposure scenario. It is assumed in Figure B-1 that humans are 
exposed to 2.5-µm-diameter CNT/CNF. The equivalent CNT/CNF size in animals also 
depends on the breathing route in humans. The corresponding impaction diameters for 
animal studies are 0.4 µm and 1.6 µm for human oral breathing and nasal breathing, 
respectively. Minute ventilations of 15 LPM and 7.4 ml/s were assumed in the calculations. 
If the exposure environment is made of various size particles, calculations must be repeated 
for each size interval. Ideally, an equivalent exposure environment must be generated with 
equivalent CNT/CNF sizes and concentrations in each size interval.
For case 2, a similar approach to the preceding one may be applied if the airborne size of a 
rat inhalation study is to be used to determine the human inhaled size of CNT/CNF. 
However, since the CNT/CNF thoracic fraction is greater in humans than rats (Figure B-1), 
CNT/CNF size correction is not needed in case 2, for which toxicity assessment is based on 
observed laboratory outcomes. Human health risk is inferred based on in vivo results, which 
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require estimation of human equivalent exposure (HEC) concentration for a given laboratory 
setting. For example, by assuming the same delivered dose for human exposure scenarios 
and rats in an inhalation study, the following relationship is obtained for the calculations of 
HEC:
(7)
where CR is the rat exposure concentration, reported from rodent inhalation studies,  is 
the minute ventilation, and δt is the exposure duration. Subscripts R and H refer to rats and 
humans, respectively. Figure B-2 presents the ratio of HEC/CR versus impaction diameter of 
CNT for equal exposure duration for humans and animals. Minute ventilations of 15 LPM 
and 7.4 ml/s were used in the calculations of Eq. (7). Exposure concentration ratio decreases 
with increasing impaction diameter of CNT/CNF. In addition, since the concentrations ratio 
is smaller than unity, HEC must be smaller than the exposure concentration in rats to yield 
the same delivered dose.
Extrapolation Based on Deposited Dose
While inhalable, thoracic, and respirable fractions are good indicators of the delivered dose 
to the lung, they do not directly correlate to the biological response because only a fraction 
of inhaled CNT/CNF is deposited on lung airway surfaces. The deposited dose is what 
triggers the biological response and must therefore be linked to it. Given that human 
exposure studies are not possible due to ethical concerns of possible adverse health effects 
and that there is a limitation to conducting animal studies from the standpoint of practicality 
and cost, lung dosimetry models have been developed to assess deposition of airborne 
materials in the lungs of humans and laboratory animals. These models allow direct 
prediction of both deposited and retained doses in the lungs of humans and animals and 
dosimetric extrapolation and comparison of such doses between animals and humans for 
cases 1 and 2.
Predictive models of inhaled aerosols in the lungs of humans and laboratory animals have 
been around for a few decades. First-generation deposition models were compartmental and 
limited in predictive capability. More realistic deposition models assumed the lung to be 
dynamic and to undergo expansion and contract during a breathing cycle. The lung 
geometry also resembled a trumpet in shape when symmetric lung geometry was assumed 
(Scherer, Shendalman, and Greene 1972; Yu 1978). These models have been validated for 
regional deposition fractions. The human lung has an asymmetric branching structure that 
affects both airflow and particle deposition. Asgharian, Hofmann, and Bergmann (2001) 
developed a multiple-path particle dosimetry model (MPPD) and used it to predict site-
specific and regional deposition of particles in 10 stochastically generated lungs of human 
adults. The stochastic lungs were based on morphometric measurements of Raabe et al. 
(1976) and developed by Koblinger and Hofmann (1985). Significant dose variations among 
the lung structures were found, which indicated the significance of intersubject variability in 
the population.
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Particle deposition models were extended to CNT/CNF by adjusting for shape and size 
effects of CNT/CNF (Asgharian and Price 2008 for cylindrical shapes). The deposition 
model consisted of four components. First is the extrathoracic component for calculating 
head losses of inhalable CNT/CNF so that the delivered dose to the lung could be obtained 
as already described. The next component was the lung geometry that enabled mechanistic 
calculations of CNT/CNF deposition in this geometry. Due to complexity of airway 
structure, multiscale dimensions of the lung, and the large population of airways, a complete 
measurement of the entire airway tree was infeasible. Airway measurements typically 
included selecting a number of pathways extending from the trachea down to the alveolar 
airways and measuring airway dimensions and angles along these paths (Raabe et al. 1976). 
By assuming lung airways to be shaped as a cylinder and performing statistical analysis of 
airway parameters, various lung geometries were developed (Koblinger and Hofmann, 1985; 
Yeh and Schum 1980) and implemented in MPPD. Lung geometries in MPPD extended 
from a typical path geometry such as that proposed by Weibel (1963) to a complete 
asymmetric geometry (Koblinger 1985).
The third component of the deposition was the lung ventilation, which in effect was the 
mechanism of transport of CNT/CNF to various locations within the lung. The dose (and 
hence the effect) at any site in the lung depends on the amount of inhaled material that 
reaches there. Hence, lung ventilation directly impacts biological response. Various 
ventilation models based on lung compliance and airway resistance were developed and 
implemented in the deposition model. At normal low frequency breathing, lung lobar 
expansion is quasi-steady and linear among lobes. Hence, MPPD implemented a uniform 
airway expansion and contraction during a complete breathing cycle (Asgharian, Hofmann, 
and Bergmann 2001).
The last component of the deposition model entailed the application of the first principles to 
develop lung-specific conservation of mass and momentum equations for inhaled CNT/
CNF. It was assumed that CNT/CNF concentration varied with lung depth and time and was 
constant across an airway cross-section. The movement of CNT/CNF in an expanding–
contracting airway was described by the simplified, cross-sectional area averaged, 
convective-diffusion (general dynamic) equation:
(8)
where A is the total airway cross-sectional area and includes the contribution of the 
surrounding the airways in the pulmonary region, C is the CNT/CNF concentration, D is the 
apparent diffusion coefficient, Q is the flow rate through the airway, λC is the number of 
CNT/CNF lost to the airways by diffusion per unit time, per unit volume, and x and t are the 
distance into the lung and elapsed time, respectively. The apparent diffusion coefficient D is 
the sum of molecular diffusion coefficient and convective diffusion (dispersion) coefficient 
by dispersion.
Losses of uncharged particles in lung airways (λAC) are designated by the last term in Eq. 
(8). Losses occurred by major mechanisms of impaction, sedimentation, diffusion, and 
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interception, which were time-invariant for a given aerosol size and lung and breathing 
parameters. It should be noted that while the functional form of Eq. (8) is the same for 
different shape particles, CNT/CNF specific shape and orientation effects were embedded in 
models for diffusion coefficient (D) and loss term (λAC) by different deposition mechanisms 
(Asgharian and Price 2008). Currently, the only deposition model for CNT/CNF is based on 
long, straight geometry. The model will be extended to other shapes of CNT/CNF by 
accounting for geometry-specific effects, which alter orientation and hence transport and 
deposition in lung airways.
Prediction of CNT/CNF deposition in the lung provides the missing link between exposure 
and biological response. In humans, CNT/CNF losses are determined based on a given 
exposure scenario, which comprises exposure concentration, duration, and CNT/CNF size 
characteristics. Losses in the lung are then directly linked to the response if the target site is 
within the respiratory tract. For extrathoracic target sites, the deposition model is linked to a 
pharmacokinetic or pharmacodynamic model to establish exposure-dose-response 
relationships. Deposition fraction of elongated CNT/CNF in the lung is calculated at 
different aspect ratios (β) for various CNT/CNF diameters ranging from 0.01 to 10 µm for 
the case of nasal breathing (Figure B-3). The minute ventilation is 7.5 LPM. For diameters 
below 0.4 µm, lung deposition fraction increases with decreasing CNT/CNF diameter and 
aspect ratio. Given that CNT/CNF equivalent diameter depends on its diameter and aspect 
ratio, deposition of submicrometer-diameter CNT/CNF is inversely proportional to its size. 
For diameters greater than 0.4 µm, lung deposition should increase with size due to 
sedimentation and impaction effects. However, the nasal filtering effect reduces the amount 
entering the lung, and as a result, deposition first increases and then drops sharply to zero. It 
is also interesting to note that the influence of aspect ratio is minimized near a CNT/CNF 
diameter of 0.3 µm.
The predictions in Figure B-3 are based on the assumption that CNT/CNF are cylindrically 
shaped. However, collected CNT/CNF on the stages of nano-MOUDI showed highly 
irregular structures and were often tangled together. In fact, very few, if any, were straight. 
Nonetheless, the shapes were clearly elongated with large aspect ratios. Therefore, modeling 
CNT/CNF behavior in the air and deposition on airway surfaces based on cylindrical 
geometry is a fair representation in the absence of experimental data. The agglomerates take 
on various shapes, including compact (spherical), elongated (cylinders), and other (irregular) 
geometries. However, the majority is believed to be elongated based on observations and 
thus can be described by MPPD models for fibers.
In lab animals, predicted deposition can be extrapolated to human exposure scenarios to find 
the HEC for risk analysis. Lab exposure concentrations at which biological responses are 
observed may be used to estimate CNT/CNF deposition in the rat lung. A dose metric such 
as deposition per unit surface area that is relevant to the observed effect is selected and used 
to extrapolate animal exposure settings to human exposure scenarios. Under the assumption 
that the same dose (deposition per unit surface area) in humans and rats gives the same 
response, HEC is obtained from the following relationship (Jarabek, Asgharian, and Miller 
2005):
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where DF is the CNT/CNF deposition fraction in the lung during one breathing cycle and 
SA is the surface area for the region of interest in the lung. Alternatively, deposition per unit 
lung weight can be selected as the dose metric if the response of concern involves the 
pulmonary interstitium rather than the epithelium, for example a fibrotic response. However, 
because this is a long-term effect knowledge about pulmonary retention kinetics in rats and 
humans needs to be available so that the HEC can be based on the retained rather than the 
deposited dose (Figure B-3). A longer term multidose inhalation study (subchronic) that 
includes a NOAEL should be the goal for dosimetric extrapolation to derive the HEC; the 
selection of a unit, surface area or mass of the lung as the basis depends on the effect seen at 
higher concentrations/doses. Preferably, surface area should primarily be selected unless 
there is strong evidence of mainly interstitial responses.
For human/rat and rat/human extrapolation modeling the requirements are:
Determining the CNT/CNF concentration best in the breathing zone of a worker, 
secondbest from area monitor.
Determining airborne particle size distribution.
Determining what size distribution for rodent exposure would mimic human exposure 
interms of deposited doses in specific regions of the respiratory tract.
Exposing rodents (preferably whole-body) to different concentrations to establish acute, 
subchronic, and chronic exposure-dose-response relationships, including exposure 
concentrations that are predicted to result in rodent retained lung burdens (per unit 
epithelial surface, or per unit lung weight) that correspond to those in exposed workers.
Analyzing results to determine rodent NOAEL for extrapolating to humans.
The MPPD deposition model was used to calculate CNT/CNF deposition fraction in rats for 
a given exposure atmosphere (concentration and CNT/CNF size characteristics) and rat lung 
and breathing parameters (functional residual capacity, tidal volume, breathing frequency, 
and breathing interval times). A dose metric was calculated based on deposition fraction per 
unit surface area or mass of the region of interest in the lung (i.e., tracheobronchial, 
pulmonary, lobar, etc.). The dose metric was used as the basis to calculate HEC by iteration: 
Deposition fraction in the human lung was calculated for different exposure concentrations 
of CNT/CNF until the predicted deposited mass per unit surface area (or mass) in humans 
matched that in rats. Figure B-4 presents HEC/CR calculations for different size CNT/CNF 
at an aspect ratio of 10 with minute ventilations of 7.5 LPM and 0.241 LPM for humans and 
rats, respectively. Equal short exposure duration is used in the calculations (δtR = δtH). The 
ratio was calculated based on tracheobronchial (TB) and pulmonary (PUL) regions as well 
as for the entire lung. The surface areas of all airways in each region were added together to 
find the total surface areas for the TB and PUL regions. The surface area in the PUL region 
did not include the alveoli surface areas, because it is not yet included in the present version 
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of the model. For losses by diffusion in the pulmonary region at diameters below 0.5 µm, 
HEC rose with increasing CNT/CNF diameter. Otherwise, HEC decreased with increasing 
CNT/CNF diameter where losses were by sedimentation and impaction. Predicted HEC was 
similar for the PUL region and the entire lung because the majority of deposition occurred in 
the PUL region. In addition, HEC was smallest if it was based on the TB region. When the 
ratio was above 1, HEC was larger than rat exposure concentration and vice versa.
Depending on the extent of available data—both from experimental animal inhalation and 
from human exposure—the HEC can be estimated based on the deposited or also—even 
more useful—on the long-term retained dose as explained in Figure B-3. While Figure B-4 
was based on equal acute exposure duration and deposition per surface area as the dose 
metric, a more relevant dose metric should be based on a lifelong exposure for both humans 
and rats. Since CNT/CNF that deposit on lung surfaces are cleared over time, the dose 
metric should be based on retained dose rather than on deposited dose. Unlike the deposited 
dose, the retained dose of CNT/CNF in the lung depends on the exposure duration taking 
clearance into account. Thus, an expression similar to Eq. (9) could not be obtained to 
predict HEC for a lifelong exposure. Instead, an iterative procedure needs to be undertaken 
in which different human exposure concentrations are selected to calculate the dose (Figure 
B-3). HEC will correspond to the human exposure concentration for which the calculated 
retained dose is the same as for the animal. Calculations of HEC based on a dose related to 
the retained dose have indicated that HEC will always be lower than CR (Jarabek, 
Asgharian, and Miller 2005).
GLOSSARY
ACGIH American Conference of Governmental Industrial Hygienists
APM aerosol particle mass analyzer
APS aerodynamic particle sizer
BALF bronchoalveolar lavage fluid
BAM beta attenuation mass monitor
BET Brunauer, Emmet, and Teller
BrDU bromodeoxyuridine
BW body weight
CIB Current Intelligence Bulletin (NIOSH)
CMAD count median aerodynamic diameter
CMD count median diameter
CNF carbon nanofibers
CNT carbon nanotubes
CNC condensation nuclei counter
CPC condensation particle counter
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CNS central nervous system
CRP C-reactive protein
DF deposition fraction
DMA differential mobility analyzer
DMA-APM, DMA particle mass analyzer
DPBS Dulbecco’s phosphate-buffered saline
DSPC disaturated phosphatidyl choline
DWCNT double-walled carbon nanotube
EM electron microscope
ENM engineered nanomaterial
EPA Environmental Protection Agency
FRC functional residual capacity
GSD geometric standard deviation
HEC human equivalent concentration
HPLC high-performance liquid chromatography
IARC International Agency for Research on Cancer
ILSI International Life Sciences Institute
ISO International Organization for Standardization
LOAEL lowest-observed-adverse-effect level
LDH lactate dehydrogenase
LPM liters per minute
MAC maximum aerosol concentration
MFTD maximum functionally tolerated dose
MMAD mass median aerodynamic diameter
MPPD multiple path particle dosimetry
mRNA messenger ribonucleic acid
MOUDI micro-orifice uniform deposition impactor
MTD maximum tolerated dose
NM nanomaterial
NIOSH National Institute for Occupational Safety and Health
NOAEL no-observed-adverse-effect level
NIR near infrared
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OECD Organization for Economic Cooperation and Development
OEL occupational exposure level
PBS phosphate-buffered saline
PDGF platelet-derived growth factor
PMN polymorphonuclear neutrophils
PPE personal protective equipment
PSP poorly soluble particle of low cytotoxicity
PTA programmed thermal analysis
PUL region, pulmonary region
SA surface area
SEM scanning electron microscope
SMPS scanning mobility particle sizer
STEM scanning transmission electron microscope
SWCNT single-walled carbon nanotube
TB tert-butylalcohol
TEM transmission electron microscope
TEOM tapered-element oscillating microbalance
TF thoracic fraction
TGF transforming growth factor
TLC total lung capacity
TV tidal volume
WHO World Health Organization
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a. MWCNT aerosols at a research facility.
Aerosols collected at a research facility during manufacture of MWCNT revealing a 
multiplicity of structures. (Han et al. 2008). Shown are samples collected in the facility after 
opening the furnace, demonstrating many non-fibrous structures in addition to some single 
fibers but mostly agglomerates of different sizes. Initially high concentrations could be 
significantly reduced following installation of proper enclosure and ventilation systems.
b. MWCNT aerosols collected at a research facility.
Aerosols collected at a research laboratory generating MWCNT by chemical vapor 
deposition (A: Tsai et al. 2009) and several commercial and research facilities 
manufacturing MWCNT (B, C, D: Methner et al. 2010). In the research facility, mostly 
agglomerates were seen and only some single filaments with numerous attached clusters of 
nanoparticles were found that consisted of carbon and included Fe from the catalyst (A). The 
aerosol in a commercial facility was described as “various forms like agglomerates, clusters, 
bundles, or nests rather than individual fibers or spherical particles” (B, C, D). These were 
collected under different working tasks (e.g., sawing, dumping). An example of the 
appearance of the few individual fibers and spherical particles is shown in (C). Total carbon 
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concentrations measured on filters according to NIOSH NMAM Method 5040 (Issue 2, 
1998) were equivalent to 1.8 mg/m3. In general, samples from both facilities indicate that 
long and individual fibers were hardly seen, in contrast to clusters/tangles of different sizes. 
The MWCNT aerosol generated experimentally for use in animal inhalation studies seems to 
be much better dispersed.
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FIGURE 2. CNF aerosols collected on impactor stages during thermal treatment
Transmission electron microscopy images of airborne CNF size selected by impactors 
located in a thermal treatment processing area for CNF. Impactor Stage A: 2.5–10 µm; 
Impactor Stage B: 1.0–2.5 µm; Impactor Stage C: 0.5–1.0 µm; Impactor Stage D: 0.25–0.5. 
Lacey carbon-coated Ni and SiO-coated Ni grids were used in impactors. (From: Birch et al. 
2011).
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FIGURE 3. Dosimetric Extrapolation of Inhaled Particles from Rats to Humans
Concept of dosimetric extrapolation of effects of inhaled materials in experimental 
animals to humans. A Human Equivalent Concentration (HEC) is derived based on study in 
rats (scenario 2 described in text) by using the MPPD model for rats to estimate the inhaled 
(delivered) and daily deposited dose in rats resulting from the specific experimental 
exposure concentrations. Knowing the material rat-specific clearance rates or retention 
halftime (T1/2) in the lung, the retained dose that has accumulated over the duration in the 
lung can be calculated, but may also be determined by analytical methods at the end of 
exposure. Using then human-specific clearance rates—if available—and breathing scenarios 
as inputs to the MPPD model for humans the HEC can be estimated for either the MMAD 
and GSD of the experimental aerosol, or for an aerosol size distribution that is known to be 
present for the human exposure scenario. The HEC is equivalent to the rat exposure in terms 
of resulting in the same deposited dose—or retained dose—in both species. Through using 
the MPPD model human and rat inhalability and respirability differences are taken into 
consideration. Deposited and retained dose can be expressed either per unit of epithelial 
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surface in the respiratory tract—tracheobronchial or alveolar—, or per unit mass of the lung. 
In addition, the material based dosemetric can be mass (as indicated in the scheme), or 
surface area or number of CNT/CNF, if respective information is available. [From: 
(Oberdörster 1989)]
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FIGURE 4. Exposure-Response and Dose-Response
Exposure-Response and Dose-Response relationships of five 3-month inhalation studies in 
rats with MWCNT, CNF and CB. The carbon black (CB) study is added as a well studied 
low toxicity particle for comparison.
Percent increase in lung lavage neutrophils (PMN) and retained lung dose were not reported 
for all of the five subchronic rat inhalation studies. Thus, to approximate retained lung 
burden of the MWCNT study by Ma-Hock et al. and for the CNF study by DeLorme et al., 
deposited and retained doses were calculated with the MPPD model, Version 2.90.3, using 
MMAD and GSD data and the packing density of the materials provided by the authors and 
a normal rat-specific pulmonary retention halftime (T1/2) of 70 days as model inputs. This 
T1/2 is appropriate for the rats exposed to the lower concentrations; for the high 
concentrations and resulting high lung burdens, a prolongation of T1/2 has to be expected 
(for example, as determined by Pauluhn et al., 2010, Table 3). Therefore, the lung burdens 
calculated for the high dose groups of these two studies are likely underestimated. The x-
axes have been truncated to better separate the individual MWCNT/CNF data, although as a 
consequence the high exposure/date points could not be displayed.
Oberdörster et al. Page 97













A: Lung weight and lung lavage neutrophil exposure-responses. B: Lung weight dose-
responses based on retained lung burden expressed as mass, surface area and volume of the 
retained material.
 - MWCNT (Pauluhn, 2010);  - MWCNT (Ma-Hock et al., 2009a);  - CNF (DeLorme et 
al., 2012);  - CB (Elder et al., 2005);  - MWCNT (Kasai et al., 2015).
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FIGURE 5. MWCNT aerosol size distribution in rodent inhalation study
A: Subchronic inhalation of different types of cigarettes and air-exposed controls in nose-
only tubes.
B: Chronic inhalation of different types of cigarette smoke and diesel engine exhaust and 
air-exposed controls in nose-only tubes.
Note: Effect of restraint stress on bodyweight in sham (clean air) exposed controls, 
highlighted in red.
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FIGURE 6. MWCNT aerosols collected in rodent inhalation study
Aerosolized MWCNT collected on filter (A, B) and carbon-coated 200 mesh N: grids (C, 
D). The MWCNT were aerosolized using an acoustic aerosol generation system (McKinney, 
Chen, and Frazer 2009) for dry powder generation. Large variations of the airborne 
structures were observed, ranging from a few single tubes to differently-sized structures of 
agglomerated CNT to larger tangles resulting in an airborne size distribution as shown in 
Figure 5. The aerodynamic, settling and diffusional behavior cannot be inferred from these 
pictures; the large tangle in section D may not be inhalable by rodents and is likely not 
respirable, but can be estimated from their aerodynamic size distribution. Such 
experimentally generated MWCNT aerosol for rodent exposures needs to be compared to 
atmospheres found at workplaces. (See Figures 1, 2).
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FIGURE 7. MWCNT aerosols collected in rodent inhalation study
Aerosolized MWCNT collected on filter (A, B) and carbon-coated 200 mesh N: grids (C, 
D). The MWCNT were aerosolized using an acoustic aerosol generation system (McKinney 
et al., 2009) for dry powder generation. Large variations of the airborne structures were 
observed, ranging from a few single tubes to differently-sized structures of agglomerated 
CNT to larger tangles resulting in an airborne size distribution as shown in Figure 8. The 
aerodynamic, settling and diffusional behavior cannot be inferred from these pictures; the 
large tangle in section D may not be inhalable by rodents and is likely not respirable, but the 
aerodynamic behavior can be estimated from their aerodynamic size distribution. Such 
experimentally generated MWCNT aerosol for rodent exposures needs to be compared to 
atmospheres found at workplaces. (See Figures 1, 2).
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Novel method using hybrid markers to quantify MWCNT in tissues. a. Lung exposed to 
MWCNT. b. Transfer of lung tissue into C99 at room temperature. c. Lung digestion in C99. 
d. Lung solution centrifugation at 12,000 rpm for 10 minutes.
e. Supernatant removal. f. Novel method using hybrid markers. Marker adsorbtion onto 
MWCNT for 15 min. g. Extraction of adsorbed B(ghi)P on MWCNTs to acetonitrile. h. 
Filtration of B(Ghi)P in the MWCNT. i. HPLC analysis.
Limit of quantitation is 0.2 µg in MWCNT in rat lung.
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FIGURE 9. MWCNT aerosol size distribution in rodent inhalation study
MWCNT aerosol size distribution as determined by a nano-MOUDI through weighing of 
deposits on the individual stages. The aerosol was generated with an acoustic aerosol 
generation system (Fig. 6) and collected with a 13-stage nano-MOUDI (NanoMoudi-II™ 
Model 125A, MSP Corp., Shoreview, MN) for 10 minutes at a flow rate of 10 l/min. Lower 
stages (10–13) were removed because deposits could not be reliably weighed; they 
contained less than 2% of the total mass. Larger structures with aerodynamic sizes >5 µm 
contribute much of the total mass concentration of the aerosol, but not to the deposition in 
the lower respiratory tract of rodents. Thus, describing a CNT/CNF aerosol exposure only 
by its total airborne mass concentration can be highly misleading when used as comparison 
to a human exposure concentration. Concepts of dosimetric rodent to human extrapolation 
discussed in this document have to be taken into consideration.
Placing a cyclone separator in line before the aerosol enters the inhalation chamber may 
eliminate the non-inhalable tangles. On the other hand, if such larger structures are still 
inhalable by humans and if they are present at the workplace, it could be considered to use 
intratracheal inhalation (Oberdörster et al., 1997) in rats to circumvent the upper respiratory 
tract. However, intratracheal inhalation requires anesthesia of rats and is not recommended 
for day-to- day repeat exposures.
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FIGURE A-1. CNT/CNF inhalability for humans and rats
CNT/CNF inhalability for humans via oral and nasal, and rats nasal breathings. 
Equivalent impaction diameter in the figure includes shape and orientation effects. dei is 
found from Equation (1) for cylindrical shapes. Additional size measurements are needed to 
develop more realistic models of dei for CNT/CNF which, while being elongated, generally 
are not cylindrical.
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FIGURE B-1. CNT/CNF thoracic fractions for humans and rats
CNT/CNF Thoracic fraction for different sizes for humans and rats at minute ventilations 
of 15 LPM and 7.4 mL/s, respectively.
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FIGURE B-2. Human to rat ratios for equal thoracic fractions
Ratio of human equivalent concentration to rat exposure concentration based on equal 
thoracic fractions for minute ventilations of 15 LPM and 7.4 mL/s in humans and rats 
respectively.
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FIGURE B-3. CNT/CNF respiratory fractions for humans at different aspect ratios
CNT/CNF deposition fraction in the human lung via nasal breathing for different aspect 
ratios. A minute ventilation of 7.5 LMP is used in the calculations.
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FIGURE B-4. HEC/CR ratios for CNT/CNF (100 nm—2 µm diameter) at aspect ratio of 10
Ratio of HEC/CR for different diameter CNT/CNF and aspect ratio of 10. Minute 
ventilations for humans and rats were 7.5 LPM and 0.241 LPM respectively.
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TABLE 2
Physicochemical Characteristics which influence Toxicity of CNTs and CNFs
1 Method of Generation
2 Shape (length, width, morphology)
3 Agglomeration/aggregation
4 Surface Properties (area, charge, defects, coating, reactivity)
5 Impurities
6 Density
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TABLE 3
90-Day Rat Inhalation Studies with MWCNT and CNF, Exposure-Dose-Response Comparison
Material





Kasai et al. (2015)
(Hodogaya Chemical
Co., LTD; MWNT-7)
DeLorme et al. (2012)
CNF (VGCF-H)
Characterization
Length/diameter, nm 100–10,000 /5–15 nm 200–1000/10 nm (micronization) 2000–5700/40–90nm 1000–14000/40–350 nm
Agglomeration Yes Yes (coiled structures) Yes Yes
Density, g/cm3 Packing: 0.043 Bulk: 0.11 – 0.33 Bulk; 0.007(production plant) Bulk: 0.077
Impurities 9.6% Al; <0.2% Co −0.5% Co 0.2 – 0.4%(not specified) 0.003% Fe
BET surf area, m2/g 250 – 300 255 24–28 m2/g 13.8
Animals
Rat strain Wistar; males/females Wistar; males/females F344, males/females Sprague-Dawley; males/females
Body weight (age) B.W. not reported (8–9 
weeks)
−228 g (m); 180 g (f); (−10 
weeks)
B.W. not reported (6 wks) B.W. not reported (>5 weeks)
Exposure
Exposure mode Nose-only Nose-only Whole body Nose-only
Generator Brush feed generator + 
cyclone
Wright-Dust Feeder Cyclon-sieve generator Accurate Bin Feeder
Duration 90 days: 6 hr/d; 5d/wk 90 days: 6 hr/d; 5d/wk 90 days: 6 hr/d; 5d/wk 90 days: 6 hr/d; 5d/wk
Conctr, mg/m3 0; 0.1; 0.5; 2.5 0, 0.1; 0.4; 1.5; 6 0; 0.2; 1; 5 0.54; 2.5; 25
MMAD µm (GSD) 2.0(2.8); 1.5(2.1); 
0.7(3.6) (Berner L.P. 
Cascade Impactor)
3.05(1.98); 2.74(2.11); 
3.42(2.14) (Marple Cascade 
Impactor)
1.5 (2.8); 1.5 (2.8); 1.5 (2.6) 
(Micro orifice Uniform Depos. 
Impact.)
1.9(3.1); 3.2(2.1); 3.3 (2.0) 
(Sierra cyclone/cyclone 
impactor)
Size distrib.nm(SMPS) 58 ± 1.8 – 64 ± 1.7 75; 320; 908; 1763 Not done Not done
Post-expos. recovery No 6 mos. (males only) No 3 mos. (males, females; 0.25 
mg/m3)
Dosimetry/Biokinetics
Lung burden (90 days, males) 47; 243; 1170 µg 
(deposited)a
−5, 25; 100; 420 µg (retained)b 
(also post-exposure)
9.69;63.60;360.90 µg (retained)c Not determined




Hilar lymphnodes; other organs 
not reported
Mediastinal lymphnodes; 
parietal pleura (diaphragm, 
capillaries of muscle), spleem
Tracheo-bronchial lymphnodes; 
rarely in brain, heart, liver, 
kidneys, spleen, intestinal tract, 
mediastinal lymphnodes (no 
adverse histopath.)
Retention halftime (T1/2, days) Not done 151; 350; 318; 375b Not done Not done
Response
Body wt. change No significant difference No significant difference No significant difference 15% lower in lowest conc. 
group; no sign. difference in 
other groups
Lung weight (90 days) + 1%; + 23%; + 81% 
(males)
+0; + 12; +27; +61% (males) +5;+17;+30% (males) −2; + 8; +22; (males)
Lymphnode wt. Increased size (high 
conc)
Increased wt (1.5 and 6 mg/m3) Not reported not reported
BAL–PMN (90 days) Not reported −0.5; 3.8; 13; 19% 0.6;13.5;45.7% 1.4; 2.7; 11.0%
BAL-PMN post-exposure (3 
mos)[6 mos] high dose only
Not done (22%) [19%] Not done (13%) [not done]
Neutrophilic, histiocytic inflam. Yes Yes Yes Yes
Granulomat. inflam. All concentrations 6 mg/m3 All concentrations Not reported
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Material





Kasai et al. (2015)
(Hodogaya Chemical
Co., LTD; MWNT-7)
DeLorme et al. (2012)
CNF (VGCF-H)
Interstitial fibrosis Fibrotic changes At 1.5 and 6 mg/m3 groups At 1 and 5 mg/m3 groups Interstitial thickening, no 
fibrosis
Alv. lipoproteinosis Yes, 0.5; 2.5 No No No
Hypercellularity Not reported Yes (0.4 and higher) Goblet cells in nasal cavity, all 
conc.
Yes (2.5 and higher conc.)
Lymphnode histology Granul. inflam, all 
conctr.
Increased cellularity, all conctr. 
(signif. at 0.4 and higher)
Not reported Not reported
Visceral pleura Not reported Thickening, collagen at 1.5 and 
6 mg/m3
Inflamm. Infiltration (5 mg/m3) Not reported
Blood neutrophilia Yes (highest conc.) Not reported Yes, females only, all conc. Not reported
Systemic Toxicity Not detected Not detected Yes (increased mRNA of 




NOAEL No 100 µg/m3 No 540 µg/m3
LOAEL 100 µg/m3 400 µg/m3 200 µg/m3 2500 µg/m3
a
estimated by authors, no clearance considered;
b
based on retained Co in lung;
c
extrapolated from amount determined in left lung and using a left to right lung weight ratio of 1:2.
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TABLE 4
Surface Areas of Respiratory Tract Regions at FRC
Rat Human
cm2 % of total cm2 % of total
Nasal 18.5 0.75 210 0.03
Trach-bronch 24 1.00 4149 0.65
Alveolar 2422 98.25 634620 99.32
Keyhani et al., 1997; Kimbell et al., 1997; Miller et al., 2011. (Keyhani, Scherer, and Mozell 1997; Kimbell et al. 1997; Miller et al. 2011).
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TABLE 5
Acute to Chronic Inhalation Exposures of Rodents to CNT/CNF for Toxicity Testing. (rat as preferred species; 
4–6 hrs/day, 5 d/wk; whole-body)
Acute/Subacute (14–28 days) Subchronic (90 days) Chronic (2 years)
• to obtain hazard ID and ranking 
(pos/neg control?)
• may be preceded by i.t. instillation or 
1 day inhalation with range of doses 
to estimate inhaled concentration 
with MPPD model
• assure and test rat respirable aerosol 
with range of concentr.
• if available use workplace or 
consumer exposure data to inform 
aerosol generation
• to determine concentration for 90-
day; (range-finding)
• to collect biokinetic data for portal of 
entry, and possibly identification of 
secondary target organs, incl. pleura, 
and fetus
• to provide guidance for dose levels 
for mechanistic in vitro testing, incl. 
secondary organs
• post-exposure observation period 
desirable (~2 months)
• to derive NOAEL
• use minimum 3 conc, including 
known or expected human 
exposure levels; both sexes 
optional
• if no effect at 50mg/m3 rodent 
respirable aerosol, then no need 
to do chronic study∗
• to identify hazard: total 
resp.tract; pleura, 
cardiovascular, CNS, bone 
marrow
• identify target organs
• to select conc, for chronic study
• detailed biokinetics: retention, 
clearance, organ accumulation,
• predicting long-term effects?
• to perform risk assessment by 
extrapolation to human via 
dosimetric extrapolation
• post-exposure observation 
period for longer-term effects 
to assess progression-regression 
(~3 months)
• to determine long latency 
effects (cancer); life shortening; 
extrapulmonary target organs
• 3 conc; based on 90-day or 
range-finding study results; 
include human exposure level; 
high dose: MTD; low dose: no 
significant effect
• to assess total respiratory tract, 
pleura and systemic effects, 
nose to alveoli; cardiovascular, 
CNS, bone marrow, others 
(reproductive?)
• to determine detailed 
biokinetics: resp.tract retention, 
clearance, organ accumulation
• to perform extrapolation to 
human for risk assessment
• post-exposure observation 
period up to a total study 
duration of 30 months (if 
survival of ≥20%)
∗
This suggestion is based on the fact that such high concentrations will never be reached in a repeat exposure scenario, and it would be a waste of 
animals (ethical) and resources ($), (Bernstein et al. 2005) to design a chronic workplace study. It should even be considered to move this 
suggestion to the acute/subacute category and not follow up with a subchronic study if an appropriate postexposure (~60 d) observation period is 
included. Even shorter-term (5 d) inhalation studies with CNT/CNF less than 10 mg/m3 or a single 6-hr. inhalation at 30 mg/m3 have induced 
significant effects (Ma-Hock et al. 2009; Ryman-Rasmussen et al. 2009a; b; Stapleton et al. 2012; Shvedova et al. 2008). Thus, a cutoff at 50 
mg/m3 in a subchronic study is very conservative.
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TABLE 7






Mass directly Membrane filter sampling Requires size selective inlet cutoff device to collect only 
structures <100 nm. However, most aerosols generated from 
nanomaterials contain larger agglomerates and aggregates so a 
size limitation may not be meaningful. Gravimetric and chemical 
analyses can be used. Major problem: separation of background.
Yes (M + Q) 
(average/integration 
over longer time)
Size selective static 
sampler
The only devices offering a cut point around 100 nm are cascade 
impactors (Berne-type low pressure impactors, or Microorifice 
impactors). Allows gravimetric and chemical analysis of samples 
on stages below 100 nm
Yes (M + Q) 
(average/integration 
over longer time)
TEOM∗ Sensitive real-time monitors such as the Tapered Element 
Oscillating Microbalance (TEOM) might be useable to measure 
nanoaerosol mass concentration on-line, with a suitable size 
selective inlet.
Yes (M + Q)
Mass by calculation ELPI™ Real lime size selective (aerodynamic diameter) detection of 
active surface-area concentration giving aerosol size distribution. 
Mass concentration of aerosols can be calculated, only if particle 
charge and density are assumed or known. Sue selected samples 
might be further analyzed off-line (as above).
Yes (M)
No (Q)
DMAS Real-time size-selective (mobility diameter) detection of number 
concentration, giving aerosol size distribution. Mass 
concentration of aerosols can be calculated, only if particle shape 
and density are known or assumed.
Yes (M)
No (Q)
Number directly CPC CPCs provide real-time number concentration measurements 
between their particle diameter detection limits. Without a 
nanoparticle preseparator, they are not specific to the nanometre 
size range. P-Trak has diffusion screen to limit top size to 1 µm.
Yes (M)
No (Q)
Number directly DMAS Real-time size-selective (mobility diameter) detection of number 
concentration, giving number-based size distribution.
Yes (M)
No (Q)
Electron Microscopy Offline analysis of electron microscope samples can provide 
information on size-specific aerosol number concentration
Yes (M + Q) and 
morphology
Mass by calculation ELPI™ Real-time size-selective (aerodynamic diameter) detection of 
active surface-area concentration, giving aerosol size 
distribution, Data might be interpreted in terms of number 




Diffusion Charger Real-time measurement of aerosol active surface area. Active 
surface area does not scale directly with geometric surface area 
for particles larger than 100 nm. Note that not all commercially 
available diffusion chargers have a response that scales with 
particle active surface area for particles smaller than 100 nm. 
Diffusion chargers are only specific to nanoparticles if used with 
an appropriate inlet preseparator.
No (M+Q)
Surface-area directly ELPI™ Real-time size-selective (aerodynamic diameter) detection of 
active surface-area concentration. Active surface area does not 
scale directly with geometric surface area for particles larger 
than 100 nm.
No (M + Q)
Electron Microscopy Off-line analysis of electron microscope samples can provide 
information on particle surface area with respect to size. TEM 
analysis provides direct information on the projected area of 
Yes (M + Q)



















collected particles, which might be related to geometric area for 
some particle shapes.
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TABLE 8
Recommendation for exposure characterization of sampled and airborne CNT/CNF (modified from 
Oberdörster et al., 2005)
Human exposure Rodent Exposure
Characterization Type Aerosol Supplied material Aerosol Filter samples
Size distribution (primary particles) E D E D
Agglomeration/aggregation state E D E D∗
Density D E D N
Shape E E E E
Surface area O E D D∗
Concentration, mass and number E − E E
Composition E E E E
Surface chemistry O E D D
Surface contamination D E D E
Surface charge – suspension/solution O O D E
Surface charge – powder D O D E
Crystal structure D E D E
Particle physicochemical structure D E D E
Solubility N E N E
Porosity N E N N
Method of production E E E E
Preparation process E E E E
Heterogeneity D E E E
Prior storage of material E E E E
E: These characterizations arc considered to be essential and to be available for each characterization at least once.
D: These characterizations are considered to provide valuable information, but are not recommended as essential due to constraints associated with 
complexity, cost and method availability.
O: These characterizations are considered to provide valuable but non-essential information.
N: These characterizations are not considered to be essential for all studies.
∗
The CNT/CNF property is assumed to be the same as in the supplied material and therefore no need to repeat measurement. If the CNT/CNF 
material has been altered from that supplied (e.g., micronization), then the new properties as used in the rodent assay have to be determined.
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